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The Novel Use of Recombinant Granulocyte-Macrophage Colony-Stimulating
Factor (GM-CSF) to Reverse Cerebral Amyloidosis and Cognitive Impairment in
Alzheimer’s Disease Mouse Models: Insights from the Investigation of Rheumatoid
Arthritis as a Negative Risk Factor for Alzheimer’s Disease

Timothy David Boyd

ABSTRACT

For many years, it has been known that Rheumatoid arthritis (RA) is a negative
risk factor for the development of Alzheimer’s disease (AD). It has been commonly
assumed that RA patients’ usage of non-steroidal anti-inflammatory drugs (NSAIDs)
have helped prevent the onset and progression of AD pathogenesis. Furthermore,
experiments in animal models of Alzheimer’s disease have looked to inhibit
inflammation, and have demonstrated some efficacy against AD-like pathology in these
models. Thus many NSAID clinical trials have been performed over the years, but all
have proven unsuccessful in AD patients. This suggests that intrinsic factors within RA
pathogenesis itself may underlie RA’s protective effect.
My dissertation research goal was to investigate this inverse relationship between
RA and AD, in order to more precisely pinpoint critical events in AD pathogenesis
toward developing therapeutic strategies against AD. It seemed improbable that any
secreted factors, produced in RA pathogenesis, could maintain high enough
concentrations in the circulatory system to cross the blood brain barrier and inhibit AD
pathogenesis, without affecting all other organ systems. It did seem possible that the
vi

leukocyte populations induced in RA, could traverse the circulatory system, extravasate
into the brain parenchyma, and impede or reverse AD pathogenesis. We thus investigated
the colony-stimulating factors, which are up-regulated in RA and which induce most of
RA’s leukocytosis, on the pathology and behavior of transgenic AD mice. We found that
G-CSF and more significantly, GM-CSF, reduced amyloidosis throughout the treated
brain hemisphere one week following bolus intrahippocampal administration into AD
mice. We then found that 20 days of subcutaneous injections of GM-CSF (the most
amyloid-reducing CSF in the bolus experiment) significantly reduced brain amyloidosis
and completely reversed cognitive impairment in aged cognitively-impaired AD mice,
while increasing hippocampal synaptic area and microglial density. These findings, along
with two decades of accrued safety data using Leukine, the recombinant human GM-CSF
analogue, in elderly leukopenic patients, suggested that Leukine should be tested as a
treatment to reverse cerebral amyloid pathology and cognitive impairment in AD
patients. It was also implied that age-related depressed hematopoiesis may contribute to
AD pathogenesis.

vii

CHAPTER 1 - INTRODUCTION
The Inverse Relationship Between Rheumatoid Arthritis and Alzheimer’s Disease
Epidemiological Studies. Several case-control and population-based studies
suggest that patients with Rheumatoid arthritis (RA) are protected from developing
Alzheimer’s disease (AD). The case-control study of Jenkinson et al., a survey of 96 AD
and 92 non-AD cases, looking for the presence or absence of RA, found that only 2% of
AD patients had RA as compared to 13% of control cases (Jenkinson, Bliss, Brain, &
Scott, 1989). In a population-based study of McGeer et al., of 973 RA patients, who
were 65 years and older and had extensive clinical history records, only 4 (0.41%) were
demented (P. L. McGeer, McGeer, Rogers, & Sibley, 1990). Similarly, the authors
examined the discharge records of 7,490 RA patients, 65 years or older, and found that
only 0.39% had concomitant AD. However, using data gathered in the Rochester AD
Incidence cohort collected between 1950 to 1975, Beard et al. reported that only 23
(4.4%) of the 521 RA cases subsequently developed AD (Beard, Kokman, & Kurland,
1991). Another population-based study, examining the causes of death within the whole
Finnish population covering the year of 1989, found that only 2 (0.12%) RA patients died
with concomitant AD (Myllykangas-Luosujarvi & Isomaki, 1994). The study also
revealed that 227 of the Finnish people that died in 1989, or only 0.54% of the whole
population cohort, had been diagnosed with AD. To put these numbers into perspective
today, it has recently been reported in the United States, that there was a 46.1% increase
in deaths attributable to Alzheimer’s disease from year 2000 to 2006, with an overall
average of 22.6% mortality rate (Alzheimer's_Association, 2010).
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Although it was concluded that RA is a negative risk factor for AD, the small
population of patients with concomitant RA and AD suggests that genetic predispositions
for AD may override RA’s protective effects. There have not been any epidemiological
studies that have examined this inverse relationship between RA and AD in regards to
AD-positive genetic risk factors, such as Apolipoprotein E type 4 (ApoE4) positivity,
amyloid precursor protein (APP) or presenilin-1 (PS1) mutations found in Familial
Alzheimer’s disease (FAD), or mutations in genes that encode immune system
components, such as complement receptor-1(CR1) or Clusterin. However, two studies
have examined the prevalence of ApoE4 in RA patients with systemic reactive
amyloidosis, and both concluded that ApoE4 may be a risk factor for developing reactive
amyloidosis (Hasegawa et al., 1996; Maury et al., 2001). Whether ApoE4 or other genetic
polymorphisms influence cerebral amyloidosis in RA patients will need to be specifically
addressed in future epidemiological studies, although the very small population of
concomitant RA and AD patients may make these analyses difficult to conduct.
NSAID Usage. Concurrent with the studies that examined RA as a negative risk
factor for AD, were similar epidemiological studies that investigated nonsteroidal antiinflammatory drugs (NSAIDs), which RA patients chronically used to ameliorate RA
symptoms, as protective against AD. A meta-analysis study reviewed 17 epidemiological
studies in which RA or NSAIDs were considered as risk factors for AD (P. L. McGeer,
Schulzer, & McGeer, 1996). In the meta-analysis, there were several case-control and 3
population-based studies that concluded that NSAID usage may be protective against AD
onset. The 3 population-based studies examined the NSAID and AD relationship by
different approaches. In an Italian study, 195 AD patients were surveyed as to whether
2

their NSAID usage was greater or less than in people of similar age (Lucca, Tettamanti,
Forloni, & Spagnoli, 1994). The authors found that NSAID usage was much less than
expected in AD patients as compared to NSAID usage in an elderly control group.
Another population-based study in Rotterdam examined 365 NSAID users, which had
only 1.4% afflicted with AD, and concluded that NSAIDs possibly prevented the risk of
developing AD (Andersen et al., 1995). In a third population-based study of 210 patients
in the Johns Hopkins Alzheimer Disease Research Center, a review of medical records of
32 AD patients who used NSAIDs compared to 177 AD patients who did not use
NSAIDs (Rich et al., 1995). The clinical, cognitive, and psychiatric measures of each
group were compared to examine which group progressed faster with AD within a one
year longitudinal study. The authors concluded that the AD patients who took NSAIDs
had a slower progression of AD pathogenesis. Altogether in the meta-analysis
examination of McGeer et al. (1996), it was likewise concluded that NSAID usage was
protective against developing AD, although the data did not deduce which specific
NSAID, or combination of NSAIDs, would be most protective against AD. It was also
concluded that anti-inflammatory drugs would reduce neuroinflammation, which was
commonly assumed to drive the pathogenesis of AD, and that clinical trials were needed
to investigate NSAIDs in order to halt the onset or progression of AD.
Since the meta-analysis of McGeer (1996), many pre-clinical and clinical research
studies have focused on investigating the reduction of inflammation as a therapeutic
approach to ameliorate AD pathogenesis. Animal studies have shown some promise in
lowering inflammation and reducing AD-like symptoms (Heneka et al., 2005; Jantzen et
al., 2002; Kukar et al., 2005; Lim et al., 2000; Q. Yan et al., 2003). However, large
3

NSAID clinical trials have been disappointing, and some have failed to show efficacy or
have even been discontinued due to adverse events (Aisen et al., 2003; Aisen,
Schmeidler, & Pasinetti, 2002; P. L. McGeer, Rogers, & McGeer, 2006; Reines et al.,
2004; Rogers et al., 1993; Scharf, Mander, Ugoni, Vajda, & Christophidis, 1999).
Moreover, the recent Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT)
study, that investigated celecoxib and naproxen, was halted due to adverse
cardio/cerebrovascular events by celecoxib and because test subjects who already had
mild cognitive impairment at the beginning of the trial tended to have accelerated
impairment and progression to AD by naproxen (Meinert, McCaffrey, & Breitner, 2009;
Strobel, 2009). However, a two-year follow-up study of the ADAPT participants, who
were cognitively normal at the beginning of the trial, and who took naproxen versus
placebo, were found to be significantly protected against incidence of AD, as well as
having a more favorable biomarker profile (Tau/Aβ1-42, proteins explained below). It was
suggested by Dr. Brietner at the 2009 International Conference of Alzheimer’s Disease
(ICAD) that “Primary prevention, not disease modification, is the ultimate cure, and
timing is everything” (Strobel, 2009). This suggestion echoes the findings of another
large epidemiology study of veterans over the age of 55 years who were on long-term
NSAID usage, particularly ibuprofen, and who were also protected against AD onset
(Vlad, Miller, Kowall, & Felson, 2008).
NSAIDs act mainly to inhibit the action of cyclooxygenases (Cox), which are
enzymes that catalyze the formation of eicosanoids, such as thromboxanes or
prostaglandins, from an arachadonic acid precursor. There are two isoforms of
cyclooxygenases,Cox-1 and Cox-2, which differ in their expression and biological
4

functions (Kaufmann, Andreasson, Isakson, & Worley, 1997; O'Banion, Sadowski,
Winn, & Young, 1991). Cox-1 and Cox-2 are constitutively expressed at low levels in
most tissues, and induced expression of Cox-2 occurs during inflammation. Traditional
NSAIDs, such as aspirin or ibuprofen, are non-selective and inhibit both Cox-1 and
Cox-2. In the brain and especially around AD-vulnerable pyramidal neurons, Cox-2 is
constitutively expressed at higher levels than Cox-1, and has enhanced expression in AD
brain (Seibert et al., 1994; Yasojima, Schwab, McGeer, & McGeer, 1999; Yermakova,
Rollins, Callahan, Rogers, & O'Banion, 1999). However, it has been found that Cox-2 is
not detectable in microglia and astrocytes in AD, but it is instead expressed in neurons.
Exposure of human microglial cultures to inflammatory mediators over-expressed in AD
brain, such as interleukin (IL)-1, IL-6, tumor necrosis factor alpha (TNFα), and amyloid
beta 1-42 (Aβ1-42), did not induce Cox-2 activity, and it was only after exposure to
bacterial lipopolysaccharide (LPS) that the microglia express Cox-2 (Hoozemans et al.,
2001). On the other hand, Cox-1 is up-regulated in AD-activated microglia and may
provide a more selective target to reduce AD-associated neuroinflammation (Hoozemans
et al., 2002). Therefore, it can be predicted that the Cox-2-selective NSAIDs, such as
celecoxib, would act mainly to inhibit peripheral pro-inflammatory effects, instead of
acting directly against AD-related neuroinflammation. As of today, there are no
clinically-approved selective Cox-1 inhibitors, and traditional NSAIDs are the only
available options for inhibiting Cox-1.
Leprosy and Dementia. It has been well known among physicians in Japan that
elderly leprosy patients who inhabit well-monitored leprosy hospitals do not tend to
develop cognitive impairment. Bacterial infection by Mycobacterium leprae causes a
5

chronic granulomatous disease of the skin and chronic inflammation of the peripheral
nervous system (Dastur & Razzak, 1971; Jacobs, Shetty, & Antia, 1987; Job, 1971; Save,
Shetty, Shetty, & Antia, 2004; Swift, 1974). A study by McGeer et al. in 1992 surveyed
living leprosy patients in Japan, aged 65 and older, for the usage of anti-leprosy drugs
and for dementia. In the 1,410 leprosy patients that had been treated with anti-leprosy
drugs, there was a 2.9% prevalence of dementia compared to 6.25% of the 1,761 leprosy
patients that had not been treated for at least 5 years. Since dapsone and other antileprosy drugs have anti-inflammatory activity, it was proposed that these drugs might
also be protective against AD, similar to the proposed efficacy of NSAIDs against AD (P.
L. Mcgeer, Harada N., Kimura H., McGeer E.G., Schulzer M., 1992; P. L. McGeer et al.,
1996). However, another epidemiological study examining inpatients in a Japanese
leprosarium with an average age of 70 and who were free from active leprosy did not
show protection against AD as compared to previous Japanese general population-based
data (Goto et al., 1995). The latest study that examined whether anti-leprosy drugs were
efficacious against AD showed that anti-leprosy drugs (dapsone, rifampicin, clofazimine,
minomycin, or ofloxacin) did not have any protective effect on the neurotoxicity of
amyloid beta (Aβ) peptides, the main component of the cerebral amyloidosis in AD
(Endoh, Kunishita, & Tabira, 1999). The authors also reviewed the medical records of
196 lepromatous patients, and found that there was no significant difference in
prevalence of dementia of those patients that were treated with anti-leprosy drugs
compared to untreated lepromatous patients. Taking into account their previous study that
did show significantly lower cerebral amyloidosis in elderly lepromatous patients
compared to controls (Chui, Tabira, Izumi, Koya, & Ogata, 1994), the authors concluded
6

that intrinsic mechanisms of Mycobacterium leprae infection itself in the central nervous
system (CNS) may underlie the protection against AD pathogenesis in active lepromatous
patients. Indeed it is a striking similarity with RA, that another chronic peripheral
inflammatory disease, such as Mycobacterium leprae infection, also confers a reported
decreased risk of AD onset, independent of anti-inflammatory pharmaceutical
intervention.
Rheumatoid Arthritis
Pathogenesis of Rheumatoid Arthritis. Rheumatoid arthritis is the most
common systemic inflammatory disorder and the most serious and disabling type of
arthritis. RA is an autoimmune disease in which the joint synovium becomes inflamed
and a highly vascularized inflammatory pannus forms that irreparably damages the
cartilage and bone, causing joint disfigurement and excruciating pain. This systemic
autoimmunity is characterized by autoantibodies against a wide range of autoantigens.
The first autoantibody, described in 1940 and named rheumatoid factor (RF) (Waaler,
1940), was later found to have specificity for the Fc region of IgG immunoglobulins.
Since then, other RA autoantigens, such as cartilage components, stress proteins,
enzymes, nuclear proteins, and citrullinated proteins have been discovered (Reviewed in
(Duskin & Eisenberg)). The autoimmunity of RA involves not only the B lymphocytic
arm of the adaptive immune system, but also a recently-described class of T helper (Th)
cell lymphocytes. This new pro-inflammatory CD4+ effector cell lineage, separate from
Th1, Th2, and Treg differentiations (Harrington et al., 2005; H. Park et al., 2005; Wynn,
2005) is termed Th17, due to their release of cytokines, IL-17A/F. These Th17
lymphocytes also secrete many other proinflammatory cytokines and chemokines that
7

work in the recruitment and activation of innate leukocytes, as well as the proliferation of
more autoimmune T and B lymphocytes. RA is not the only autoimmune disease with a
Th17 phenotype, as Th17 lymphocytes have also been found to be greatly implicated in
the pathogenesis of Multiple Sclerosis, Crohn’s disease, Inflammatory Bowel Disease
and Systemic Lupus Erythematosus (Furuzawa-Carballeda, Vargas-Rojas, & Cabral,
2007; Nalbandian, Crispin, & Tsokos, 2009; Sarkar, Tesmer, Hindnavis, Endres, & Fox,
2007; Thakker et al., 2007).
Of the innate leukocytes involved in RA, differentiated myeloid-lineage
monocytic cells are major contributors to the pathogenesis of RA. The hematopoietic
growth factor, M-CSF (Macrophage Colony-Stimulating Factor), produced by synovial
endothelial cells and macrophages, is highly expressed and drives macrophage and
osteoclast production and differentiation. The TNF family member, RANKL (receptor
activator of NF-κB ligand), secreted by bone marrow stromal cells and T lymphocytes,
binds to their RANK receptors on these macrophage/osteoclast progenitors and activates
an intracellular transduction cascade involving TRAFs, JNK, and NF-κB in order to
induce functional osteoclasts. Secreted osteoprotegerin (OPG) is induced in RA synovial
fluid to work as a negative regulator of this process (Karsenty, 1999). Besides increased
bone resorption due to osteoclasts in RA, the innate leukocytes work in combination with
the above-mentioned autoimmune lymphocytes in the production of inflammatory-related
cytokines,chemokines, hematopoietic factors, enzymes, and other soluble factors, such as
TNFα, IL-1, IL-6, IL-8, IL-15, IL-17A/F, IL-18, CXCL16, ADAM10, M-CSF, G-CSF,
GM-CSF, MCP-1 (monocyte chemotactic protein 1), and MIF (macrophage migration
inhibitory factor). There is also elevated expression of angiogenic factors, VEGF-A
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(vascular endothelial growth factor – A) and IGF-1 (insulin-like growth factor 1), by
synovial macrophages, fibroblasts, and vascular smooth muscle cells, as well as, the
increased expression of their receptors, VEGFR-1,2 on endothelial cells and
macrophages, and secreted IGF Binding Protein (IGFBP)-3 (Matsumoto & Tsurumoto,
2002; Murakami et al., 2006). Thus the combined innate and adaptive autoimmunity in
the inflammatory pannus of RA cause a chronic feed-forward mechanism to increase
leukocyte populations, further cytokine and chemokine induction, increased
osteoclastogenesis, resultant synovial joint deformation, and extensive
neovascualarization as the pannus grows.
Alzheimer’s Disease
History of Alzheimer’s Disease. Alzheimer’s disease was first described at a
scientific meeting in November 1906 by German physician, Alois Alzheimer. He was the
physician of a 51 year old patient, Frau Auguste D., who was brought to him by her
family for memory problems, unfounded suspicions, and increasing difficulty in the
ability to process new events. During Dr. Alzheimer’s care, these symptoms rapidly
progressed until the death of Mrs. Auguste D. in the spring of 1906. Since Dr. Alzheimer
had never encountered these symptoms in a patient, he requested the permission to
perform an autopsy on Mrs. Auguste D. Examination of her brain revealed atrophy of the
cerebral cortex, fatty deposits in the cerebral microvasculature, abnormal extracellular
and intracellular deposits, and evidence of active neurodegeneration. Dr. Alzheimer
published his work in 1907, and the disease was named after him in 1910 (Graeber et al.,
1997; Graeber, Kosel, Grasbon-Frodl, Moller, & Mehraein, 1998).
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Statistics of Alzheimer’s Disease. Alzheimer’s disease is the most common type
of dementia today, accounting for 60 – 80% of all cases of dementia, followed secondly
by vascular dementia, although many patients may have hallmark pathologies of both
(Alzheimer's_Association, 2010). Approximately 1 out of 8 people over the age of 65,
and 1 out of 2 over the age of 85 will be diagnosed with AD. As of 2010, there were over
5.3 million Alzheimer’s patients in the United States, costing $172 Billion in annual
costs. AD is the 7th leading cause of death, and although its prevalence is increasing, the
mortality from cardiovascular disease, cancer, and other diseases are decreasing. It is
estimated that by 2030, there will be 7.7 million Alzheimer’s patients over the age of 65,
and between 11 and 16 million by 2050. The disease is characterized initially by shortterm forgetfulness with the inability of the individual to learn any new things, along with
fluctuations in the individual’s mood and attention span. As the disease progresses, the
AD patient gradually withdraws from daily life, can become easily agitated, and starts to
forget the names and identities of family and loved ones. Slowly and inexorably, the
ability of carry out familiar tasks, to reason and exercise judgment, and to carry on
conversation declines to the state of bedrest, followed by certain fatality. The lifespan of
Alzheimer’s patients averages about 10 years from diagnosis, and the overall physical
condition and age of onset may influence how fast the disease progresses. The cause of
death is usually by AD directly, such as by dehydration and malnutrition from the
inability of patients to swallow, or by other diseases, such as pneumonia, stroke, etc., as
the body’s general health slowly deteriorates (Alzheimer's_Association, 2010).
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Pathological Hallmarks of Alzheimer’s Disease.
Overview. Alzheimer’s disease is a fatal, age-related, and progressive
neurodegenerative disorder that presents clinically in patients as a progressive decline in
cognitive and executive functions. Its dementia is associated with extracellular deposits
of amyloid, intracellular aggregates of neurofibrillary tangles (NFTs), and cerebral
microvascular occlusions and other ischemic defects. The hippocampus, amygdala, and
cerebral cortex are the major areas of the brain in which these hallmark pathologies occur
(Hopper & Vogel, 1976; Woodard, 1966). Although Dr. Alzheimer described these
pathologies in his 1907 publication, it took over 7 decades to develop the laboratory
techniques and tools in which to identify the principle components of the then-called
senile plaques and neurofibrillary tangles (Glenner & Wong, 1984). It is now known that
oxidative stress, neuroinflammation, excitotoxicity, apoptosis, and aneuploidy may all
contribute to the pathogenesis of AD.
Amyloidosis. Amyloid beta (Aβ) peptides are the primary component of amyloid
deposits in the Alzheimer’s disease brain. Aβ is proteolytically derived from the amyloid
precursor protein (APP), a transmembrane protein expressed in almost all tissues
(Glenner & Wong, 1984). Three APP isoforms (APP695, APP751, and APP 770) are
found in mammals, with APP695 being the isoform mainly expressed on the surface of
neurons (Tanaka et al., 1988; Tanaka et al., 1989). Whether APP contains a chondroitin
sulfate glycosaminoglycan site or a Kunitz protease inhibitor domain differentiates the
three isoforms from each other (Sisodia & Price, 1995).
APP is a synaptic receptor whose function has not been elucidated completely,
but its processing is thought to influence dendritic spine development and maintenance
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(Dewji & Singer, 1996; Ho & Sudhof, 2004; K. J. Lee et al., 2010; Lorenzo et al., 2000;
P. Wang et al., 2005). The processing of APP occurs by three enzymes, α, β, and γsecretases, and depending on whether α or β-secretase cleaves the APP will determine
whether the resultant peptides are non-amyloidogenic or amyloidogenic, respectively. For
the amyloidogenic pathway, cleavage by β-secretase is the rate-limiting step for Aβ
generation (Hussain et al., 1999; Sinha et al., 1999; Vassar et al., 1999; R. Yan et al.,
1999). There are two isoforms of β-secretase, BACE1 and BACE2, and although both
isoforms compete for the same substrate and cleave at the same β-site of APP, BACE2
activity is much less abundant and thought to be masked in the brain (Ahmed et al., 2010;
Basi et al., 2003; Farzan, Schnitzler, Vasilieva, Leung, & Choe, 2000; Hussain et al.,
2000; Sun et al., 2005; R. Yan, Munzner, Shuck, & Bienkowski, 2001). Cleavage of APP
by BACE1 results in the extracellular release of soluble APP beta (sAPPβ), a large
N-terminal ectodomain of APP with unknown function, leaving a transmembrane
C-terminal fragment of 99 amino acids (C99), which is then intramembranely-cleaved by
γ-secretase to produce extracellular Aβ peptides of either 39, 40, or 42 amino acid
residues in length. The C-terminal APP intracellular domain (AICD) is thought to play a
feed-back regulatory role in the transcription of genes implicated in AD pathogenesis
(Slomnicki & Lesniak, 2008). For the non-amyloidogenic pathway, cleavage by
α-secretase at the APP α-site, which lies within the Aβ sequence, generates a
transmembrane C-terminal fragment of 83 amino acids in length (C83), with the
extracellular release of the large N-terminal soluble APP alpha (sAPPα). It is interesting
to note that the gene for BACE2 is located in the Down’s syndrome critical region of
Chromosome 21, and although purified BACE2 cleaves at the β-site of APP, it can also
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process APP downstream of the α-site (R. Yan et al., 2001). Overexpression of BACE2
in a human embryonic kidney (HEK) cell line stably-expressing the Swedish mutant of
APP, resulted in reduced Aβ production, but an increase in soluble APP species (sAPP,
which includes sAPPα, sAPPβ, and BACE2-generated sAPP) (Sun et al., 2005).
Although the authors did not determine relative levels of each type of sAPP, they did find
that knockdown of BACE2 results in an increase of APP C83, indicative of the nonamyloidogenic pathway. Although the authors concluded that BACE2 is not involved in
the formation of amyloid plaques, Down’s patients chronically overexpressing BACE2,
as well as BACE1, would have both species of BACE competing against α-secretase,
which may have yet undescribed physiological effects, since the biological functions of
sAPPα and over-expressed BACE2-generated sAPP have not been completely elucidated.
The γ-secretase is a multiprotein intramembrane-cleaving aspartyl protease
complex, which consisits of Presenilin (PS, which can be either of two isofoms, PS1 or
PS2), Pen2, Aph1 (anterior pharynx-defective 1 protein), and nicastrin (NCT). PS
contains the catalytic site (De Strooper et al., 1998; Y. M. Li et al., 2000; Wolfe et al.,
1999), Pen2 and Aph1 have functions that have not been fully elucidated, and NCT is
thought to contain the substrate binding site (Shah et al., 2005), as well as stabilizing
γ-secretase, since the trimeric PS/Pen2/Aph1 complex is highly unstable (Zhao, Liu,
Ilagan, & Kopan, 2010). Mutations in PS1 and PS2, as well as the APP gene, have been
found to lead to increased production of pathogenic Aβ and cause early onset familial AD
(FAD) (Chartier-Harlin et al., 1991; Fidani et al., 1992; Goldgaber, Lerman, McBride,
Saffiotti, & Gajdusek, 1987; St George-Hyslop et al., 1990; Tanzi, George-Hyslop, &
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Gusella, 1991). There are over 160 known mutations that predispose individuals to FAD,
with PS1 mutations accounting for the majority of FAD.
Amyloid-associated Proteins. Over 30 other proteins have also been found to be
associated with extracellular amyloid plaques, including complement proteins,
complement regulatory proteins, growth factors, proteases, protease inhibitors,
coagulation factors, proteoglycans, acute phase reactants, receptors, adhesion molecules,
and other soluble factors (P. L. McGeer, Klegeris, Walker, Yasuhara, & McGeer, 1994).
The majority of these proteins are directly associated with the immune system, but the
characterization and determination of each protein’s role in amyloid deposition and
subsequent AD pathogenic pathways have not yet been fully elucidated. It is known that
the plaque-associated proteins, apolipoprotein E (ApoE) and Alpha-1-antichymotrypsin
(ACT) work to catalyze the formation of Aβ filaments in vitro (Ma, Brewer, & Potter,
1996; Wisniewski & Frangione, 1992) and formation of amyloid beta-pleated sheets in
vivo (Abraham, Selkoe, & Potter, 1988; Bales et al., 1999; Ma, Yee, Brewer, Das, &
Potter, 1994; Nilsson et al., 2001; Potter, Wefes, & Nilsson, 2001). ApoE acts
systemically in the transport of lipid proteins, but in the brain, it is released by astrocytes
and microglia during neuroinflammation. ApoE allele ε4 (ApoE4) confers a very high
risk for developing AD, ApoE allele ε2 (ApoE2) is associated with low risk and high age
of onset, and ApoE allele ε3 (ApoE3) confers intermediate risk and age of onset
(Strittmatter et al., 1993). ACT is an acute-phase serine protease inhibitor (serpin) that is
released systemically by hepatocytes and monocytes during inflammatory responses, and
by neutrophils to work as a suicide inhibitor of Cathepsin G during vascular remodeling
(Kalsheker, 1996). However, in the brain, ACT is induced and released by astrocytes in
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response to microglial release of IL-1β, trauma, infection, or amyloidosis (Abraham,
2001; Das & Potter, 1995). Not only does ACT work to catalyze amyloid plaque
formation, it also induces intracellular neuronal Tau hyperphosphorylation
(Padmanabhan, Levy, Dickson, & Potter, 2006).
Tauopathy. The hyperphosprorylation of Tau leads to paired helical filaments
(PHFs), which themselves aggregate intracellularly to form neurofibrillary tangles
(NFTs), another major hallmark pathology of AD(Grundke-Iqbal, Iqbal, Quinlan et al.,
1986; Grundke-Iqbal, Iqbal, Tung et al., 1986). Tau is a cytosolic protein that is involved
in the assembly and stabilization of microtubules (MT), and the hyperphosphorylation of
Tau, impedes Tau from binding MTs and performing this role, since it undergoes
misfolding, dissociation from MTs, and aggregation (Chung, 2009; V. M. Lee, Balin,
Otvos, & Trojanowski, 1991). Tau is primarily expressed in neurons, and mutations in
the Tau gene, encoded by 16 exons on Chromosome 17, leads to tauopathies, such as
Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration, Pick’s disease, and
parkinsonism linked to chromosome 17 (FTDP-17) (Baker et al., 1997). Although, these
tauopathies also present with progressive dementia, Tau mutations have not been
identified in AD pathogenesis, and the various taupathies present in different brain
regions and specific types of neurons (Arima, Murayama, Oyanagi, Akashi, & Inose,
1992; Delisle et al., 1999; Galloway, 1988; Hauw et al., 1990; Kertesz et al., 2000;
Ksiezak-Reding et al., 1994; Mori, Nishimura, Namba, & Oda, 1994; Nasreddine et al.,
1999; Poorkaj et al., 1998; Schneider & Mandelkow, 2008; Spillantini et al., 2000). There
are 85 reported phosphorylation sites that have been identified on Tau, and 45 of these
have been identified to contribute to AD pathogenesis. Tau is primarily phosphorylated
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by glycogen synthase kinase-3beta (GSK-3β), cyclin-dependent kinase 5 (cdk5),
calcium/calmodulin-dependent protein kinase 2 (CaMKII) and secondarily by
extracellular signal-related kinase (ERK), casein kinases 1 (CK1) (Singh, Grundke-Iqbal,
& Iqbal, 1995; Singh, Grundke-Iqbal, McDonald, & Iqbal, 1994), and cAMP-dependent
protein Kinase A (PKA) (G. Li, Yin, & Kuret, 2004; F. Liu et al., 2006; Pei et al., 2002;
Trojanowski, Mawal-Dewan, Schmidt, Martin, & Lee, 1993). Regulation and
dephosphorylation occurs by known phosphatases, PP2A, PP1, and PP2B. A
peptidyl-prolyl cis-isomerase, Pin-1, is involved in the assembly, folding, and transport of
Tau. For example in AD, Pin-1 binds Tau when Tau is phosphorylated at its Threonine
residue 231 (Thr231), in order to facilitate dephosphorylation of Thr231 by PP2A
(Butterfield et al., 2006). The mechanisms into the hyperphosphorylation of Tau, and its
subsequent aggregation into NFTs, are currently a very active area of research, as levels
of NFTs correlate closely with AD prognosis.
Cerebrovasculature Dysfunction. Another major hallmark pathology of AD is the
extensive cerebrovascular damage that occurs as AD progresses. Cerebrovascular damage
was noted as early as 1911, by Dr. Alois Alzheimer from his second senile dementia case
study of a 56 year-old demented man, Johann Feigel, who was admitted to the Royal
Psychiatric Clinic in Munich on November 12, 1907 with possible vascular dementia and
who died on October 3, 1910 with pneumonia-like symptoms, and was described by Dr.
Alzheimer to have degeneration of the smaller cerebral blood vessels (Graeber et al.,
1997). An immunohistochemical study that looked at deceased AD patients and agematched control subjects found that over 90% of those with AD had an absence of
endothelial staining for capillaries, even though it appeared that their basement
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membranes remained, suggesting that the capillaries had collapsed and degenerated,
concomitant with Aβ deposition (Kalaria & Hedera, 1995). Other studies have shown in
the cerebrovasculature of AD patients that the basement membranes thicken, that the
pericytes degenerate, that endothelial cell morphology is altered, and that luminal
buckling occurs (Buee et al., 1994; Claudio, 1996; Mancardi, Perdelli, Rivano, Leonardi,
& Bugiani, 1980; Perlmutter, Myers, & Barron, 1994; Prasher et al., 1998; Scheibel,
1987; Scheibel, Duong, & Tomiyasu, 1987; Zarow, Barron, Chui, & Perlmutter, 1997).
These microvascular abnormalities and degeneration of capillary vessels result in reduced
cerebral blood flow and deficient delivery of oxygen and glucose to the brain (de la
Torre, 2004, 2009, 2010; de la Torre & Stefano, 2000). As discussed later, this damage to
the cerebral vasculature may also impair the clearance mechanisms of Aβ from the brain
(Chapters 2 and 6).
Although these capillary abnormalities can be examined post-mortem in AD
patients, non-invasive techniques are not available to longitudinally study these
microvascular effects in vivo. However, experimental animal models, such as chronic
cerebral hypoperfusion in aged rats over one year, induced by permanent surgical
occlusion of both common carotid arteries (two-vessel occlusion), results in almost
identical microvascular pathology as in AD patients, such as basement membrane
thickening, deposition of collagen, distortion of endothelial cell morphology,
degeneration of pericytes, and vessel lumen buckling, all within the CA1 hippocampal
region and which also correlates with a progressive decline in spatial memory function
(De Jong et al., 1999; Farkas, De Jong et al., 2000; Farkas, De Vos, Jansen Steur, &
Luiten, 2000). The immense cerebrovascular damage found in AD pathogenesis can also
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be demonstrated by vascular corrosion casting (VCC) of Tg AD mice. A recent study
which used the VCC technique, employed a new polyurethane low-viscosity resin and
other special resins to perfuse young and old Tg AD mice (Heinzer et al., 2006; Krucker,
Lang, & Meyer, 2006; Meyer et al., 2007; Meyer, Ulmann-Schuler, Staufenbiel, &
Krucker, 2008). After perfusion and time for the resins to polymerize, chemical removal
of the surrounding tissue was performed. These resins that were used have minimal
shrinkage, leaving high quality replicas of the lumens of even the smallest capillaries.
VCC allows for 3-dimensional, very high resolution examination of the
microvasculature’s morphology under scanning electron microscopy, which can even
determine endothelial cell imprints and show distinction between arterial versus veinal
vessels within the vascular tree (Heinzer et al., 2008; Weiger, Lametschwandtner, &
Stockmayer, 1986). The authors found that amyloid deposits begin to accumulate on the
capillary vessels at very early ages in the AD mice, in shapes described as ‘pompoms or
cubes’ of Aβ species, as determined by mass spectrometry analysis, and in doing so, the
microvessels begin to crimp and become occluded. These ‘pompoms or cubes’ are not
found in normal age-matched control mice, and also would not be detectable by
conventional histochemistry, since conventional histochemistry does not retain the 3D
architecture of the entire cerebral vasculature and capillary vessels. As the AD mice age
and plaques became large enough to view by conventional histochemistry, VCC showed
that the vasculature becomes deformed, truncated, or occluded surrounding the amyloid
plaques, forming significant holes in the vascular system (Figure 1) (Beckmann et al.,
2003; Meyer et al., 2008). There also was extensive increased vascular remodeling
around the truncated ends of the vessels, as the vessels were studded with knobs,
18

budding, and other abnormal protrusions, in an apparent attempt to circumvent the
amyloid plaques. However, the intrinsic nature of Aβ itself is anti-angiogenic and
accelerates the senescence of endothelial cells at very early stages of vascular
development (Donnini et al., 2010), possibly by mechanisms, such as the direct binding
of Aβ to the receptor for VEGF (Patel et al., 2010). Indeed, a ten amino acid peptide with
Aβ itself, has been recently reported to inhibit tumorigenesis via anti-angiogenic effects
(Paris et al., 2010). Thus, although the vasculature attempts to circumvent the amyloid
plaques, it is prevented by the intrinsic anti-angiogenic nature of Aβ, and only after
physical enzymatic dissolution, degradation, or phagocytic removal of Aβ, would the
vascular remodeling have a chance to be successful and restore cerebral blood flow.
Down’s Sydrome, Aneuploidy, Cell Cycle, and Alzheimer’s Disease. Down’s
Syndrome (DS) individuals invariably develop Alzheimer’s disease by their third or
fourth decade of life (Epstein, 1990; Glenner & Wong, 1984; Olson & Shaw, 1969). DS
individuals are born with three copies of Chromosome 21 in every cell because of meiotic
chromosome mis-segregation (Lejeune, Gautier, & Turpin, 1959; Mrak & Griffin, 2004),
and the gene encoding amyloid precursor protein (APP) is located on Chromosome 21.
Genetic mutations in APP have been found to result in FAD (Goate et al., 1991; Naruse
et al., 1991; Tanzi et al., 1991), and it has been thought that DS individuals should
overexpress APP throughout their life more than non-DS individuals. DS individuals
begin accumulating fibrillar Aβ deposition in their brains by age of adolescence (Lemere
et al., 1996; Mrak & Griffin, 2004; Rumble et al., 1989). A specific case of a DS 78 year
old woman, who had only partial trisomy 21 with only two alleles of APP and who died
without any clinical or AD pathology, showed that extra expression of APP is necessary
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for AD onset in DS patients, but not for development of DS (Mrak & Griffin, 2004;
Prasher et al., 1998). However, extra APP expression does not completely account for the
onset of AD in non-DS individuals. For instance, autopsy of deceased individuals from
the Nun Study (Davis, Schmitt, Wekstein, & Markesbery, 1999; Gold et al., 2000; Riley,
Snowdon, & Markesbery, 2002), showed that there were subjects with high levels of
cerebral amyloidosis but who had no documented cognitive impairment, indicative of
AD, before their death. Moreover, in the halted AN1792 immunotherapy clinical trial,
follow-up autopsy of some individuals who had received anti-Aβ therapy and who had
died with progressive dementia, were found to be almost devoid of cerebral amyloid
deposition (Holmes et al., 2008). Furthermore, DS fetal tissues and cultured primary
fibroblasts do not show an overexpression of APP, arguing against a gene dosaging effect
for APP (Argellati et al., 2006; Cheon et al., 2003; Engidawork et al., 2001; Farrer et al.,
1997). On the other hand, duplication of the APP locus on Chromosome 21(Sleegers et
al., 2006), along with just 5-12 adjacent genes in the centomeric Down syndrome critical
region (Fuentes et al., 1995; Rahmani et al., 1989), has been reported in families with
autosomal-dominant early-onset AD, which coincided with cerebral amyloid angiopathy
(CAA) (Rovelet-Lecrux et al., 2006). Thus, these seemingly-conflicting observations
actually suggest that there may be other factors contained within the genes of the extra
Chromosome 21 that also predispose DS individuals to AD, especially since some DS
individuals develop onset of AD dementia by as early as their thirties. Besides APP, there
are about 323 other genes expressed on Chromosome 21 (Antonarakis, Lyle,
Dermitzakis, Reymond, & Deutsch, 2004),and some such as S100B, Dual-specificity
tryrosine (Y)-phosphorylation Regulated Kinase 1A (DYRK1A) and Down’s Syndrome
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Candidate Region-1(DSCR1, also known as RCAN1), have been described to contribute
to pathology consistent with AD.
S100B is an astrocyte-secreted cytokine, which stimulates phosphoinositide
hydrolysis by phospholipase C in order to mobilize intracellular calcium stores (Barger &
Van Eldik, 1992; Griffin et al., 1989). These actions are neurotrophic to neurons,
promoting neurite outgrowth, and to glia, promoting proliferation and differentiation
(Selinfreund, Barger, Welsh, & Van Eldik, 1990). However, lifelong overexpression of
S100B in DS individuals may actually cause a decrease in any trophic actions. For
instance, transgenic mice that overexpress human S100B have increased hippocampal
dendrites when they are young, but this dendritic density decreases throughout the age of
the mice, and young S100B mice also show behavioral and learning defects that may also
be analogous to DS developmental abnormalities (Whitaker-Azmitia et al., 1997). S100B
has been reported to have levels much more than 1.5 times as expected in DS brains than
for normal brains, throughout the entire life of the DS individual (Griffin et al., 1998).
These levels correlate with chronic overexpression of Interleukin-1 (IL-1) (Griffin et al.,
1989), and S100B regulates the expression of IL-1 in neurons by transcription factor,
Sp1, and in microglia and astrocytes by transcription factor, NFκB (nuclear factor kappalight-chain-enhancer of activated B cells) (L. Liu, Li, Van Eldik, Griffin, & Barger,
2005). IL-1 has been shown to induce Aβ production (Forloni, Demicheli, Giorgi,
Bendotti, & Angeretti, 1992; Goldgaber et al., 1989), and in turn, S100B and Aβ induce
IL-1 (Barger & Harmon, 1997; L. Liu et al., 2005), forming a feed-forward mechanism
that can contribute to AD pathogenesis, through Tau-related and other
neuroinflammatory actions.
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The kinase DYRK1A has also been shown to directly affect AD pathogenesis. For
instance, DYRK1A has been shown to interact with and directly phosphorylate tau and
APP in immortalized H19-7 hippocampal progenitor cells (J. Park, Yang, Yoon, &
Chung, 2007). It is known that DYRK1A mRNA levels in the hippocampus are
significantly elevated in patients with AD. In the brain of AD Tg mice, DYRK1A mRNA
levels were found to be upregulated along with an increase in Aβ deposition. In
neuroblastoma cells overexpressing tau, it was shown that Aβ induces an increase in the
DYRK1A transcript, which also leads to tau phosphorylation at Thr212 (R. Kimura et al.,
2007). Another study has shown that Tg mice that over-express human DYRK1A protein
have elevated phospho-Tau at serine-202 and serine-204, which are two
hyperphosphorylated Tau residues that are indicated in the formation of neurofibrillary
tangles (NFTs) (Ryoo et al., 2007). This group also demonstrated in mammalian cells that
APP is phosphorylated at Thr668 by DYRK1A , and that phospho-APP, Aβ, and
DYRK1A are elevated in the transgenic mice and in DS brains (Ryoo et al., 2008). Taken
together, DYRK1A over-expression induces a feed-forward mechanism with increased
Aβ deposition, which then induces additional DYRK1A expression, resulting in more Aβ
deposition and phosphorylation of both APP and Tau at sites consistent with AD
pathogenesis.
However, DYRK1A’s involvement with Aβ and Tau may be only a portion of its
role in AD pathogenesis. In a recent publication by Baek et. al., DYRK1A and DSCR1,
another gene mapped to Chromosome 21, were both shown to significantly inhibit
angiogenesis and provide compelling reason for why DS individuals do not develop solid
tumors (Hasle, Clemmensen, & Mikkelsen, 2000), since all solid tumors require
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neovascularization to grow larger than 2mm, invade tissues, and metastasize (Folkman,
1992). Both DSCR1 and DYRK1A suppress the VEGF-calcineurin angiogenic pathway.
This pathway is activated by VEGF binding to its receptor (VEGFR), which then causes
an intracellular cascade of events in which the transcription factor, Nuclear Factor of
Activated T-cells, cytoplasmic 2 (NFATc2), is dephosphorylated and activated and
translocates to the nucleus to induce Cox-2 expression (Hernandez et al., 2001).
Cox-2 expression and activity is also induced by various stimuli, including
hypoxia (Schmedtje, Ji, Liu, DuBois, & Runge, 1997), TNFα (Jones, Carlton, McIntyre,
Zimmerman, & Prescott, 1993), basic fibroblast growth factor (Kage et al., 1999), IL-1α
(Karim, Habib, Levy-Toledano, & Maclouf, 1996), and LPS (Inoue, Yokoyama, Hara,
Tone, & Tanabe, 1995). As mentioned above, Cox-2 is only expressed in reactive
microglia by LPS, and these other stimuli would only affect neuronal Cox-2 expression,
especially in AD-vulnerable pyramidal neurons (Hoozemans et al., 2001; Hoozemans et
al., 2002). Prostaglandin E2 (PGE2), the major end product from Cox-2 activity, is a
stimulator of angiogenesis (Form & Auerbach, 1983) and works by inducing the
up-regulation of the transcription factor Hypoxia-inducible Factor-1α (HIF-1α) (X. H.
Liu et al., 2002), which can then bind to promoter/enhancer elements of VEGF and other
hypoxia-sensitive genes (G. L. Wang, Jiang, Rue, & Semenza, 1995).
In the study of Baek et al., the authors report that just one extra allelic copy of
DSCR1 and DYRK1A are sufficient to prevent tumor growth and that this tumor
inhibition is directly related to DSCR1 and DYRK1A suppression of angiogenesis
through the VEGF-calicineurin pathway (Baek et al., 2009). One mechanism by which
DSCR1 could inhibit angiogenesis may be by binding to Raf-1 (Cho, Abe, Kim, & Sato,
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2005), putatively causing disruption of the retinoblastoma (Rb)-Raf-1interaction, and
preventing Raf-1 from phosphorylating and inactivating Rb, which when Rb is
inactivated, is involved in cell proliferation and VEGF-mediated angiogenesis (Dasgupta
et al., 2004). While the supernumerary expression of DYRK1A and DSCR1 may prevent
tumorigenesis, the resultant reduction in cerebral blood flow throughout life may also
predispose DS individuals to the deficient neurodevelopment observed in all DS
individuals. DS individuals have smaller brains than normal and also have less density of
neurons. Their neurons have ramified dendritic trees, but the number and complexity of
them does not progress through age, causing the neurons to be described from
histochemistry as having “a tree in winter” type of appearance (Takashima, Becker,
Armstrong, & Chan, 1981; Takashima, Iida, Mito, & Arima, 1994).
The vascular and nervous systems are intricately associated throughout
neurodevelopment, with the same classical axonal-guidance proteins, such as netrins,
ephrins, semaphorins, and slits, also being used as the cues to direct the cerebral blood
vessel growth down predestined tracks (Carmeliet, 2003; Carmeliet & Tessier-Lavigne,
2005; Weinstein, 2005; Zacchigna, Lambrechts, & Carmeliet, 2008). Both nerves and
blood vessels grow together to their ultimate destination, and VEGF regulates neuronal
patterning of some types of neurons (Schwarz et al., 2004). One could thus hypothesize
that the reduced cerebral blood flow from birth may contribute to the developmental
cognitive deficits seen in DS individuals, as well as contributing to the later onset of
severe AD pathogenesis, by both anti-angiogenic and amyloidogenic mechanisms. In
support of this hypothesis, an epidemiological study in 1987 of 14 DS individuals, 46 AD
patients, and 114 age-matched controls showed that DS patients have a similar reduction
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in cerebral blood flow throughout their brains as do AD patients (Melamed, Mildworf,
Sharav, Belenky, & Wertman, 1987). It is similarly noteworthy that people with the
ApoE4 genotype, who are at very high risk for developing AD, have widespread decline
in regional cerebral blood flow over time and before they develop onset of dementia
(Thambisetty, Beason-Held, An, Kraut, & Resnick, 2010). Furthermore, it is plausible
that the anti-angiogenic effects from Cox-2 inhibition (Hyde & Missailidis, 2009; Raut et
al., 2004; L. Wang, Chen, Xie, He, & Bai, 2008) may indeed be an underlying factor for
many of the failures of the NSAID clinical trials against AD, as reversal of AD would not
only require removal of cerebral amyloidosis, but also would subsequently require
neovascularization to correct the truncated and occluded microvasculature where the
plaques were located (Meyer et al., 2008).
Besides the greater than 1.5 times overexpression from gene loading of the APP,
S100B, DYRK1A, and DSCR1 genes described above, there are other factors within
trisomy 21 cells that may also contribute to AD pathogenesis, such as the involvement of
kinesins and dyneins, which play roles in the chromosomal duplication and missegregation during mitosis and meiosis, as well as in axonal transport in mature neurons.
It has been hypothesized that in normal individuals, defective mitosis, likely due to
microtubule (MT) dysfunction, may generate the accumulation of trisomy 21 cells in
their bodies throughout life, and within the brain it could contribute to the development
of AD, just as trisomy 21 invariably predisposes DS individuals to AD (Potter, 1991).
Many studies have confirmed that trisomy 21 mosaicism may indeed contribute to AD
pathogenesis, as trisomy 21 and other aneuploid cells have been found in primary skin
fibroblast cultures of both familial (genetically predispositioned to develop AD early in
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life) AD patients and sporadic (occurring later in life) AD patients (Geller & Potter,
1999), as well as trisomy 21 being found in peripheral leukocytes, buccal cells, and brain
neurons of sporadic AD patients (Iourov, Vorsanova, Liehr, & Yurov, 2009; Migliore et
al., 1999; Mosch et al., 2007; Thomas & Fenech, 2008; Yang, Geldmacher, & Herrup,
2001). Mothers, who have a DS child before the age of 35, have a five times greater risk
of developing dementia, with trisomy 21 mosaicism being found in their lymphocytes,
than that of control mothers (Migliore et al., 2006; Schupf, Kapell, Lee, Ottman, &
Mayeux, 1994). Sporadic AD patients, who develop AD in mid-life, have been found to
have between 1-10% trisomy 21 mosaicism, suggesting that even minimal amounts of
aneuploidic mechanisms are sufficient to induce their early AD onset (Puri, Zhang, &
Singh, 1994; Ringman, Rao, Lu, & Cederbaum, 2008; Rowe, Ridler, & Gibberd, 1989).
It can also be predicted under this chromosome mis-segregation/MT hypothesis
for AD that the same genes that are responsible for familial AD onset when mutated
might also participate in the cell cycle, mitotic machinery, and contribute to trisomy 21
mosaicism. Indeed it has been shown that polymorphisms in PS-1 cause an increased risk
of both AD onset and propensity to have DS children (Higuchi, Muramatsu, Matsushita,
Arai, & Sasaki, 1996; Lucarelli et al., 2004; Petersen et al., 2000; Wragg, Hutton, &
Talbot, 1996). It has also been shown that endogenous PS-1, APP, their proteolytic
products, and their interacting proteins are intricately involved in the mitotic process and
cell cycle, being localized at the nuclear envelope, centrosomes, or kinetochores and also
being involved in microtubular transport (Honda et al., 2000; Johnsingh et al., 2000; N.
Kimura et al., 2001; J. Li, Xu, Zhou, Ma, & Potter, 1997; Nizzari et al., 2007; Tezapsidis,
Merz, Merz, & Hong, 2003; Zimmermann et al., 1988; Zitnik, Wang, Martin, & Hu,
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2007). Aberrant incomplete neuronal re-entry of the cell cycle has been implicated in the
neurodegeneration of AD pathogenesis (Ogawa et al., 2003; Varvel et al., 2008; Vincent,
Rosado, & Davies, 1996), as evidenced by about 3% tetraploid neurons and about 30%
aneuploid cells (between 2n and 4n) in late-stage AD patients (Mosch et al., 2007; Yang
et al., 2001). It is also known that APP and Tau are hyperphosphorylated during mitosis
and contribute to paired helical filaments, the precursors of NFTs (Pope et al., 1994;
Preuss, Doring, Illenberger, & Mandelkow, 1995; Suzuki et al., 1994).
As mentioned above, trisomic overexpression of S100B induces chronic IL-1
expression (Griffin et al., 1989), which in turn induces the expression of
alpha-1-antichymotrypsin (ACT), an acute phase serine protease inhibitor, which
promotes polymerization of Aβ (Abraham, Shirahama, & Potter, 1990; Das & Potter,
1995), Tau hyperphosphorylation, and neuronal apoptosis (Padmanabhan et al., 2006). A
recent study examining transgenic (Tg) mice with FAD mutant forms of APP or PS-1
showed that aneuploidy is significantly induced in both the spleen and in the brain of the
mice compared to wild-type age-matched controls, and that these findings are confirmed
in transfected mammalian cells. Moreover, the authors showed that administration of
either of the prevalent Aβ species (1-40 and 1-42), and only to normal cells containing
APP and Tau, induce rapid chromosome mis-segregation and aneuploidy, highlighting a
mechanism by which Aβ disrupts MT function and induces more aneuploidy. Thus DS
individuals, who are predisposed to accumulation of cerebral Aβ deposition as they age,
will have more aneuploidy and MT defects, which will affect neurogenesis and neuronal
function, and which will also contribute in a feed-forward mechanism for additional
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amyloidosis, aneugenesis, and progressive dementia (Granic, Padmanabhan, Norden, &
Potter, 2010).
Conclusions and Research Theory. The above-described feed-forward
mechanisms of Aβ to propagate itself through DYRK1A’s up-regulation and vice versa,
for Aβ to disrupt MT function and result in more aneuploidic and trisomic 21 cells, for
these effects to reduce cerebral blood flow and prevent neovascularization through
DSCR1 and DYRK1A, and for the resultant up-regulated and self-propagating S100BIL-1-ACT-Aβ neuroinflammatory Aβ polymerization pathway, which all work in
combination to deposit extracellular amyloid plaque, to induce intraneuronal tauopathy,
and to cause cerebral microvascular occlusions and dystrophic neurites surrounding the
amyloid plaques, portrays the insidious but progressive nature of Alzheimer’s disease.
Thus in theory, to inhibit and reverse AD pathology, there must first be simultaneous
strategies to remove the cerebral amyloidosis and to provide neuroprotection to the
micro-penumbras that surround the plaques and occluded vessels. Then after removal of
amyloid, there must be strategies to immediately induce neovascularization in the
infarcted areas where the plaques were located and to also induce neuritogenesis and/or
neurogenesis to rebuild the neural and vascular networks in order to restore cognitive
function. The following chapters report on the investigation of a biological therapeutic,
whose human analogue has been safely used for two decades in leukopenic patients, and
which has actions that attack all of these defects just described in the preceding theory.
The next chapter will first outline the rationale, investigative plan, and working
hypotheses, and the following chapters continue with the results and conclusions of the
experiments. These experiments shed light on the inverse relationship between
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Rheumatoid arthritis and Alzheimer’s disease, and putatively indicates a therapeutic for
AD which quickly removes amyloid deposition in aged transgenic AD mice by two
different routes of administration, which quickly reverses cognitive impairment following
daily peripheral subcutaneous administration, while also increasing synaptic area and
microglial density, and which has been reported to be neuroprotective in the penumbras
of ischemic infarcts, to induce cerebral neovascularization after ischemic infarct, and to
stimulate the proliferation and differentiation of neural stem cells, which are known to
migrate to sites of cerebral injury.

29

Figure 1. Extensive Cerebrovascular Damage in AD. Artistic rendition of scanning
electron microscopy results (Meyer et al., 2008) in which specialized polurethane resin
was perfused into aged APP23 mice, and in which the resultant corrosion casting reveals
microvessel distortions, occlusions, and truncations in the cerebrovasulature that
surrounds the area which contained an amyloid plaque, that was chemically removed
during the VCC processing of the tissue.
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CHAPTER 2 – RESEARCH RATIONALE
Introduction
In the period leading up to 2006, our interest in the role of inflammation in AD
led us to think that perhaps RA protected against AD not because of the use of NSAIDs
but because of some intrinsic anti-inflammatory or possibly inflammatory factor released
during RA. This interest came to a head as a consequence of NSAID clinical trial failures
in AD patients and we began to look again at the inverse relationship of RA and AD. If
indeed, the NSAIDs are not responsible for preventing AD, a neurodegenerative disorder,
then there must be some intrinsic characteristic(s) of RA pathogenesis itself, a peripheral
disorder, that has the capability to traverse the body and reach the brain, where it would
exert its protective effects. Since RA is a highly-inflammatory autoimmune disease, both
aspects of the immune system, innate and adaptive, could potentially be acting against
AD, including not only the various cells of the immune system, but also through their
secreted products. This chapter will examine these cellular characteristics of RA that may
impact AD pathogenesis and outline the research plan to investigate RA as a negative risk
factor of AD from a non-NSAID perspective.
Secreted Factors in RA and AD
Many of the factors (Chapter 1) that are up-regulated in RA pathogenesis have
also been reported to have circumstantial relationships in AD pathogenesis. For instance,
Macrophage Migration Inhibitory Factor (MIF) has been found to have the ability to act
as an Aβ-binding protein (Flex et al., 2004; Lashuel et al., 2005), and is absolutely
necessary for the progression of RA, as MIF-deficient mice do not develop experimental
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arthritis and anti-MIF neutralizing antibodies ameliorate RA in mouse models (Onodera
et al., 2007; Popa et al., 2006). MIF has also recently been shown to be up-regulated in
the brains of transgenic AD mice, and in the cerebrospinal fluid of MCI and AD patients,
and it is proposed to contribute to the neuroinflammation of AD, since MIF is a known
cytokine that elicits production of other inflammatory mediators, such as TNFα, IL-6, and
IFNγ (Bacher et al., 2010; Bryan et al., 2008; Popp et al., 2009). In fact, in vitro studies
show that murine and human neuronal cell lines are protected from Aβ-induced cellular
toxicity by Iso-1, a small molecule inhibitor of MIF (Bacher et al., 2010). On the other
hand, MIF’s functions have not all been elucidated, as a recent paper reports that MIF is
actually expressed by astrocytes in the CNS and is involved in hippocampal cell
proliferation. In this study, it was found that MIF is expressed in the subgranular zone of
the dentate gyrus within neurogenic stem cells, cells undergoing proliferation, and in
newly proliferated cells, but not in mature neurons, microglia, or oligodendrocytes. MIF
antagonism by Iso-1 and in MIF knockout mice resulted in behavioral dysfunction and
impaired hippocampus-dependent memory (Conboy et al., 2010).
Monocyte Chemoattractant Protein-1, (MCP-1, also known as CCL2: chemokine
C-C motif ligand 2), IL-6, and IL-8 have also been reported to be up-regulated in both
RA and AD (Ishizuka et al., 1997; Sokolova et al., 2009), but contrasting studies have
reported that while MCP-1 is elevated in MCI patients, its expression is lost as MCI
patients progress to AD (Dawson, Miltz, Mir, & Wiessner, 2003; Galimberti et al., 2006).
Another study reports elevated levels of osteoprotegerin (OPG) in AD and Vascular
Dementia patients, proposes a role for OPG in microglia function and phagocytosis of Aβ
plaques, and suggests that OPG could be a biomarker for these diseases (Emanuele et al.,
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2004).TRAF6 (TNF receptor-associated factor 6), also known as E3 ubiquitin ligase, is
involved in the ubiquination of Tau, as shown in TRAF6-knock out mice (Babu, Geetha,
& Wooten, 2005). TRAF6 is also activated, along with NFκB, after proteolysis of
membrane receptors, p75NTR and neurotrophin receptor homolog NRH2 (Kanning et al.,
2003). Like APP and Notch, p75NTR is a ligand for γ-secretase intramembrane cleavage
after α-secretase extracellular domain cleavage. The α-secretase that is expressed in RA
for the cleavage of RANKL and the T lymphocyte chemokine, soluble CXCL16, is
ADAM10. ADAM10 is found abundantly expressed by RA macrophages expressing the
chemokine, CXCL16, which is involved in effector/memory T cell function (van der
Voort et al., 2005), and anti-TNFα therapy for RA down-regulates this CXCL16
expression (van Lieshout et al., 2007). In the brain, ADAM10, along with PS1, works to
cleave N-cadherin following NMDA activation, and this activity has been found to be
inhibited in an AD mouse model (Uemura et al., 2007). Furthermore, ADAM10 overexpression has been shown to decrease Aβ plaque formation and prevent cognitive
deficits in another AD murine model (Fahrenholz & Postina, 2006; Postina et al., 2004).
There are also angiogenic factors contributing to the pannus growth in RA that are
associated with AD pathogenesis, such as Insulin-Like Growth Factor 1 (IGF-1), which is
upregulated in RA synovial fluid, but is reduced in the AD brain, and has been associated
with cognitive deficits (Rivera et al., 2005; Svensson et al., 2006). IGF-1 levels are
similarly decreased in patients with Diabetes Type II, a positive risk factor for AD onset,
and it is reported that systemic administration of IGF-1 in diabetic rats prevents cognitive
deficits (Lupien, Bluhm, & Ishii, 2003, 2006). VEGF’s relationship in AD pathology is
still not completely clear and has been debated in the literature. Although it is reported to
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bind Aβ and to be found associated with amyloid plaques, reports also suggest VEGF to
have neuroprotective activity (Moser & Humpel, 2005; S. P. Yang, Kwon, Gho, & Chae,
2005). VEGF upregulation and endothelial activation are found in AD brain, even
though cerebrovascular degeneration occurs and correlates with Aβ deposition (Miao et
al., 2005; Schultheiss et al., 2006). A recent study investigating cardiovascular disease in
PS2/APP mice, reported that administration of IGF-1 improved cognitive function,
reduced VEGF levels, reduced endothelial cell proliferation, and thus normalized
vascular density (Lopez-Lopez, Dietrich, Metzger, Loetscher, & Torres-Aleman, 2007).
Although many of these above-mentioned inflammatory mediators participate in
the chronic neuroinflammation that contributes to AD pathogenesis, if they are also
up-regulated in RA pathogenesis, it would not be expected that these specific factors are
the reason for the inverse relationship between RA and AD. On the other hand, if they are
deficient in AD, but are up-regulated in RA, they might provide insight into RA’s
protective effect against AD. However, they would also have to be secreted in high
enough concentrations to be able to circulate through the vasculature, reach the brain,
cross the Blood Brain Barrier (BBB), and initiate a set of protective events against AD
onset. These actions would be very improbable without affecting all other organ systems
in the process, which would have been reported in all RA patients. Since this is not the
case, the peripheral secretion of inflammatory mediators may not be the most likely
reason for RA and AD’s inverse relationship. Nonetheless, they cannot all be completely
ignored in this comparison, since they are secreted by the leukocytes of RA, which do
have the ability to traverse the circulatory system, diapedese across the BBB, and could
secrete these factors into the brain’s parenchyma to elicit protective effects. Of all the
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above-mentioned factors, a couple that are deficient in AD, but are upregulated in RA,
are IGF-1 and ADAM10, and these do have the potential to provide benefit to AD
pathogenesis if they can localize into the brain parenchyma. However, they are
secondary to the RA-induced leukocytes, which must secrete them into the brain, and
thus the primary focus for elucidating RA’s negative risk factor against AD should be on
the leukocytes themselves.
Leukocytes in RA and AD
Although up-regulated leukocytes in RA could potentially enter into the brain
and inhibit development of AD pathology and/or neuronal dysfunction, lymphocytic
infiltrates into AD patient brains have not been reported. The lack of lymphocyte
infiltration suggests that RA-induced proliferation and activation of the innate immune
system might be responsible for preventing AD pathology in RA patients. Evidence
supporting the innate immune system’s role in AD pathogenesis show that bone marrowderived microglia play a critical role in restricting amyloid deposition, and indeed,
microglia activation and many associated receptors and enzymes, such as CD36,
scavenger receptor A, receptor for advanced glycation end products, neprilysin, insulysin,
and matrix metalloproteinases, decline with age as risk of AD pathology increases (J. El
Khoury et al., 2007; Hickman, Allison, & El Khoury, 2008; Simard, Soulet, Gowing,
Julien, & Rivest, 2006). Further evidence implicating the role of the innate immune
system in AD are that complement proteins are highly up-regulated in AD brain, and that
inhibition of C3 convertase significantly increases amyloid pathology in AD mice (WyssCoray et al., 2002). A chronic upregulation of complement proteins in AD suggests that
innate leukocytes need to also be increased to phagocytically remove the complement51

bound complexes, via the complement receptors that they contain on their surface. Both
the complement system and the ability for peripheral phagocytes to enter the brain
represent two broad immunological areas of active research that show many implications
in the pathogenesis of AD, and which will be discussed further in the following sections.
Complement System and its Involvement in AD
Overview. The complement system is a cascade of about 30 cell bound or
circulating proteins that aid in the clearance of immune-stimulatory molecules, whether
contained on pathogens, on endogenous cells, or secreted within the body. As part of the
innate immune system, the complement system is a powerful amplifier and mediator of
inflammation, and functions to opsonize antigens for phagocytosis, to release chemotactic
molecules for attracting phagocytes, to lyse membranes of cells via the membrane attack
complex (MAC), to aggregate antigenic proteins, to induce naïve B lymphocyte
activation, and to neutralize viral activity (Carroll, 2008; Jayasekera, Moseman, &
Carroll, 2007; Roitt IM, 1998). The complement system is activated in three biochemical
pathways, known as the classical (since it was first identified), the lectin, and the
alternative pathways (see Figure 2 for an overview of the complement cascade) .
Classical Pathway. The classical complement pathway is usually activated by
either IgM or IgG binding to an antigen, which then triggers complement component,
C1q, to bind to the first conserved regions of these immunoglobulins. Clq can also bind
independent of antibodies to DNA, RNA, C-reactive protein, serum amyloid P, LPS
(from Gram - bacteria), fungal/viral membranes, and in AD, it has been shown to bind
directly to amyloid plaques (Afagh, Cummings, Cribbs, Cotman, & Tenner, 1996;
Eikelenboom, Hack, Rozemuller, & Stam, 1989; Jiang, Burdick, Glabe, Cotman, &
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Tenner, 1994; Rogers et al., 1992; Tacnet-Delorme, Chevallier, & Arlaud, 2001;
Veerhuis, Janssen, Hack, & Eikelenboom, 1996; Zanjani et al., 2005). C1q binding
causes a conformational change in itself, which activates two molecules of the serine
protease, Clr, to cleave and activate two molecules of another serine protease, Cls. This
process results in the formation of the C1 complex (C1q-C1r2-C1s2), which then acts to
cleave complement components C4 and C2 into C4a, C4b, C2a, and C2b. The binding of
C4b and C2a form the C3-convertase (C4b2a) of the classical pathway.
Although the regulatory protein for C1 complex, C1-inhibitor, is normally
produced in the brain and is the only known inhibitor of C1r and C1s, it has been found
in human AD brains to be cleaved and this reacted form is localized to dystrophic
neurites and neuropil threads (Walker, Yasuhara, Patston, McGeer, & McGeer, 1995).
C1-inhibitor has also been found to be slightly elevated only in the regions of prominent
AD pathology, such as the entorhinal cortex, hippocampus, medialtemporal gyrus and
medialfrontal gyrus, but this slight over-expression is unable to inhibit complement
activation (Yasojima, McGeer, & McGeer, 1999). Of particular interest is the finding
that the N-terminal 1-11 region of the Aβ1-42 peptide binds to C1q and activates the
classical complement cascade in the absence of C1-inhibitor and at a physiological ratio
of up to 8:0 of C1-inhibitor:C1 (Tacnet-Delorme et al., 2001). This finding might explain
a relationship between both ACT (Ma, Brewer, & Potter, 1996; Ma, Yee, Brewer, Das, &
Potter, 1994; Potter, Wefes, & Nilsson, 2001) and the inhibition of the complement
cascade to exacerbate cerebral amyloid deposition (Wyss-Coray et al., 2002).
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Lectin Pathway. The lectin complement pathway is similar to the classical
pathway, except that ficolins and mannose-binding lectin (MBL) are the opsonins, which
then activate the MBL-associated serine proteases (MASP)-1 and -2, in a manner
analagous to the C1r and C1s, respectively. The ficolin- or MBL-MASP1,2 complex then
splits C4 and C2, resulting in the same C3-convertase, C4b-2a. MBL, similar in structure
to Clq (J. Lu, Wiedemann, Timpl, & Reid, 1993)and ficolins (types L, H, or M in
humans) are pattern-recognition molecules, with MBL binding mannose (J. H. Lu, Thiel,
Wiedemann, Timpl, & Reid, 1990), N-acetylglucosamine (GlcNAc, a component of
Gram + bacterial cell walls), and some forms of LPS (Neth et al., 2000), and with ficolins
binding various N-acetylated saccharides, including GlcNAc (Matsushita, 2009). Ficolins
have not been implicated in AD, but H-Ficolin has been shown to be highly expressed by
human astrocytic glioma cell lines (Kuraya, Matsushita, Endo, Thiel, & Fujita, 2003). On
the other hand, while serum levels of MBL have been found to be associated with the
cerebrovasculature at similar levels in both AD patients and normal controls, MBL is
reduced in the cerebrospinal fluid of AD patients as compared to controls, suggesting
increased MBL consumption is associated with complement activation in AD patients
(Lanzrein et al., 1998).
Alternative Pathway. The alternative complement pathway is activated
independent of C4 and C2 and initiates in a process called “C3 tickover”, which is the
spontaneous reaction between C3 and water to break C3’s internal thioester bond and
form iC3 (C3-H2O), which induces a conformational change that allows the serum
protein, complement Factor B, to bind and form the iC3B complex. This iC3B complex
allows, in the presence of Magnesium (Mg2+), for Factor D, a serine protease also known
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as adipsin, which is released into the blood by adipocytes, to cleave Factor B into Ba and
Bb, leaving the fluid-phase alternative complement pathway C3-convertase (iC3Bb). This
activated iC3Bb can then cleave circulating C3 into C3a and C3b, but fluid-phase iC3Bb
is liable for proteolytic degradation unless it comes in contact with a surface to bind, in
which case another serum protein, Factor P (also known as properdin), will bind and
stabilize the complex, forming iC3Bb-P, which is now a surface-bound C3-convertase
capable of cleaving many molecules of C3 and forming a positive feedback amplification
loop (Roitt IM, 1998).
It was initially thought that only the classical complement pathway was involved
in AD, and not the alternative pathway (McGeer, Akiyama, Itagaki, & McGeer, 1989).
However, it has recently been shown that the alternative pathway components, Ba and
Bb, as well as the regulatory protein, Factor H, are indeed increased in AD brain
compared to controls (Strohmeyer, Ramirez, Cole, Mueller, & Rogers, 2002; Strohmeyer,
Shen, & Rogers, 2000). Furthermore, the Chromosome 13 dementias, familial British
dementia (FBD) and familial Danish dementia (FDD), which present with
neuropathological similarities as AD, such as neurodegeneration, NFTs, parenchymal and
vascular cerebral amyloidosis, and associated gliosis, have positive immunohistochemical
staining for activated complement components of both the classical and alternative
pathways associated with their pathology (Rostagno et al., 2002).
C3-Convertase. Both the surface-bound C4b2a C3-convertase from the classical
and lectin pathways and the iC3Bb-P C3-convertase work to amplify the production of
the opsonin C3b and release the chemotaxin C3a. In this amplification loop, newly
cleaved C3b can covalently bind a surface and intiate the same alternative pathway with
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Factor B binding, then C3bB getting cleaved by Factor D in the presence of Mg2+, and
leaving a new surface-bound C3-convertase, C3bBb which continues the amplification
loop (Roitt IM, 1998).
As with any feed-forward mechanism, there needs to be regulatory proteins to
inhibit uncontrolled amplification, and if left unchecked, there would be complete
depletion of complement component C3 (which is analogous to the effects of cobra
venom in the body (Janssen et al., 2009)). Some regulation occurs by the released soluble
C3b being quickly hydrolyzed and inactivated by water, unless it comes into contact with
a surface that it can covalently bind first. Also, the fluid-phase iC3bBb undergoes rapid
dissociation, by the binding of soluble Factor H. Surface-bound C3b can be cleaved by
Factor I, using Factor H as a cofactor, to produce surface-bound inactive C3b, which can
then undergo additional cleavage by Factor I to split inactive C3b into C3c and C3dg.
This last step to produce C3c and C3dg occurs with the help of Complement Receptor 1
(CR1, also known as CD35) and with Membrane Cofactor of Proteolysis (MCP, also
known as CD46). Both CR1 and MCP are membrane-bound and work in the
disassociation of the classical C3-convertase, C4b2a. Another regulator, C4-binding
protein (C4BP), cleaves activated C4 before it can act on C2 to inhibit the formation of
the classical C3-convertase, as well as being another cofactor for Factor I. The final
known human regulator of C3-convertase is surface-bound Decay Accelerating Factor
(DAF, also known as CD55) which competes with Factor B on the cell surface to inhibit
the C3bBb complex, as well as inducing the disassociation of Bb and C2a from
already-formed C3-convertases (Roitt IM, 1998). In mice, the widely-expressed regulator
on most cell membranes, Complement receptor-1related gene/protein Y (Crry), functions
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as the structural analog of both DAF and MCP, and is the main inhibitor of
C3-convertase in mice, blocking both the classical and alternative pathways.
C3 and AD. Many of the components and regulators in the formation of
C3-Convertase have been implicated in the pathogenesis of AD. Amyloid plaques have
been examined by electron immuno-microscopy and found to contain C3b, C3c, C3d, C4,
as well as C1q on the amyloid fibrils, but not elsewhere such as normal or degenerative
neurites, NFTs, and glial cells (Eikelenboom & Stam, 1982; Ishii & Haga, 1984).
Furthermore, Aβ was shown to actually induce the production of C3 in primary
microglial cultures (Haga, Ikeda, Sato, & Ishii, 1993), and as already mentioned, the
experimental blockage of C3-convertase, by the overexpression of soluble Crry (sCrry),
resulted in increased amyloid deposition in transgenic AD mice. Conversely, it was also
shown that increased C3 production resulted in decreased amyloidosis (Wyss-Coray et
al., 2002).
The C4BP regulator has also been found localized to amyloid plaques, to directly
bind Aβ, to bind to apoptotic and necrotic cells, but not to bind to viable astrocytes,
neurons, or oligodendrocytes (Trouw et al., 2008). Whether C4BP has a protective or
deleterious effect in AD is not known. Of similar association with AD is Factor D
(Adipsin), which is upregulated when γ-Secretase is inhibited (Searfoss et al., 2003), and
thus may play a role in FAD with PS mutations, or since it is highly expressed in obese
individuals, may contribute to Type II Diabetes (Flier, Cook, Usher, & Spiegelman,
1987), a positive risk factor for AD. Also of unknown relevancy to AD pathogenesis is
Factor H, mentioned above to be upregulated in late onset AD (Strohmeyer et al., 2002),
and which was reported to correlate in abundance with disease prognosis (Hye et al.,
57

2006). However, polymorphisms in Factor H were not found to be related to late onset
AD (Hamilton et al., 2007).
One regulator of C3 that does have significant involvement with AD pathogenesis
is Complement Receptor-1 (CR1, also known as CD35). CR1 is located on B
lymphocytes, glomerular epithelial cells, follicular dendritic cells,
monocytes/macrophages, neutrophils, and especially on erythrocytes (Lambert et al.,
2009; Roitt IM, 1998). While CR1’s actions to inhibit the formation of C3-convertase
was described above and is certainly important in preventing excessive C3-convertase
activity, CR1’s major role in the pathogenesis of AD may be peripheral, instead of
parenchymal, since it is most abundantly expressed on erythrocytes. CR1’s major ligands
are C3b, iC3b, C4b, and C1q, which are all capable of binding Aβ, as described above,
and aggregated Aβ can bind C3b and activate C3’s production (Kuo et al., 2000; Rogers
et al., 2006; Webster, Bradt, Rogers, & Cooper, 1997) . A recent 2009 large
genome-wide association study (GWAS) of 6010 AD patients and 8625 control
individuals from France, Belgium, Finland, Italy, and Spain found that the genes for CR1
and CLU (clusterin, also known as ApoJ, another complement regulator described below)
were confirmed as risk loci for AD, in addition to the other known susceptibility locus of
ApoE (Lambert et al., 2009). An earlier study looking at the amount of erythrocyte-bound
Aβ within the blood of AD, MCI, and non-demented (ND) individuals, showed that AD
patients had the least amount of bound Aβ, and that MCI patients had more bound than
AD but significantly less than ND individuals (Rogers et al., 2006), suggesting that
C3-dependent adherence of Aβ to erythrocytes may provide for its clearance from the
bloodstream (Kuo et al., 2000; Zhou, Fonseca, Pisalyaput, & Tenner, 2008). Ligand
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bound to erythrocytic CR1 is removed via the CR1g receptors on liver Kupffer
macrophages (Helmy et al., 2006; Wiesmann et al., 2006), and thus provide a mechanism
for peripheral clearance of parenchymal-to-blood transport of Aβ.
C3 Receptors. There are 4 known receptors (CR1, CR2, CR3, and CR4) that
bind the three surface-bound C3 products (C3b, iC3b, and C3dg). CR1, just described
above, can bind to C3b and iC3b. CR2 (also known as CD21), expressed on B
lymphocytes, follicular dendritic cells, and some epithelial cells, binds iC3b and C3dg
and functions in roles independent of AD pathogenesis. However, CR3 (also known as
CD11b/CD18) and CR4 (also known as CD11c/CD18) are expressed on monocytic
lineage innate leukocytes and microglia, and they both bind C3b and iC3b, and can
function to promote phagocytosis and removal of complement-bound Aβ complexes
(Choucair-Jaafar et al., 2010). An increase in the amount of these phagocytic receptors
could presumably aid in the clearance of amyloid plaque from the brain. The phagocytes
containing these receptors,will be discussed further in the section below, “Leukocyte
Recruitment in the Brain”.
Formation of the Membrane Attack Complex (Figure 2). After the formation
of either C3-convertase, complement component C3 is cleaved into C3a and C3b. C3a is
released into the fluid phase and C3b remains to bind with either C3-convertase to form
the two C5-convertases, C4b2a3b and iC3BbC3b-P, which then can cleave complement
component C5 into C5a and C5b. As with C3a, C5a is also released into the fluid phase
and C5b remains with the complex in the progression of the full complement cascade to
the Membrane Attack Complex (MAC), which forms a hydrophobic pore through the
cellular membrane upon which the complement is attached, usually resulting in lysis of
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the cell. The components C6 through C9 bind stepwise and non-enzymatically, with the
binding of C7 beginning the hydrophobic interactions within the membrane. Up to
fourteen C9 components may bind in the formation of the MAC. As with the prior steps
of the complement cascade, the formation of the MAC is also tightly regulated. The
three known regulators of the complement cascade after C5-Convertase are Vitronectin
(also known as the S-protein), Protectin (also known as CD59), and Clusterin (CLU, also
known as ApoJ).
Regulation of the MAC.
Vitronectin. Vitronectin is a plasma protein that acts to inhibit the formation of
the MAC in either of two ways. It can prevent the C5b-7 complex from binding the
membrane, resulting in soluble C5b-7 (sC5b-7), which is lytically-inactive, or it can
prevent the polymerization of C9 (Podack, Kolb, & Muller-Eberhard, 1977; Podack &
Muller-Eberhard, 1978; Sheehan, Morris, Pussell, & Charlesworth, 1995). Vitronectin is
a multifunctional glycoprotein that has other roles besides complement regulation, such
as cellular adhesion, coagulation, and fibrinolysis ( Reviewed in (Preissner, 1989)).
Vitronectin has also been shown to be involved in the migration of smooth muscle cells
through the vitronectin receptor, αVβ3 integrin (Brown, Lundgren, Nordt, & Fujii, 1994),
and to play an essential role in vascular remodeling of human microvessel endothelial
cells (Salasznyk et al., 2007; Wilcox-Adelman, Wilkins-Port, & McKeown-Longo,
2000). Thus, Vitronectin may be responsible for participating in the aberrant
vascularization around amyloid plaques, as was illustrated by the VCC of Tg AD mice in
Figure 1 (Chapter 1). Vitronectin has also been found within AD amyloid plaques and
thoughout the body in other amyloid pathologies, such as in deposits associated with age60

related macular degeneration, atheroslcerosis, systemic amyloidosis, and deposits within
the glomeruli. Furthermore, Vitronectin was recently reported to readily form soluble
amyloid oligomers and fibrils itself, although these actions are not known to be relevant
in vivo (Shin et al., 2008). Thus the exact roles of Vitronectin in AD pathogenesis are
still unclear.
Protectin. Protectin (also known as CD59) is a membrane-bound protein that
inhibits the final step in MAC formation, by binding to C8 and preventing the
polymerization of the C9 subunits. CD59 is constitutively expressed at low levels in
neurons and oligodendrocytes and it is slightly upregulated during complement activation
(McGeer et al., 1991). Using CD59 knockout mice (Holt et al., 2001), CD59 has been
shown to play a protective role against neurodegeneration following traumatic brain
injury (Stahel et al., 2009), and thus CD59 might also be expected to be neuroprotective
against dementia pugilistica. Another recent report has also shown that CD59 is
neuroprotective after cerebral ischemia (Harhausen et al., 2010). However in AD, the
expression of CD59 has been reported to be deficient, and that this deficiency may
contribute to AD pathogenesis (L. B. Yang, Li, Meri, Rogers, & Shen, 2000; Yasojima et
al., 1999).
Clusterin. Clusterin (also known as ApoJ), like vitronectin, is a plasma protein
that has multifunctional roles in the CNS. Clusterin acts, along with vitronectin, to
inhibit the insertion of the MAC into the cell membrane, by binding to the C7 and
β-subunits of C8 and C9 and resulting in a lytically-inactive clusterin- and
vitronectin-bound soluble MAC (SMAC) (Tschopp, Chonn, Hertig, & French, 1993).
Systemically, SMAC has been described as part of circulaing imune complexes, which
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have been found in renal tissue deposits and implicated in SLE pathogenesis (Chauhan &
Moore, 2006; Murphy, Davies, Morrow, & d'Apice, 1989). In the CNS, Clusterin was
first demonstrated in 1990 to be increased in the hippocampus of AD patients, and to be
expressed within pyramidal neurons and some non-pyramidal neurons of the
hippocampus and entorhinal cortex (May et al., 1990). It was proposed that clusterin may
be involved in the neuroprotection from complement-mediated cell lysis (May & Finch,
1992). As mentioned above, Clusterin’s gene was also found in the GWAS to be a major
risk locus for the development of AD (Lambert et al., 2009). Clusterin, protectin,
vitronectin, and C5-9 components have all been detected colocalized with dystrophic
neurites and NFTs in AD and DS (McGeer et al., 1989; McGeer, Kawamata, & Walker,
1992; Stoltzner et al., 2000; Zanjani et al., 2005), but of these, only clusterin and
vitronectin were found to intensely stain amyloid plaques, and clusterin had only
scattered staining with NFTs (McGeer et al., 1992). In the study by Yasuhara et al.
(1994) of the tauopathy, Pick’s disease, virtually all of the Pick bodies, contained within
the dentate fascia, hippocampal pyramidal layers, entorhinal cortex, and affected
neocortices were strongly immunopositive for MAC and protectin, but were weakly
stained for vitronectin, and did not stain at all for clusterin. However, clusterin did
strongly stain pyramidal neurons in the parahippocampal gyrus, including ballooned
ones, as well as in some scattered neurons of the affected cortical areas (Yasuhara, Aimi,
McGeer, & McGeer, 1994). Taken together, these studies show that Protectin, which has
insufficient levels in AD, can be found in areas of extreme tau pathologies, while the
soluble vitronectin and clusterin MAC inhibitors are deficiently expressed, although
vitronectin and clusterin do strongly associate with amyloid plaques, which are not
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colocalized with NFTs in AD pathology. Thus, it could be hypothesized that in AD,
clusterin and vitronectin are being sequestered by Aβ deposits, and resultingly, they are
not in sufficient concentrations around the areas of NFTs where the MAC may be
contributing to neurodegeneration.
Futher support for this hypothesis comes from examining Clusterin (ApoJ) in its
other major role within the brain. Clusterin and ApoE are the most abundant
apoliproteins in the CNS (May & Finch, 1992; Roheim, Carey, Forte, & Vega, 1979).
Both clusterin and ApoE bind to Aβ and are found in amyloid plaques (Calero et al.,
2000; May et al., 1990), as well as contributing to the fibrillogenesis, neurotoxicity, and
deposition of Aβ (DeMattos et al., 2002; Potter et al., 2001). However, these
apolipoproteins are also thought to help clear Aβ from the brain across the BBB,
especially Aβ1-42 (Bell et al., 2007; DeMattos et al., 2004; Holtzman, 2004; Holtzman et
al., 1999; Lambert & Amouyel, 2007). Clusterin is the main protein carrier for Aβ in
biological fluids (Calero et al., 2000) and its multiligand receptor, low-density lipoprotein
receptor-related protein-2 (LRP2, also known as Megalin) is expressed at the BBB and at
the blood-CSF barrier in the choroid plexus (Chun, Wang, Pasinetti, Finch, & Zlokovic,
1999; Hammad, Ranganathan, Loukinova, Twal, & Argraves, 1997; Zlokovic et al.,
1996). The recent study by Bell et al. (2007) showed that soluble, free Aβ1-42 is cleared at
the BBB at a rate of about 1.9-fold lower than soluble, free Aβ1-40, that LRP2 is required
by Clusterin for efflux across the BBB, and that Aβ1-42 binding to Clusterin accelerated
Aβ’s clearance across the BBB by over 80 percent (Bell et al., 2007). Another recent
study by Carro et al. (2005), using two Tg AD mouse models and other murine models,
reported that LRP2 is involved in the transport of exercise-induced IGF-1(Carro, Nunez,
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Busiguina, & Torres-Aleman, 2000) from the blood and into the brain. The authors used
viral-directed overexpression, as well as RNA interference of LRP2, to show that IGF-1
is induced systemically from regular physical exercise (on a Letica treadmill for 1h/day at
17m/min for 4 weeks at 5d/week), that circulating IGF-1 induces the clearance of Aβ
from the brain through LRP2, that tau hyperphosphorylation and cognitive deficits were
subsequently prevented by these actions, and that LRP2 expression is decreased in
normal aged animals (Carro, Spuch, Trejo, Antequera, & Torres-Aleman, 2005).
Thus in consideration of both of Clusterin’s main roles in the CNS, it could be
hypothesized that Clusterin’s ability to transport soluble-free Aβ across the BBB through
LRP2 may decrease with age-related declining LRP2 expression, while allowing
parenchymal Aβ deposition to occur, in which Clusterin is sequestered and may even
participate in this amyloid deposition, and which subsequently causes Clusterin to be
deficiently expressed homogeneously throughout the brain and unable to prevent MAC
from acting on NFT-prone neurons.
Proteolytic Fragments of Complement. The formation of the two
C3-convertases yields three different secreted fluid-phase molecules: C2b, C4a, and Ba.
In the classical and leptin pathways, surface-bound C4b allows C2 to bind in the presence
of Mg2+, in which C2 is then cleaved by activated C1s or MASP-2, respectively, to form
a surface-bound C4b2a C3-convertase and a released 30 kDa N-terminal C2b fragment
into the fluid phase (Krishnan, Xu, Macon, Volanakis, & Narayana, 2009). The exact role
of C2b in the fluid phase is not completely known, but one study has reported C2b to
enhance vascular permeability and lead to angioedema (Strang et al., 1988). Since
complement activation is induced by amyloid in AD pathogenesis, C2b production would
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be expected to also be increased, but whether C2b contributes to any cerebrovascular
dysfunction in AD is unknown. Similarly, any involvement of C4a in AD pathogenesis
has not been reported. However, C4a may have future utility as a biomarker for Multiple
Sclerosis (MS) prognosis (Ingram, Hakobyan, Robertson, & Morgan, 2010), for rare
central nervous system (CNS) vasculitis (Langlois, Sharon, & Gawryl, 1989), and for
other autoimmune diseases, such as Systemic Lupus Erythematosis (SLE) (Rupert et al.,
2002). The role of the alternative pathway component, Ba, in AD pathogenesis is also
not clear, but it has been reported to be significantly up-regulated in AD brain
(Strohmeyer et al., 2002).
The released fluid phase anaphylotoxins, C3a and C5a, from the C3- and
C5-convertases, are involved in the activation and chemotaxis of myeloid-lineage
leukocytes, through their surface-bound receptors C3aR and C5aR, respectively.
Although both C3a and C5a have similar functional type roles, they have distinct
biological activities within the brain. For example, C3a has been shown to be
neuroprotective against N-Methyl-D-Aspartate (NMDA)-induced excitotoxicity (van
Beek et al., 2001), to induce human microglial cells to produce nerve growth factor
(NGF) (Heese, Hock, & Otten, 1998), and to have a protective anti-inflammatory effect
in the CNS after LPS-induced septic shock (Boos, Szalai, & Barnum, 2005), while C5a
was reported to participate in septic pathogenesis (Gerard, 2003; Guo & Ward, 2005).
Furthermore, C3aR and C5aR have varied expression after acute focal cerebral ischemia.
Both receptors are constitutively expressed on neurons and glial cells, but after
experimental permanent middle cerebral artery (MCA) occlusion, they had induced
expression on the endothelial cells of blood vessels within the ischemic cortex at 6 hours
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and 2 days postocclusion, as well as increased expression on myeloid cells and reactive
astrocytes one week later (Van Beek et al., 2000). However, a similar follow-up study
found that only C5aR is highly elevated at 3 hours after acute MCA, while C3aR is
reduced at 3 hours post-MCA to only 25 percent of the expression in control
sham-operated animals. Interestingly, at 24 hours post-MCA, C3aR expression had
recovered and was increased similarly to the study by Van Beek et al.(2000), and both
C5aR and C3aR had peaked to their highest levels of the study at 24 hours (Barnum et
al., 2002). Other studies have shown that inhibiting both C3aR and C5aR 6 hours post
intracerebral hemmorhage can be protective (Garrett et al., 2009; Rynkowski et al.,
2009), and that complement activation contributes to injury in humans in acute ischemic
stroke (Szeplaki et al., 2009).
While acute ischemia is a much different pathology than the chronic
neurodegeneration of AD, it is also suggested in AD that C3a, C5a, and their respective
receptors may have similar differential roles, which may either be neuroprotective or
deleterious. Amyloid plaques in AD have long been reported to contain C1q, C4, and C3
fragments, but are devoid of C3a, indicating an activated complement cascade in which
C3a has been released into the fluid phase (Eikelenboom et al., 1989). As already
mentioned, blockage of C3-convertase exacerbates amyloidosis, and that increasing C3
production reduces amyloidosis (Wyss-Coray et al., 2002). Conversely, the findings that
the MAC is co-localized with dystrophic neurites and NFTs in human AD patients
(Itagaki, Akiyama, Saito, & McGeer, 1994), that blockage of C5aR in transgenic AD
mice reduces amyloidosis and improves behavior (Fonseca et al., 2009), and that C5aR is
up-regulated in the microglia surrounding amyloid plaques (Ager et al., 2010), suggests
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that progression from C3-convertase to C5-convertase is a critical tipping point or
theshold in the pathogenesis of AD, with the complement cascade going from a
neuroprotective role to that of a deleterious role.
Conclusion. The complement cascade plays a significant role in the pathogenesis
of AD at almost every step of the process. Complement activation has been shown to be
necessary for the clearance of amyloid from the brain, especially by C1q binding to Aβ at
a site that is known to promote amyloid deposition by ACT involvement and also by the
activation of C3-Convertase. On the other hand, a dysregulated complement system, from
C5 through MAC insertion, appears to be deleterious and contribute to neurodegeneration
at areas of tau pathology. The recent findings, reported at ICAD in 2009, shed light on
both of these components of the complement cascade. These findings of CR1 and CLU
should not be surprising considering the vast cerebrovascular damage found in AD, as
demonstrated from VCC studies and which is illustrated in Figure 1 (Chapter 1). This
damage begins with accumulation of Aβ (‘pompoms and cubes’) on the parenchymal
surfaces of the microvessels, which induces some luminal crimpage at first, presumably
from the deficient transport of Aβ across the BBB (age-dependent decrease in LRP2) or
from the lack of receptors to bind and clear complement-bound Aβ, both within the
parenchyma (by CR3 and CR4) and in the vasculature (by CR1, CR3, and CR4). These
effects result in a feed-forward mechanism from age-related reductions in cerebral blood
flow, further defects in vasculature, decreased expression of necessary Aβ clearance
receptors, and inversely with increased amyloidosis and subsequent tau
hyperphosphorylation. As the occlusions continue to narrow and inhibit more cerebral
perfusion, the vessels eventually pinch off and become completely occluded and
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truncated around a growing parenchymal anti-angiogenic amyloid plaque, which could
essentially be described as progressive microvasculature ischemia and infarct.
Leukocyte Recruitment in the Brain
Bone Marrow-Derived Cells (BMDCs) in the CNS. Although the
developmental origin of microglia has been debated (Altman, 1994; Theele & Streit,
1993) as to whether microglia are derived from neuroepithelial cells (Kitamura, Miyake,
& Fujita, 1984; Lewis, 1968; Neuhaus & Fedoroff, 1994) or from hematopoietic
monocytic cells (Eglitis & Mezey, 1997; Ling & Wong, 1993; Perry & Gordon, 1988), it
is now generally-accepted that BMDCs can cross the BBB and become functional cells
within the CNS . One study that has demonstrated this phenomenon transplanted wildtype male bone marrow into recipient PU.1null female mice (Reviewed in (Mezey &
Chandross, 2000)). PU.1 is a transcription factor expressed exclusively in hematopoietic
lineage cells, and mice with a homozygous mutation in PU.1’s gene are born extremely
leukopenic, with an inability to produce new macrophages, neutrophils, mast cells,
osteoclasts, or B/T lymphocytes, and they die within 48 hours from severe septicemia
(McKercher et al., 1996; Tondravi et al., 1997). These mice can be rescued to normal by
intraperitoneal administration of wild-type bone marrow. Using these mice, Mezey et al.
observed Y chromosome-containing cells thoughout both the white and gray matter of the
brain, having phenotypes of astrocytes (GFAP immunopositivity) and neurons
(NeuN-immunopositive nuclei within neuron-specific enolase immunopositive cells).
There was an increased accumulation of these Y chromosome-containing cells in the
choroid plexus, the ependyma of the ventricular system, and in the subarachnoid space ,
and up to 5% of all cells evenly distributed thoughout the areas of the brain involved in
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AD pathogenesis, including the cerebral cortex, hypothalamus, hippocampus, amygdala,
periaqueductal gray, and striatum (Mezey, Chandross, Harta, Maki, & McKercher, 2000).
Another study that was reported simultaneously with Mezey et al., administered bone
marrow, which was harvested from 8- to 10-week-old transgenic mice and which
ubiquitously expressed green flourescent protein (GFP+), into isogenic age-matched
lethally-irradiated mice, and allowed the recipient mice to age for 1 to 6 months
(Brazelton, Rossi, Keshet, & Blau, 2000). The authors found upon subsequent
examination of the mice brains, that significant amounts of GFP+ neurons and microglia
populated the brain throughout the CNS, such as in the hippocampus, cerebral cortex,
cerebellum, and olfactory bulb, a specific area of the brain where neuronal regeneration is
frequently ongoing (Hinds, 1968; Lois & Alvarez-Buylla, 1994; Luskin, 1993). Since
these two studies, many other investigations have used these techniques to study the roles
of bone marrow-derived cells within the brain and CNS and under various disease and
experimental conditions (Beck et al., 2003; Beers et al., 2006; Boissonneault et al., 2009;
Corti et al., 2004; Hess et al., 2002; Keshet et al., 2007; Malm et al., 2005; Priller et al.,
2001; Sanchez-Ramos et al., 2009; Simard & Rivest, 2004).
BMDCs and AD. One such study of GFP+ bone marrow transplantation into
recipient lethally-irradiated Tg AD mice, aimed to investigate whether the microglia that
decorate amyloid plaques are bone marrow-derived or whether the amyloid plaques
sequester the resident microglia already in the brain (Malm et al., 2005). The authors
transplanted GFP+ bone marrow into young 2.5-month-old Tg mice (Study I), which had
not yet acquired amyloidosis, and into old 21- or 25-month-old Tg mice (Studies II and
III respectively), which already had established amyloid deposition. In Study I, the mice
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were aged 26 weeks post-transplantation of GFP+ bone marrow and subsequent
examination of their brains revealed that the number of engrafted GFP+ cells were
significantly higher in the brains of Tg AD mice, compared to age-matched wild-type
control mice, and that about 6% of the total GFP+ cells found within the brains were
associated with amyloid plaques. In Study II of 21-month-old Tg mice and age-matched
controls, which received GFP+ bone marrow and were aged 14 weeks
post-transplantation, examination of the brains did not reveal any difference in GFP+
bone marrow-derived microglia between the Tg and wild type groups and only 3% of the
GFP+ microglia, that were found within the Tg AD brain parenchymas, were associated
with amyloid plaque. However, when comparing BMDC recruitment between the young
and old Tg mice, there was a 17-fold higher number of GFP+ microglia surrounding the
plaques in Study I than were found in Study II, suggesting that there is significant BMDC
recruitment into the brain as amyloid is being deposited, but not after plaque deposition is
already established. To examine the established amyloid plaques further, in Study III,
25-month-old Tg AD mice were transplanted with GFP+ bone marrow, allowed to age
for 16 weeks, and then LPS was injected ipsilaterally into the right hippocampi and saline
control injected contralaterally. One week post-injections, the mice were sacrificed and
examined, which revealed that the LPS-injected hippocampi had a 6-fold increase in
GFP+ microglia (as distinguished by CD11b immunopositivity), a 5-fold increase of
these GFP+ microglia associated with the amyloid plaques, and a significant 24%
reduction in the total Aβ burden. The authors concluded that the infiltration of BMDCs
contribute to the microglial reaction in AD, and that local inflammation can recruit
BMDCs which reduce amyloid burden.
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A similar study followed that examined the actual role of the BMDCs in relation
to amyloid plaques (Simard et al., 2006). Transplantation of GFP+ bone marrow into
2-month-old lethally-irradiated Tg AD mice, and then the mice aged for 2 to 7 months
post-transplantation, also showed that GFP+ microglia associated with amyloid plaques,
that the average amyloid plaque area gradually increased each month up to 6 months of
age, and that at 6 months, bone marrow-derived GFP+ plaque-associated microglia were
significantly increased. However, at 9 months, the average amyloid plaque area had
dramatically increased, while the number of plaque-associated GFP+ microglia had
modestly decreased. Although this microglial decrease was just briefly mentioned by the
authors, we took notice and hypothesized that the rapid increase in Aβ deposition might
be due to age-related depressed hematopoiesis and that strategies to increase BMDCs
might inhibit or reverse amyloidosis. The authors further work supports this hypothesis,
in which they had created a new transgenic animal model (denoted here as PS/APP/TK
mice), in which a Tg AD mouse line expressed a mutant thymidine kinase (TK) protein
under the control of the CD11b promoter, such that when the mice were treated with
ganciclovir, every cell expressing TK (monocytic lineage cells only) would be eliminated
during cellular division. Since global administration of ganciclovir in these mice would
cause severe leukopenia, and anemic or septic mortality after chronic administration for
10 days, the authors continuously infused ganciclovir for 28 days intracerebroventicularly
via commercial osmotic alzet pumps into the 15- to 24- week-old PS/APP/TK mice. The
authors demonstrated that if treated with ganciclovir, these mice at 6 months of age have
significantly increased amyloid deposition. Furthermore, confocal microscopy of the
brain tissue from the GFP+ bone marrow-transplanted mice at 6 months of age, showed
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that in the GFP+ bone marrow-derived microglia, and not the resident microglia, Aβ was
present and had been phagocytosed. Taken together the authors concluded that it is the
bone marrow-derived microglia which are able to remove amyloid deposition via a
cell-specific phagocytic mechanism, and that depletion of these BMDCs will exaccerbate
AD pathology.
In further support of the notion that BMDC recruitment into the brain could
ameliorate AD pathogenesis comes from a study that inhibited the migration of BMDCs
into the brains of Tg AD mice (J. El Khoury et al., 2007). In this study, the authors
generated APP mice that were deficient in the chemokine receptor, CCR2. CCR2 has
been shown to be involved in mononuclear phagocyte infiltration into the brain of MS
patients (Izikson, Klein, Charo, Weiner, & Luster, 2000), and to be required for
macrophage infiltration into damaged areas of the hippocampus following axonal injury
(Babcock, Kuziel, Rivest, & Owens, 2003). CCR2 binds to its ligand Chemokine C-C
motif Ligand 2 (CCL2, also known as MCP-1)(Charo & Peters, 2003), and as mentioned
above, CCL2 has been reported to be upregulated in AD brain (Ishizuka et al., 1997;
Sokolova et al., 2009), but expression may be lost as AD pathogenesis increases (Dawson
et al., 2003; Galimberti et al., 2006). CCL2 has been shown to be produced by microglial
and astrocytic cultures (J. B. El Khoury et al., 2003; Smits et al., 2002), and that
neutralizing antibodies against CCL2 inhibit Aβ-stimulated chemotaxis of microglia and
monocytes (J. B. El Khoury et al., 2003). In another study by El Khoury et al. (2007), the
authors demonstrated that Tg AD mice, which were deficient in CCR2, had significant
exacerbation of amyloidosis and premature mortality, and that these effects correlated
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with expression of CCR2 gene dosage. The authors concluded that increased microglial
density may indeed play a protective role against AD by promoting the clearance of Aβ.
Research Plan
The notion that NSAIDs may not account for RA being a negative risk factor
against AD, and that secreted factors within RA pathogenesis itself were also unlikely to
explain this phenomenon alone, we hypothesized that the RA up-regulated leukocytes,
especially those of the innate immune system, may potentially provide beneficial effects
against AD and provide insight into this inverse relationship between RA and AD. A
significant amount of literature regarding different components of the innate immune
system lent credence to this idea, from extensive involvement of the complement system
in AD, to the critical requirement of BMDCs to infiltrate the brain and affect AD
pathology. It was also highly consistent with the literature that increasing the cellular
components of the innate immune system may overcome age-related depressed
hematopoiesis and also provide therapeutic benefit.
Thus, to investigate the interactions between the innate immune system and AD,
we studied the effects on AD pathology of three colony-stimulating factors (M-CSF,
G-CSF, and GM-CSF), which are up-regulated during RA pathogenesis and that drive
much of the leukocytosis involved in RA pannus formation (Kawaji, Yokomura,
Kikuchi, Somoto, & Shirai, 1995; Nakamura et al., 2000; Olszewski et al., 2001; Xu,
Firestein, Taetle, Kaushansky, & Zvaifler, 1989). These CSFs enhance the survival and
function of their respective leukocytes and drive their proliferation and differentiation
from myeloid lineage precursors. GM-CSF induces dendritic cells, macrophages, and
granulocytes (neutrophils, basophils, and eosinophils), while M-CSF and G-CSF
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respectively induce the macrophage and granulocyte subsets of the innate immune
system. These innate cells have the ability to diapedese from the circulatory system and
to differentiate further into various specialized immune cells within organs (microglia,
Langerhan’s cells, etc.). Specifically, we hypothesized that the activation/differentiation
of innate immune system cells by colony stimulating factors released during RA might
lead to phagocytosis/removal of the pathogenic lesions of AD and to cognitive
improvement.
GM-CSF and G-CSF are also known to be involved in erythropoiesis, and
GM-CSF and erythropoietin act synergistically in the maturation and proliferation of the
burst-forming and colony-forming erythroid units to the normoblast stage of
erythropoiesis (Emerson et al., 1985; Wu, Liu, Jaenisch, & Lodish, 1995). As noted
above, circulating Aβ binds to complement opsonins in an antibody-independent fashion,
and these opsonized particles bind to the complement receptor, CR1, on erythrocytes and
subsequently to CR1g on liver-resident kupffer macrophages (Helmy et al., 2006; Rogers
et al., 2006). Thus these CSFs could provide function in both the peripheral clearance of
Aβ, in neovascularization and resultant increased cerebral blood flow, and in bone
marrow-derived microglial activity because they are involved in the proliferation,
differentiation, and maintenance of most innate leukocytes involved in these functions
(see Figure 3 for overview of the hematopoietic system).
The following chapters detail the results on cerebral amyloid deposition from
intrahippocampal administration of the three CSFs into aged transgenic AD mice, as well
as the behavior and pathological effects from daily subcutaneous administration of
GM-CSF, the most active of the CSFs in the hippocampal injections.
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Figure 2. Overview of the Complement System. Many regulatory proteins of the
complement system are implicated in AD and all are highlighted here in red text. Figure
adapted and redrawn from (Tegla et al., 2009).
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Figure 3. Overview of the Hematopoietic System. G-CSF acts primarily to induce
granulocytic cells from myeloid precursor cells, while M-CSF upregulates macrophages.
Although not indicated here, M-CSF also induces Myeloid-Derived Suppressor Cells.
GM-CSF induces cellular populations of each of these innate hematopoietic cells.
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CHAPTER 3 – DEVELOPMENT OF BILATERAL BRAIN INFUSION
METHODOLOGY
Introduction
In 2007, at the start of the experimental investigation into whether or not the
hematopoietic colony stimulating factors (CSFs) would affect AD pathology in mice,
several reports suggested that M-CSF might be the most promising CSF to reverse
amyloidosis. For instance, it was reported that osteopetrotic (op/op) mice, that do not
produce functional M-CSF, developed amyloid plaques in their brain, and had
neurodegeneration (Kaku et al., 2003; Kawata et al., 2005). When 30 day old op/op mice
were intracranially-injected with M-CSF, they had reduced brain plaques, even though
their microglial populations only increased to two-thirds that of wild-type mice (Kaku et
al., 2003). Furthermore, in vitro studies showed that M-CSF was induced in Aβ-treated
microglia cells (Ito et al., 2005), suggesting that the brain’s Aβ-activated microglial
might secrete hematopoietic growth factors in an attempt to increase phagocytic
microglial populations. Additionally, microglia that overexpressed the receptor for
M-CSF were reported to be neuroprotective (Mitrasinovic et al., 2005). However, there
were no in vivo reports that had administered M-CSF into the CNS. Since a proposed
endpoint of our study was to show an alteration in cerebral amyloidosis, due to M-CSF
administration, we wanted an adequate amount of M-CSF delivered. Thus we decided to
use a novel bilateral brain infusion methodology (Bennett et al., 2009), that we were
developing in 2007, to continuously infuse M-CSF into the lateral ventricles of aged AD
mice. This chapter explains the construction of the bilateral brain infusion catheters, and
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the results from the usage of these catheters in transgenic AD mice with infusion of
alpha-1-antichymotrypsin (ACT) or M-CSF.
Available Commercial Catheters
The only commercially-available infusion system for delivering drugs or
investigational materials in vivo is the Alzet® pump system. There are certain
characteristics of this system that make it unusable for our experiment. For instance,
since the average mouse’s skull measures between 8-9mm in width, there can physically
be only one catheter placed into the test subject’s brain due to the 5.9mm diameter round
catheter head (Figure 4). Additionally, the thickness of the catheter head does not allow
for the scalp to be completely sutured closed, without tightness of the scalp and
subsequent chronic irritation to the mouse during the trial period, in which they will rub it
against their cage or scratch at it. There will also be chronic inflammation and propensity
for infection, due to the scalp not closing appropriately. Moreover, the tubing that
connects to the catheter head often lies partially outside of the skin, allowing the mouse
to sometimes scratch it loose and compromise the experiment. Furthermore, the catheter
head is flat and does not contour well to the skull, requiring a large amount of cement to
be applied to secure the catheter head to the skull. Thus, the cure time for the cement
causes the mouse to remain long times under anaesthesia, and contribute to increased
surgery mortalities. These issues combine to make the commercial Alzet® catheters not
ideal for our experimentation, especially since both ACT and M-CSF are mediators of the
immune system, and their effects may be skewed throughout the trial.
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Figure 4. Commercial Alzet® catheter.
The 5.9mm diameter round catheter head
glues to the skull of the test animal and has
the 3.0mm stainless tubing extending
through a drilled hole in the skull and into
the brain’s parenchyma. There are 0.5mm
washer-like plastic spacers that can be added
underneath the catheter head to reduce the
distance that the tubing penetrates the brain.
The 3.4mm pedestal, used for mechanical
placement of catheter, can be clipped off
after the glue cures.

Bilateral Brain Infusion Catheter Construction
The catheters (patent pending- PCT/US08/73974) used for this experiment were
made by first taking a 1.25 cm length of 30 gauge stainless steel tubing (Small Parts, Inc.
Miramar, Fl) and carefully bending it at 2.5 mm under a dissecting microscope (Leica,
Heerbruug, Switzerland), to approximately 90 degrees, being careful not to crimp the
tube. The remaining length of the tube was bent again at 5 mm to an angle of 120-160
degrees, approximating the contour of each animal’s skull. These metal cannulae were
inserted into a 3 cm length of polyethylene (PE-10) tubing with an internal diameter of
0.28 mm and an outer diameter of 0.61 mm. One centimeter of the PE-10 was then itself
inserted into a 4.5 cm length of sterile polyvinyl tubing (PV-50-I.D. 0.69 mm/ O.D. 1.14
mm, Durect Corp., Cupertino, Ca), held in place using a bead of Locktite 454 adhesive
(Plastics One. Roanoke, VA.), and cured overnight. The following day, sterile water was
forced through each catheter assembly to ensure that the lines were not obstructed. The
osmotic pumps were then filled with solution, attached to the catheters and primed and
implanted as described below. The proven catheters were later custom manufactured by
Braintree Scientific (Braintree, MA) with some minor changes: The adhesive was
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supplanted by heat sealing PE-10 to PE-50 tubing and, because the diameters of the PV50 and new PE-50 were not exactly the same, a sheath of silicone (SIL 047) was placed
over the PE-50 with an extra 2 mm overhang to attach it to the flow modulator of the
pump, forming a tight, leak-proof seal (Figure 7).
Transgenic Mice
PS/APP (presenilin 1/amyloid precursor protein) mice and PS/APP/ACT mice
were generated by crossing heterozygous PDGF-hAPP (V717F) mice with PDGF-hPS1
(M146L) on both Swiss Webster and C57BL/6 backgrounds. In some cases, PS/APP
mice were bred with mice harboring a gene for human ACT (hACT) under a GFAP
promoter (Nilsson et al., 2001) were used to be compared to ACT-infused animals.
Genotyping was performed using comparative real-time PCR (Bio-Rad iCyclerHercules, CA). Pathogenically, these Alzheimer’s mouse models are characterized by
robust accumulation of amyloid plaques and the development of microgliosis between 610 months. The mice used in these studies ranged from 9-10 months of age.
Materials
Purified human α-1-antichymotrypsin (ACT) was purchased lyophilized from
Fitzgerald (Concord, MA) and purified mouse M-CSF was purchased from R&D
Systems (Minneapolis, MN). Both were reconstituted in artificial CSF (aCSF) (Harvard
Apparatus, Holliston, MA) to a concentration of 1mg/mL. ACT was infused directly into
the hippocampal parenchyma or lateral ventricles for 28 days and M-CSF was infused
into the lateral ventricles for 14 days using the novel catheters attached to Alzet osmotic
minipumps (Alzet model 1004, Durect Corp. Cupertino, CA) with an average flow rate of
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0.12μL/hour. The pumps and catheters were submerged in 0.9% sterile saline at 37oC
and primed for 48 hours prior to implantation.
Intracranial Infusions
All procedures involving experimentation on animals were performed in
accordance with the guidelines set forth by the University of South Florida Animal Care
and Use Committee. Animals (9 month-old PS/APP- 25-35g) were anesthetized with 12% isoflurane, shaved and scrubbed with 10% Betadine solution at the site of incision,
and placed into a dual arm stereotaxic frame (Kopf Instruments. Tujunga, Ca.). A small
(5 cm) incision was made, exposing the skull and neck, and double bladed scissors (10
cm curved Strabismus, Fine Science Tools, Foster City, CA.) were used to form a
subcutaneous pocket along the back of the animal into which 2 osmotic minipumps were
inserted with catheters attached. One of the stereotaxic arms held an Ideal Micro-drill
(Roboz Surgical Instrument Co., Gaithersburg, MD) holding a 0.32 mm diameter carbide
drill bit. Using the drill bit on the stereotaxic arm to find the proper coordinates (from
Bregma -2.2-2.5 mm anterior-posterior, +/- 2.2-2.5 mm medial-lateral), two holes were
carefully drilled into the skull and a 30 gauge needle from a Hamilton syringe (Hamilton
Co., Reno, Nevada) was attached to the second arm of the stereotaxic frame. The needle
was inserted to the appropriate depth (2.2-2.5 mm corresponding to the posterior portion
of the CA1/CA2 hippocampus) and allowed to sit for 5 minutes for the surrounding tissue
to adjust. Alternatively, holes were drilled corresponding to the lateral ventricles at the
following coordinates: from Bregma -0.2 mm anterior-posterior, +/- 1.0 mm mediallateral, and to a depth of 2.2-2.5 mm. After removing the needle, the tips of the cannulae
were held directly over the holes with forceps and then gently inserted straight into place.
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Pulling back on the catheters from the base of the osmotic pumps while inserting the
cannulae provided sheer which prevented them from moving and potentially damaging
tissue while they were firmly affixed. The cannulae were affixed to the skull with
Locktite 454 adhesive (Plastics One. Roanoke, VA.) and secured down with a piece of
nitrile, approximately 1 cm in diameter. After the adhesive cured, the scalp was closed
with 6-7 silk sutures. For analgesia, the animal received an immediate subcutaneous dose
of ketoprofen (10mg/kg) and up to every 6 hours, as needed, for a maximum of 48 hours
post-operatively. After the 28 day period, the animals were given an overdose
(~150mg/kg) of sodium pentobarbital (i.p.) and were transcardially perfused with 0.9%
saline. The brains were carefully removed and analyzed as outlined below. At this time,
the integrity of the catheters was confirmed again by forcing water through them, and the
pumps were also determined to be empty.
Histology and Immunohistochemistry
Mouse brain tissues were fixed in 10% formaldehyde (formalin) for 72 hours and
then passed through a series of sucrose solutions (10-30%) over another 72 hours. Brains
were frozen to the peltier stage (Physitemp, Clifton, NJ) of a histoslide (Leica,
Heerbruug, Switzerland) and sectioned coronally at 25 μm. After incubating the sections
with blocking buffer (Tris-buffered saline with 10% normal goat serum, 0.1% Triton X100, and 0.02% sodium azide) for 60 min, primary antibodies against ACT (1:500- Dako,
Glostrop, Denmark) and Aβ (6E10,1:1000- Covance, Princeton, NJ) were applied and
incubated at 4 o C overnight. After thorough washing, the sections were incubated with
secondary antibodies, Alexa 488 and 594 fluorophores (1:1000, 1:4000-Invitrogen) in the
dark at ambient temperature for 2 hours. This incubation was followed by a Hoechst
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(1:10,000, Sigma, St. Louis, MO) nuclear stain, and the sections were washed and sealed
with Gel-Mount (Electron Microscopy Sciences, Hatfield, PA). The images were
analyzed on a Zeiss Imager Z1 fluorescence microscope with a Zeiss Axiocam Mrm
camera (Oberkochen, Germany) using Axiovision 4.7 software, and ACT sections were
quantified using Image J. For animal to animal, hemisphere to hemisphere plaque
comparison, 5 sections from 6 mice (30 total) were stained using Thioflavin S to label the
beta-pleated amyloid deposits from anterior to posterior hippocampus in each hemisphere
of each mouse. Coronal sections of brain (25µm) were mounted to slides and let to
adhere overnight. The sections were then rinsed with deionized water and submerged in
a 1% Thioflavin S aqueous solution (Sigma-Aldrich, St. Louis, MO) for 5 minutes. The
sections were differentiated in 70% ethanol for 5 minutes, rehydrated in 30% ethanol for
5 minutes, washed with deionized water coverslipped, imaged, and quantified.
Results
Animal Recovery. Intracranial delivery of molecules, though invasive, is a
common procedure to confirm results from in vitro experiments in an in vivo system and
to test various compounds in transgenic animals via targeted delivery. As an additional
advantage, the novel method described here bypasses concerns related to the blood-brain
barrier permeability of the administered compound. ACT, a serine protease inhibitor that
is known to contribute to the formation of amyloid pathology in Alzheimer's disease, was
infused into the hippocampi or lateral ventricles of 9-month-old PS/APP mice for a
period of 28 days. ACT was infused into one hemisphere and aCSF (vehicle) into the
other hemisphere, thus allowing a comparative analysis to be made within the same
animal. In all cases, the animals recovered very quickly from the procedure and resumed
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eating and grooming within minutes of awakening. All animals were monitored closely
during the 4 week infusion. In only a few instances did animals scratch at the incisions,
but in no case were they able to open the wound and remove or damage any of the
implanted pumps and catheters. In most cases, the hair grew back within 2 weeks, and
the animals became virtually indistinguishable from non-treated animals, with the
exception of bulges on the haunches from the implanted osmotic pumps (Figure 9A).
The implants caused minimal discomfort to the animals, and procedural mortality was
practically eliminated from these studies. When harvesting tissues following the 28 day
infusion, the catheters were checked to ensure they were still connected to the pumps
(Figure 9B) and to the cannulae (Figure 9C). The nitrile cap is indicated by the arrow in
figure 9D. The entire assembly is shown attached to an Alzet osmotic minipump model
1004 (Durect Corp., Cupertino, CA.) in Figure 9E. Finally, when removing the brains
only 2 small holes are visible (Figure 9F) showing that there is no lateral movement of
the cannulae during infusion. No serious damage or impairment was caused by the
cannula, although tissue is displaced where inserted. Figure 10 shows, on the left
hemisphere, exactly where the cannula was placed and that surrounding tissue was intact
following infusion. Figure 11 A and B show a region of the hippocampus anterior to the
infusion site which also does not show signs of damage. To be noted, the gauge of the
cannulae used in this experiment (30g or 0.30 mm O.D.) is the same of those used in
commercially available cannulae (Alzet, PlasticsOne, Braintree Scientific), but without
the irritation to the animal, inflammation, occasional motor impairment, and high
mortality rates associated with them.
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Bilateral Brain Infusions. Due to the increased variability in plaque load
between animals, even within a largely inbred transgenic mouse line, it is often difficult
to compare treated and untreated mice with a reasonably small number of animals. This
phenomenon was observed upon staining the M-CSF-infused mice for amyloidosis
(Figure 5), and can be caused by phenotypic variability and/or differential expression of
transgenes. Upon analysis of 6 untreated PS/APP mice at 10 months of age, we found
that plaque load can vary significantly from animal to animal (75% mean standard
deviation in pixel count). This fact makes it difficult to draw conclusions on the effects
that different molecules might have on amyloid deposition or other features of the
transgenic brain when comparing animals where hemispheres vary only about half as
much (39%). Figure 6 and Figure 7 demonstrates the variation in plaque load between
hemispheres and within untreated animals of this genotype. Therefore, in order to study
promoters and inhibitors of AD pathology directly in the brain, it would be preferable
(almost twice the efficiency) to compare the individually-treated hemispheres of each
animal rather than to compare the brains of littermates or matched cohorts from other
litters. Immunocytochemical techniques demonstrated that our catheters functioned
properly and that ACT was delivered successfully to the ventricles and parenchyma,
respectively (Figures 10 and 11). If ACT is infused into a PS/APP mouse that has
plaques for it to interact with, it binds to the plaques and diffuses very little (Figure 11C
& D). However, if ACT is delivered into the hemispheres of nontransgenic mice it
diffuses, but still remains in the intended hemisphere (Figure 11A and B).
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Interaction of ACT and Amyloid. It is well established that ACT is localized,
together with the Aβ peptide, in the amyloid plaques of Alzheimer’s disease (Abraham,
Selkoe, & Potter, 1988). However, the mechanism and effect of this interaction are still
under investigation. Previous in vitro experiments indicated that ACT can bind to Aβ
and become integrated into amyloid filaments as they are formed, and the same
mechanism was presumed to occur in vivo (Ma, Brewer, & Potter, 1996; Ma, Yee,
Brewer, Das, & Potter, 1994; Mucke et al., 2000). Using the application method
described here, we successfully delivered ACT into individual brain hemispheres of adult
PS/APP mice and found that ACT binds to the perimeter of existing plaques in a similar
manner as found for ACT association with amyloid plaques in PS/APP/ACT transgenic
mouse (Nilsson et al., 2001) (Figure 12). While the application of exogeneous ACT did
not lead to increased amyloid load during the time frame of these experiments, it should
be noted that ACT was infused for only 28 days. A longer exposure could result in an
increased plaque load and is currently being investigated. At the same time, while ACT
is known to enhance plaque formation, the perimetrical binding of ACT to pre-exisiting
Aβ plaques, as shown here, might indicate that ACT involvement in AD pathogenesis not
only occurs concurrent with plaque formation but also afterwards. This conclusion is
consistent with the fact that ACT is highly upregulated in adult AD brains (Abraham et
al., 1988) and also induces the phosphorylation of tau (Padmanabhan, Levy, Dickson, &
Potter, 2006).
Conclusions. Although there is evidence that ACT's involvement in AD is not
restricted to its participation in plaque formation, the purpose of using ACT in this model
was to demonstrate the utility of our system. The catheters and cannulae described here
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served as an outstanding tool for targeted delivery of ACT into individual brain
hemispheres and will facilitate further examination of the mechanistic involvement of
ACT and other molecules in the pathology of Alzheimer's disease. As for the bilateral
M-CSF infustions into the lateral ventricles, we were not able to determine whether
M-CSF had any affect on amyloidosis due to the significant variation in plaque load
between animals. Nor could we be certain that the M-CSF extravasated from the
ventricles and into the brain’s parenchyma. However, the data from the ACT infusions, of
which the infused recombinant ACT peptide remained localized to the hemisphere in
which it was delivered, allowed us to formulate a research plan to give bolus
intrahippocampal injections of each CSF (M-CSF, G-CSF, and GM-CSF) into a
respective hemisphere and artificial cerebrospinal fluid control into the contralateral
hemisphere. The following chapter will discuss the results from these experiments.
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Figure 5. Significant Variation of Amyloid Plaque Load Between Mice Infused with
M-CSF. Standard fluorescent immunohistochemistry used 6E10/Alexa 488 and Hoechst
nuclear stain (blue). Bright green spots indicate amyloid plaques. Pictures taken at 5X.
Mouse numbers 148,160,171, and 211 received bilateral intracerebroventricular infusions
of M-CSF and mice 164, 170, 176, and 177 received bilateral intracerebroventricular
infusions of artificial cerebrospinal fluid.
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Figure 6. Significant Variation of Amyloid Plaque Load Between Mice. Thioflavin S
staining on 25μm coronal sections (montages) of 3 different PS/APP mice at 10 months
of age showing plaque variability in the hippocampus and neighboring cortex.
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Figure 7. Scatter-plot of Plaque Load Between Mice. Data from 5 brain sections
through 6 ten-month-old PS/APP mice comparing standard deviation (plaque variance)
between local hemspheres of the same animal (28%), between sides of the same section
(11%), and between animals (78%). All the data from the left hemisphere are compared
with the right for each mouse (Hemi-Hemi, 1 data point for each mouse); the left half of a
single slice is compared wth the right side (Left-Right, 1 data point for each slice); and a
permuted comparison of each mouse with every other mouse (Mouse-Mouse, 1 data point
for each pair of mice). Where data were aggregated (Hemi-Hemi and Mouse-Mouse, the
mean of the aggregared counts was used to make the standard deviation comparable to
the single slice data (standard deviation of two numbers).
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Figure 8. Catheter Assembly. A- First bend of 30g stainless steel tubing. B- Second
“contour” bend. C- polyethylene PE-10 tubing. D- Heat seal. E- PE-50. F- Silicone sleeve
(SIL047).

Figure 9. Catheters Usage in vivo. A 10 month-old PS/APP mouse with 2 osmotic
pumps following 28 days of infusion. While still active (A) and after transcardial
perfusion showing the Alzet pumps (B) and cannulae (C) still securely attached. The
arrow in figure D shows the nitrile cap used to affix the catheters to the skull and Figure
E shows the entire assembly attached to an Alzet 1004 osmotic minipump. When the
brain is removed, only small holes are visible where the cannulae were inserted (F).
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Figure 10. Double Immunohistochemistry of Aβ and ACT. A) A montage of images
taken at 10x from 25μm sections of an animal treated with ACT on the left and aCSF
control on the right. The top section is immuno-labelled with the Aβ antibody 6E10 and
the bottom with ACT antibodies. Inlays (40x) show Aβ in green, ACT in red, and
Hoechst nuclear stain in blue.
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Figure 11. Recombinant Peptides Remain Localized to Infused Hemispheres.
Montage images of 25μm coronal sections of 10 month old nontransgenic (A & B) and
PS/APP mice (C & D) immune-labeled with and antibody against α- 1 antichymotrypsin
following 28 day infusion demonstrating that ACT stays on the infused hemisphere with
or without the presence of plaques.
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Figure 12. Replication of Transgenic Animal Models. Comparison of ACT with
amyloid plaques (40x) from a PS/APP/ACT transgenic mouse (A) and a PS/APP ACTinfused mouse (B) both at 9 months of age. Immuno-labeling of Aβ is shown in green
(6E10 antibody), ACT in red, and Hoechst nuclear stain in blue.
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CHAPTER 4 – INTRAHIPPOCAMPAL ADMINISTRATION OF CSFs
Introduction
To investigate the consequences of interactions between the innate immune
system and AD, we studied the effects on AD pathology of the three colony-stimulating
factors (M-CSF, G-CSF, and GM-CSF), which are up-regulated in the synovium and
serum during RA pathogenesis (Kawaji, Yokomura, Kikuchi, Somoto, & Shirai, 1995;
Nakamura et al., 2000; Olszewski et al., 2001; Xu, Firestein, Taetle, Kaushansky, &
Zvaifler, 1989). The first objective was to induce the specific leukocytic phenotype of
each CSF in the brains of aged transgenic AD mice. In the periphery, these CSFs enhance
the survival and function of their respective leukocytes and drive their proliferation and
differentiation from myeloid lineage precursors. GM-CSF primarily induces dendritic
cells, macrophages, and granulocytes (neutrophils, basophils, and eosinophils), while
M-CSF and G-CSF respectively induce the macrophage and granulocyte subsets of the
innate immune system. These innate cells have the ability to diapedese from the
circulatory system and to differentiate further into various specialized immune cells
within organs (microglia, Langerhan’s cells, etc.). However, these specific leukocytic
populations have not been described in the brain’s parenchyma and leukocytes are
broadly classified as just ‘microglia’. Since the bilateral intracerebroventricular infusions
of M-CSF into similar-aged AD mice showed significant variations in amyloidosis and
since we observed that infused recombinant proteins remain localized within their
respective-infused brain hemispheres (Chapter 3), we determined the effects of each CSF
by bolus intrahippocampal injection into the ipsilateral brain hemisphere and bolus
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vehicle injection contralaterally. This chapter shows the effects that each CSF induced
into the brains of aged transgenic AD mice. Specific microscopy and image analysis
procedures, and a novel device for paraffin-embedded immunohistochemistry were also
developed to analyze these effects (Boyd et al., 2010 In Press).
Methodology of Transgenic Mouse Studies Involving Intrahippocampal
Administration of CSFs
Transgenic Mice. PS/APP mice in this study, which begin accumulating robust
amyloid plaques at 6-8 months, were generated by crossing heterozygous PDGF-hAPP
(V717F) mice with PDGF-hPS1 (M146L) on both Swiss Webster and C57BL/6
backgrounds. All procedures involving experimentation on animals were performed in
accordance with the guidelines set forth by the University of South Florida Animal Care
and Use Committee. Transgene detections were performed using QPCR (Bio-Rad
iCycler, Hercules, CA).
Intrahippocampal Injections of CSFs. All three CSFs were stereotaxicallyinjected (5 µg/injection) into the (ipsilateral) hippocampus, with artificial cerebrospinal
fluid vehicle injected contralaterally into four PS/APP mice each (all 10-12 months old,
25-35 g, both genders). Two holes were drilled into the skull (from bregma -2.5 mm
anterior-posterior, +/- 2.5 mm medial-lateral, and the 30 gauge needle inserted to a depth
of 2.5 mm (Figure13)). Mice were perfused with 0.9% cold saline 7 days later and their
brains placed in 10% neutral buffered formalin. Recombinant mouse GM-CSF
(rmGM-CSF), recombinant murine G-CSF (rmG-CSF), and recombinant mouse M-CSF
(rmM-CSF) (R&D Systems, Minneapolis, MN) will be referred to as GM-CSF, G-CSF,
and M-CSF throughout this publication.
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Immunohistochemistry and Image Analysis of Intrahippocampal-injected
Mice. Formalin-fixed brains were either coronally cryosectioned at 14-µm, or paraffinembedded and sectioned at 5-µm, with standard deparaffination and antigen retrieval
steps (boiled in 10mM Sodium Citrate buffer for 20 minutes) performed before
immunohistochemical staining. To significantly reduce cost of reagents and antibodies
with paraffin-embedded slides, a novel magnetic immunohistochemical staining device
(Figure 13) was developed (patent pending, Tech ID# 09A015). Standard fluorescent
immunohistochemical techniques used primary anti-Aβ antibodies 6E10 (Covance,
Emeryville, CA, 1:1000), and MabTech’s 3740-5 (MabTech, Cincinnati, OH, 1:5000) to
immunolabel amyloid deposition coupled with Alexa fluorophore-labelled secondary
antibodies (Molecular Probes, Eugene, OR, 1:1000, 1:4000), and Hoechst (Sigma)
nuclear staining. Immunofluorescence was detected and all pictures per section were
taken at the same exposure on a Zeiss Imager.Z1 microscope (Oberkochen, Germany)
using Axiovision 4.7 software. Digital images were quantified using a novel ImageJ
protocol (see Appendix D for slides outling the complete ImageJ ).
Microscopy and Method of Image J Analysis of Amyloid Deposition. Lateral
rows of photomicrographs were taken of coronal sections in a manner that ensured
minimal overlap between each photomicrograph and corresponding anatomical areas in
each hemisphere. Hoechst nuclear staining was used as a tool to scroll through sections,
allowing for minimal overlap between each photomicrograph, and then the image was
taken with the appropriate fluorescence. After all photomicrographs of the section were
taken, they were montaged into a full coronal picture of the section, with the outline of
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each photomicrograph displayed (Axiovision 4.7 Panorama Module software).
Photomicrograhs were then selected for analysis from each hemisphere (Figure 15). The
histogram of each photomicrograph was analyzed and the resulting means and standard
deviations were entered into a spreadsheet. One photomicrograph of the section was then
thresholded to select the amyloid plaques. This thresholded value was used in the
spreadsheet to normalize the threshold values of the other photomicrographs to the same
standard deviation from their respective histogram mean (Figure 16a). Each
photomicrograph was then analyzed for Area, Perimeter, Feret Diameter, and Integrated
Density values from their predetermined threshold values. Any threshold-selected data,
which came in contact with the edges of any photomicrograph, were deleted via the
Image J “Analyze Particles” dialogue box, so that overlap of photomicrographs did not
allow quantification of any amyloid deposition more than once.
Within the Image J “Analyze Particles” dialogue box, the Oulines mask was also
selected to visually confirm that the plaques were quantified accurately (Figure 16b).
This Outline mask also numbered each plaque, which was used for selecting and
eliminating artifact from the results. The results from each individual photomicrograph
were copied into a 2nd separate spreadsheet, such that the data were separated into their
respective hemispheres (CSF-treated versus artificial cerebrospinal fluid-treated). After
all photomicrographs from a coronal section had been analyzed and data entered into the
spreadsheet, the Area and Perimeter values were totaled and averaged. The Feret
Diameter and Integrated Density values were also averaged. The overall data from each
section (sums and averages) were then entered into a 3rd spreadsheet . A total of 5
sections per mouse, anterior to posterior, were analyzed and entered into this 3rd
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spreadsheet. A total of 4 mice per intrahippocampal-injected CSF were analyzed. For
GM-CSF-injected mice, each section quantified contained analysis of 15-25 individual
10X pictures of each hemisphere, with fewer pictures quantified in the anterior brain and
more in posterior brain. For G-CSF- and M-CSF-injected mice, each section quantified
contained analysis of 7-9 individual 5X pictures of each hemisphere Statistical
significance was obtained from comparing parameter values of ipsilateral CSF-injected
hemispheres versus contralateral artificial cerebrospinal fluid-injected hemispheres.
Significance per mouse and over all 4 mice per CSF was determined by paired Students
t-test with p values <0.5 considered significant .
Results
Bolus Intrahippocampal Injections of CSFs. M-CSF intrahippocampal
injections into mice resulted in swelling of the entire hemisphere as compared to the
control side, and in one mouse, an apparent hyperplasia had formed at the injection site
(Figure 17 a-c). Quantification of amyloid plaque loads from anterior to posterior of each
mouse showed similar deposition in the M-CSF-injected hemispheres as compared to the
control sides (data not shown). In contrast to M-CSF, G-CSF intrahippocampal injections
did not induce swelling and showed some modest reductions of amyloid deposition
(Figure 18 a-b). Since the analyses were conducted on low magnification (5X)
photomicrographs, only the area and integrated density values achieved significance
(p<0.05). Reductions in amyloidosis was subsequently corroborated by independent
observations from fellow investigators following peripheral G-CSF administration
(Sanchez-Ramos et al., 2009).
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GM-CSF-injections, however, demonstrated pronounced decreases in amyloid
deposition, as compared to control hemispheres, in visual observations of coronal tissue
sections (Figure 19 a-d). High magnification (10X) quantification of amyloid plaques
anterior to posterior revealed significant reductions within individual mice and significant
overall reductions for all plaque parameters measured (Figures 20 and 21 a-f).
Conclusion. The differential effects from each injected CSF was surprising and
exciting. Although M-CSF did not show any expected alteration of amyloidosis, its
ability to rapidly induce a hyperplasia, as opposed to G-CSF and GM-CSF, supports
similar literature and helps advance the field’s knowledge with the parenchymal
overexpression of M-CSF (Kirma et al., 2004). Further investigation by other researchers
into the biology of M-CSF-induced hyperplasias would be welcomed. However, based
upon the very pronounced and significant reductions in amyloidosis, after only one week
of ipsilateral intrahippocampal bolus injection of GM-CSF as compared to contralateral
vehicle injection, we wanted to investigate whether GM-CSF would also show benefit in
cognitive function. Although G-CSF also showed some reductions in amyloidosis, it was
not as robust and was currently being researched by fellow investigators (Sanchez-Ramos
et al., 2009). Therefore, we decided to immediately focus our efforts on the investigation
of GM-CSF by subcutaneous delivery, since that would likely be the potential route of
treatment to AD patients. The following chapter will discuss the daily subcutaneous
treatment of mice with recombinant mouse GM-CSF and its effects thereof.
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Figure 13. Schematic of the Intrahippocampal Injection Sites. Either M-CSF,
G-CSF, or GM-CSF were injected into the hippocampus between the CA2 and CA3
regions of one hemisphere, and artificial cerebrospinal fluid would have been injected in
the same contralateral site.
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Figure 14. Magnetic Immunohistochemical Device. This novel device was designed to
minimize the amount of reagents needed during the immunohistochemical staining of
paraffin-embedded slide-mounted tissue sections. The washer-style magnets have an
inside diameter of 0.5 inches that encircles the coronal tissue section. Once the slide and
magnet are placed upon the bracket, the magnetic force holds the slide in place and
provides a barrier to the liquid reagents. Further detail is provided in the patent
application attached in Appendix E. (a) Illustration of pipetting 250 – 300µL of reagent
to magnetic well. (b) Illustration of slide tray contain 3 tissue slides with pipet, that
would have to have to deliver 8– 10mL of reagent to cover slides, as opposed to the
magnetic immunohistochemical device containing 500-600 µL of reagent on two tissue
slides.
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Figure 15. Method of Identifying Individual Photomicrographs for Analysis.
(a) Montaged coronal section of individual 10X photomicrographs that were taken in a
lateral row proceedure with mininal overlap between each one, that was then demarcated
to show which individual photomicrographs would be analyzed for amyloid deposition.
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Figure 16. Method of ImageJ Analysis of Amyloid Plaques. (a) Depiction of the
‘Thresholding’ of one photomicrograph and the subsequent usage of its threshold value
that was entered into a spreadsheet to find the threshold value, at the same standard
deviation from the mean, for all other photomicrographs that are to be analyzed and
which are contained within the same coronal section.
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Figure 16. Method of ImageJ Analysis of Amyloid Plaques (continued). (b) Example
of an ImageJ Oulines mask, that allows for visual confirmation of the plaques that were
analzyed, as well as the underlying ImageJ spreadsheet data that will be entered into a
compilation spreadsheet containing the data of the other photomicrographs of the same
coronal section.
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Figure 17. Intrahippocampal Injection of M-CSF. M-CSF injected left hemisphere
and artificial cerebrospinal fluid (aCSF)-injected right hemisphere. (a) The image is a
montage of ~35 5X pictures and is representative of the effects seen from anterior
hippocampus to posterior in all 4 M-CSF-injected mice. (b) This photo shows
enlargement of the M-CSF-injected left hemisphere, as seen following saline perfusion.
Note the small bump at the site of injection (arrow). (c) Image shows cyst or tumor-like
growth formed in the needle track at the site of M-CSF injection. Cryosectioned at 14 µm
and stained with 6E10/Alexa 488 and Hoechst. Picture taken at 20X.
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Figure 18. Intrahippocampal Injection of G-CSF. G-CSF injected left hemispheres
and artificial cerebrospinal fluid (aCSF)-injected right hemispheres. (a) Images are
montages of ~35 5X pictures each. Amyloid plaques indicated as white spots.
Cryosectioned at 14 µm and stained with 6E10/Alexa546 and Hoechst nuclear stain.
Sections numbered 1 through 6 and correspond with anterior to posterior.
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Figure 18. Intrahippocampal Injection of G-CSF (continued). (b) Amyloid plaques
show a modest reduction of plaque in the left G-CSF-injected hemisphere. Error bars are
± Standard Error of the Mean. (Area, Integrated Density: p < 0.05).
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Figure 19. Intrahippocampal Injection of GM-CSF. GM-CSF injected left
hemispheres and artificial cerebrospinal fluid (aCSF)-injected right hemispheres. (a-d)
Representative sections of each mouse proximal to injection site. Tissue sections stained
with MabTech α-Aβ/Alexa 488. White spots indicate amyloid plaque immunolabelling.
Images are montages of about 145 pictures taken at 10X. Figures 18 (a-c) are from 14 µm
frozen sections, and 18 (d) is from a 5 µm paraffin-embedded section.
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Figure 20. Overall Percent Reductions in Aβ Burden by GM-CSF. Averages of all
four GM-CSF-injected mice showing significant overall plaque reductions in all four
plaque parameters measured from 5 quantified sections per mouse (n = 4 mice). Error
bars are ± Standard Error of the Mean. (Area: p < 1.11E-07; Perimeter: p < 1.41E-06;
Feret Diameter: p < 2.36E-09; Integrated Density: p < 1.11E-07).
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Figure 21. Individual Parameter Reductions in Aβ Burden by GM-CSF.
GM‐CSF‐injected left hemispheres versus artificial cerebrospinal fluid (aCSF)‐injected
right hemispheres. There were 5 montaged sections per mouse quantified. Each montaged
section contained over 140 10X pictures and of these, 15 - 25 pictures per hemisphere
were selected to quantify as described in Appendix D. Each figure shows the total or
average values from the five sections per mouse with statistical significance per
individual mouse and significance over all four mice. Error bars are ± Standard Error of
the Mean: (a - b) plaque areas (c - d) perimeter values
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Figure 21. Individual Parameter Reductions in Aβ Burden by GM-CSF (continued).
(e) average feret diameters (f) average integrated densities.
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CHAPTER 5 – SUBCUTANEOUS ADMINISTRATION OF GM-CSF
Introduction
Based upon the positive results from the GM-CSF intrahippocampal injections
(Chapter 4), we investigated the effect of subcutaneous GM-CSF administration on
cognitive function and AD pathology in aged transgenic AD mice. Prior to these
experiments, there were no published reports involving in vivo behavioral tasks after
administration of Colony Stimulating Factors. We determined an appropriate dosage of
GM-CSF for in vivo administration, which would be comparable to dosages prescribed
for Leukine (sargramostim), the human GM-CSF analogue. This chapter describes the
types of animal behavioral tasks performed, and the alteration of animal cognitive
function and pathophysiology after 20 days of daily recombinant mouse GM-CSF
administration (Boyd et al., 2010 In Press).
Methodology of Behavioral Transgenic Mouse Study Involving Daily
Subcutaneous Treatment with GM-CSF
Transgenic Mice. Mice in this study were derived from the Florida Alzheimer’s
Disease Research Center mouse colony, wherein heterozygous mice carrying the mutant
APPK670N, M671L gene (APPsw) are routinely crossed with heterozygous PS1 (Tg line
6.2) mice to obtain APPsw/PS1, APPsw, PS1, and non-transgenic (NT) genotype
offspring with a mixed C57/B6/SW/SJL background. All procedures involving
experimentation on animals were performed in accordance with the guidelines set forth
by the University of South Florida Animal Care and Use Committee. Transgene
detections were performed using QPCR (Bio-Rad iCycler, Hercules, CA).
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Radial Arm Water Maze (RAWM) and Cognitive Interference Tasks. Eleven
APPsw and 17 NT mice, all 12-months old, were selected and evaluated for 8 days in the
RAWM task of working memory to obtain baseline cognitive performance before
GM-CSF treatment (Arendash et al., 2001). For RAWM testing, aluminum inserts were
placed into a 100 cm circular pool to create 6 radially-distributed swim arms 30.5 cm in
length and 19 cm wide emanating from a central circular swim area 40 cm in diameter.
The inserts rise 5 cm above the surface of the water. A submerged escape platform (9 cm
diameter) is placed with equal distance from the back and side walls in one of the arms
for each day of testing. The platform location was changed daily to a different arm, with
different start arms for each of the 5 trials semi-randomly selected from the remaining 5
swim arms. On the outside of each arm lies a visual cue that is different for each arm.
Mice do not prefer to be in water, and they readily seek out the submerged escape
platform to get out of the water (Figure 22a). For any given trial, the mouse is placed into
that trial’s start arm facing the center swim area and given 60 seconds to find the platform
with a 30 second stay. Each time the mouse enters a non-platform containing arm it is
gently pulled back into the start arm and an error is recorded (Figure 22b). An error is
also recorded and the mouse is pulled back into the start arm for that trial if the mouse
fails to enter any arm within 20 seconds or if a mouse enters the platform-containing arm
but does not find the platform. If the mouse does not find the platform within a 60-second
trial, it is guided by the experimenter to the platform, allowed to stay for 30 seconds, and
assigned a latency of 60 seconds. An error is also assigned to any animal that, for any one
minute trial, does not find the goal arm and refuses to make at least 3 choices on their
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own during that trial (such as just swimming in a circular pattern). This number of
‘3-choices’ was calculated by averaging errors for all animals that do not locate the
platform for Block 1 (day 1 through day 3) on trial 1. Both the number of errors
(incorrect arm choices) and escape latency were recorded for each daily trial. The number
of errors prior to locating which one of the 6 swim arms contained the submerged escape
platform was determined for 5 trials per day. The numbers of errors during trials 4 and 5
are both considered indices of working memory and are temporally similar to the
standard registration/recall testing of specific items used clinically in evaluating AD
patients.
Following the 8 days of pre-treatment RAWM testing (Figure 23a), the 11 Tg
mice were divided into two groups, balanced in RAWM performance. The 17 NT mice
were also divided into two groups, balanced in RAWM performance. Two weeks
following pre-treatment testing, one group of Tg mice (n = 5) and one group of NT mice
(n = 9) were started on a 10-day treatment protocol with GM-CSF (5 µg/day given
subcutaneously), while animals in the control Tg group (n=6) and control NT group (n =
8) concurrently received daily vehicle (saline) treatment subcutaneously. On the 11th day
of injections, all mice began four days of RAWM evaluation, were given 2 days of rest,
then evaluated in 4 days of Cognitive Interference task testing. This task was designed
measure-for-measure from a Cognitive Interference task used to discriminate normal
aged, MCI, and AD patients from one another (Echeverria et al., 2009; Loewenstein et
al., 2004). This analogous interference task for mice involves two radial arm water maze
(RAWM) set-ups in two different rooms, each with different sets of visual cues. The task
requires animals to remember a set of visual cues, so that following interference with a
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different set of cues, the initial set of cues can be recalled to successfully solve the
RAWM task. A set of four behavioral measures were examined. Behavioral measures
were: A1–A3 (Composite three-trial recall score from first 3 trials performed in RAWM
“A”), “B” (proactive interference measure attained from a single trial in RAWM “B”),
A4 (retroactive interference measure attained during a single trial in RAWM “A”), and
“A5”(delayed-recall measure attained from a single trial in RAWM “A” following a 20
minute delay between A4 and A5). As a distracter between trials, animals are placed in a
Y-maze and allowed to explore for 60 seconds between successive trials of the three-trial
recall task, as well as during the proactive interference task. As with the standard RAWM
task, this interference task involves the platform location being changed daily to a
different arm for both of the RAWM set-ups utilized, and different start arms for each
day of testing for both RAWM set-ups. For A1 and B trials, the animal was initially
allowed one minute to find the platform on their own before they were guided to the
platform. Then the actual trial was performed in each case. As with the standard RAWM
task, animals were given 60 seconds to find the escape platform for each trial, with the
number of errors recorded for each trial. Animals were tested for cognitive interference
performance on four successive days, with statistical analysis performed for the two
resultant 2-day blocks. For both RAWM (combined T4 and T5 overall) and cognitive
interference testing (each of the four measures overall), swim speed was analyzed by
dividing error numbers by latency and statistical significance was determined by one-way
ANOVA followed by post hoc Fisher’s LSD (least significant difference) test to
determine significant group differences at p < 0.05.
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Daily GM-CSF and saline injections were continued throughout the behavioral
testing period. After completion of behavioral testing at 20 days into treatment, all mice
were euthanatized, brains fixed in 10% Formalin, and paraffin-embedded. Careful visual
examination of all tissues upon necropsy revealed no morphological abnormalities, and
the mice tolerated daily subcutaneous injections well. Each analysis was done by a single
examiner blinded to sample identities, and statistical analyses were performed by a single
examiner blinded to treatment group identities. The code was not broken until analyses
were completed.
Immunohistochemistry and Image Analysis of Subcutaneous GM-CSFtreated Mice. Five 5-μm sections (150-μm apart) were made of formalin-fixed, paraffinembedded sections throughout the hippocampus of each mouse and immunoreactivity
was developed using the Vectastain ABC Elite kit (Vector Laboratories, Burlingame,
CA) coupled with the diaminobenzidine reaction, according to the manufacturer’s
protocol. Immunostaining used biotinylated anti-Aβ clone 4G8 (Covance, Emeryville,
CA, 1:200), synaptophysin (DAKO, Carpinteria, CA, undiluted), and Iba1 (Wako,
Richmond, VA, 1:1000) as primary antibodies. Since the 4G8 antibody was obtained
with biotin label, the secondary step of the ABC protocol was omitted. However,
treatment with 70% formic acid prior to the pre-blocking step was necessary. For 4G8
immunohistochemistry, phosphate-buffered saline (0.1 mM, pH 7.4) was used instead of
primary antibody or ABC reagent as a negative control. For Iba 1 and synaptophysin
immunohistochemistry, normal rabbit serum was used instead of primary antibody or
ABC reagent as a negative control. Images were acquired using an Olympus BX60
microscope and digital images were quantified using SimplePCI software (Compix Inc.,
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Imaging Systems, Cranberry Township, PA), according to previous methods (SanchezRamos et al., 2009). Briefly, a threshold optical density was obtained that discriminated
staining from background, and each region of interest was manually edited to eliminate
artifacts. Data are reported as percentage of immunolabeled area captured (positive
pixels) relative to the full area captured (total pixels). To evaluate synaptophysin
immunoreactivity, after the mode of all images was converted to gray scale, the average
intensity of positive signals from each image was quantified in the CA1 and CA3 regions
of hippocampus as a relative number from zero (white) to 255 (black).
Statistical significance between GM-CSF-treated versus saline-treated groups was
determined by two-tailed homoscedastic Student’s t-test with a p value of < 0.05
considered significant. Each analysis was done by a single investigator blinded to sample
identities and genotype.
Results
Daily Subcutaneous Injections of GM-CSF. Prior to GM-CSF treatment,
APPsw (Tg) mice were first confirmed by RAWM testing to be cognitively-impaired for
working memory (Figure 23a). Both the non-transgenic control mice (NT) and the Tg
mice were then sub-divided into two cognitively-balanced groups, for either GM-CSF or
saline treatment. RAWM testing, that began on the 11th day of injections, re-confirmed
that Tg control mice were substantially impaired compared to NT control mice. This
impairment was not only evident in individual blocks of testing, but also over all 4 days
of testing (Figure 23b). In sharp contrast, GM-CSF-treated Tg mice performed equally
well or better than NT control mice during individual blocks and overall. GM-CSFtreated NT mice performed as well as or slightly better than NT controls (Figure 23b).
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Before evaluation in the Cognitive Interference Task, the mice rested two days,
while daily injections continued. This task mimics human interference testing, which
discriminates between normal aged, MCI, and AD patients (Loewenstein et al., 2004). In
three of four cognitive interference measures assessed over 4 days of testing (Figure 23c),
Tg control mice were clearly impaired compared to NT mice, and Tg mice treated with
GM-CSF exhibited significantly better three-trial recall and delayed recall compared to
Tg controls. Indeed, for all four cognitive measures, GM-CSF-treated transgenic AD
mice performed similarly to NT mice. A particularly strong effect of GM-CSF treatment
in Tg mice was evident for the proactive interference measure during the first half of
testing (Figure 23d), wherein GM-CSF-treated Tg mice performed substantially better
than Tg controls and identically to both groups of NT mice. Including this strong effect
on proactive interference testing, GM-CSF treatment resulted in significantly better
performance of Tg mice for all four measures of cognitive interference testing. Proactive
interference susceptibility has been reported to be a more sensitive marker for
differentiating MCI and AD patients from aged normals than traditional measures of
delayed recall and rate of forgetting (Loewenstein et al., 2004). Parenthetically, even the
GM-CSF-treated NT mice showed a trend towards improved cognition in behavioral
studies, albeit not statistically significant. Analysis of swim speed for both the RAWM
and cognitive interference tasks revealed that Tg control mice were significantly faster
than the other three groups in the RAWM task and for two of four measures in the
Cognitive Interference task (3-trial recall and delayed recall). However, since error
numbers were utilized for statistical analysis of both tasks, this difference in swim speed
was negated since it is important only if latency measures had been used.
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Following completion of all behavioral evaluations, subsequent analysis of brains
from Tg mice of this study revealed that GM-CSF treatment induced large reductions in
amyloid burdens within entorhinal cortex (↓55%) and hippocampal (↓57%) compared to
control Tg mice (Figure 24). The improved cognitive function and reduced cortical
amyloidosis of GM-CSF-treated Tg mice were paralleled by increased microglial density
as compared to saline-treated Tg mice (Figure 25), implying an augmented ability to bind
and remove amyloid deposition (El Khoury et al., 2007; Hickman, Allison, & El Khoury,
2008). The GM-CSF-treated Tg mice similarly demonstrated increased synaptophysin
immunoreactivity in both CA1 and CA3 regions (Figure 26), indicating increased
synaptic area in these hippocampal regions. Prior work has shown that adult neural stem
cells in hippocampal dentate gyrus (DG) express GM-CSF receptors, and GM-CSF
increases neuronal differentiation of these cells in a dose-dependent fashion (Kruger,
Laage, Pitzer, Schabitz, & Schneider, 2007). Thus, one mechanism for the observed
GM-CSF-induced cognitive improvement is enhanced removal of deposited Aβ in
hippocampus, with ensuing neuronal growth/synaptic differentiation of DG mossy fiber
innervation to CA3, resulting in increased innervation/synaptogenesis of Schaffer
collaterals into CA1. Removal of deposited Aβ from entorhinal cortex may also increase
perforant pathway viability to hippocampal projection fields in DG and CA1.
Conclusions. This is the first study that has examined GM-CSF’s effects on
cognitive function in vivo, and the reversal of pre-determined cognitive impairment gives
hope that the human recombinant GM-CSF, Leukine (sargramostim) may have the same
effects in AD patients. GM-CSF-induced reduction of amyloidosis and enhancement of
hippocampal/entorhinal cortex circuitry, critical for working (short-term) memory, may
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underlie GM-CSF’s reversal of working memory impairment in Alzheimer’s Tg mice.
Furthermore, there may be other mechanisms which are induced by GM-CSF
administration, both peripherally and in the brain, that contribute to the restoration of
cognitive function and reversal of AD pathology. The following chapter will discuss
recent reports of GM-CSF in relation to other neurodegenerative disorders that may shed
light on additional mechanisms for GM-CSF’s pronounced effects in AD models.
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Figure 22. Radial Arm Water Maze Task. (a) RAWM non-error. Depiction of mouse
that has found the submerged escape platform. (b) RAWM error. Depiction of mouse
performing an error in the RAWM task.
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Figure 23. Behavioral analysis following daily subcutaneous GM-CSF injections.
(a)Standard Radial Arm Water Maze Errors Prior to Treatment. The final block and
overall performance of the Tg and NT mice during 8 days of consecutive daily
pre-treatment testing in the RAWM maze. The data were analyzed in four 2-day blocks
and overall (Blocks 1-4). (*p < 0.02 or higher significance).
(b) Standard Radial Arm Water Maze Errors. Tg control mice (n = 6) show
substantial impairment on working memory trials T4 and T5 compared to NT control
mice (n = 8) in individual blocks of testing (upper), and over all 4 days of testing (lower).
GM-CSF-treated Tg mice (n = 5) performed as well as or better than NT control mice on
working memory trials T4 and T5 during individual blocks and over all. GM-CSF-treated
NT mice (n = 9) performed similarly to or slightly better than NT controls (Note
significantly better performance of NT+GMCSF group versus NT group for T4 of Block
1), although this effect was not significant overall. (**p < 0.02 or higher significance
versus all other groups; † p < 0.02 or higher significance versus Tg+GM-CSF and
NT+GM-CSF).
(c) Cognitive Interference Task. Overall (4 Days) Tg control mice are impaired
compared to NT mice on all four cognitive measures assessed. GM-CSF-treated Tg mice
exhibited significantly better 3-trial recall (A1-A3) and delayed recall (A5) compared to
Tg controls and performed similarly to NT mice in all four cognitive measures. GM-CSF
treatment of NT mice did not result in significantly better performance compared to NT
controls, although trends for a beneficial GM-CSF effect in NT mice were evident
overall. (*Tg significantly different from NT+GM-CSF, **Tg significantly different from
all other groups).
(d) Cognitive Interference Task. Proactive Interference Testing (First 2 days).
GM-CSF-treated Tg mice performed significantly better than Tg controls and equally to
NT and GM-CSF-treated NT mice.
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Figure 24. Amyloid Deposition in Subcutaneous GM-CSF-injected Mice. (a-d)
Photomicrographs of coronal 5-µm paraffin-embedded sections immunolabelled with
anti-Aβ antibody (clone 4G8) in Entorrhinal cortex (E) and hippocampus (H)). Pictures
are representative of amyloid load closest to the mean of the GM-CSF- or saline-treated
Tg groups. Scale bar = 50 µm.
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Figure 24. Amyloid Deposition in Subcutaneous GM-CSF-injected Mice (continued).
(e) Percent of amyloid burden from the average of five 5-μm sections (150-μm apart)
through both anatomic regions of interest (hippocampus and entorhinal cortex) per mouse
of GM-CSF-treated (n = 5) versus saline- treated (n = 6). Entorhinal cortex (*p < 0.026),
and Hippocampus (p = 0.12).
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Figure 25. Microglial Immunostaining in Subcutaneous GM-CSF-injected Mice.
(a-d) Photomicrographs of coronal 5µm paraffin-embedded sections immunolabelled
with Iba-1 antibody in Entorrhinal cortex (E) and hippocampus (H). Pictures are
representative of Iba-1 immunolabelling closest to the mean of the GM-CSF- or saline
control- treated groups. Scale bar = 50µm.
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Figure 25. Microglial Immunostaining in Subcutaneous GM-CSF-injected Mice
(continued). (e) Percent of Iba1 burden from the average of five 5-µm sections (150 µm
apart) through both anatomic regions of interest (H and EC) per mouse of GM-CSFtreated (n = 5) versus saline-treated (n = 6). H(p < 0.02), EC(p < 0.05).
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Figure 26. Synaptophysin Immunostaining in Subcutaneous GM-CSF-injected
Mice. (a-d) Photomicrographs of coronal 5-µm paraffin-embedded sections
immunolabelled with anti-synaptophysin antibody. Pictures are representative of
synaptophysin immunolabelling closest to the mean of the GM-CSF- or saline controltreated groups. Scale bar = 50 µm.
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Figure 26. Synaptophysin Immunostaining in Subcutaneous GM-CSF-injected Mice
(continued). (e) Percent of synaptophysin immunoreactivity from the average of 5
sections per mouse of GM-CSF-treated (n = 5) versus saline control-treated (n = 6).
CA1(p < 0.0013), CA3(p < 0.0023).
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CHAPTER 6 – DISCUSSION
Introduction
The disappointing results from NSAID clinical trials prompted us to consider
immunological factors within RA pathogenesis as being protective against AD onset.
Since it appeared most likely that cellular effects and not fluid-phase factors would
account for RA’s protective effect, we decided to induce leukocyte populations within Tg
AD mouse models to study whether these induced leukocytes would have effects against
cerebral amyloidosis, which these PS/APP mice begin accumulating at about 6 months of
age. There are three major hematopoietic factors (M-CSF, G-CSF, GM-CSF) which
contribute to most of the pathogenic leukocytosis in RA, and under disease and
non-disease conditions, they are known to contribute to specific peripheral innate cellular
phenotypes. For instance, G-CSF induces granulocytic leukocytes, which are the most
abundant type, usually constituting over half of all circulating leukocytes. On the other
hand, M-CSF induces the differentiation of monocytic precursors towards macrophage
phenotypes, although M-CSF can also contribute to other cellular types, such as
osteoclasts and Myeloid Derived Suppressor Cell (MDSC) populations. Macrophages are
usually characterized as either an M1 phenotype, in which they are classically activated
by microbial infection and drive a T-helper (Th)-1 response, or as an M2 phenotype, in
which they are described as alternatively activated and considered to be
immunosuppressive, driving a Th-2 reponse. Although considered immunosuppressive,
M2 macrophages also contribute to disease, such as in tumor-associated macrophages
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(TAMs) which drive angiogenesis and tumor development (Mantovani, Sozzani, Locati,
Allavena, & Sica, 2002; Murdoch, Muthana, Coffelt, & Lewis, 2008).
Since peripheral leukocyte populations are greatly increased in RA and possess
the ability to infiltrate into the brain, we wanted to differentially express each leukocyte
phenotype by M-CSF, G-CSF, or GM-CSF induction after direct administration of these
CSFs into the brain, in order to determine which CSF might most affect amyloidosis. In
the vasculature, all three CSFs work to drive the proliferation, differentiation, and
survival of their respective innate leukocytes from monocytic precursors (see Figure 3)
and we hypothesized that they might also have similar differential effects on microglial
populations.
Chronology of Initial Experiments
In our studies, we initially began with the investigation of M-CSF administration
into the brains of Tg AD mice. In the beginning of 2007 at the time of these experiments,
the literature suggested that a deficiency of M-CSF in osteopetrotic mice could cause a
deficit in microglial populations, neuronal loss, and an accumulation of cerebral amyloid
plaques (Kaku et al., 2003; Kawata et al., 2005). Also, at that time, there was no guiding
literature to suggest dosage amounts for intracerebral administration of M-CSF. Thus we
decided to maximize the dosage through continuous bilateral intracerebroventricular
infusion for two weeks using our newly-developed osmotic catheter system (Chapter 3
and Appendix A). Subsequent immunohistochemical analyses of the plaque burden in the
mice revealed significant unexpected variations of amyloidosis between mice of the same
genotype and of similar age (Figures 5, 6). Furthermore, there was concern whether M-
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CSF was able to readily extravasate from the ventricles and into the brain’s parenchymya
in order to induce an effect on amyloidosis.
Meanwhile, we had contacted Dr. Kaku to request his expertise for M-CSF
dosage amounts. Although he could not provide guidance for dosage, he did inform us
that subsequent studies had shown that the antibody, in which he used for his 2003 study,
was non-specifically immunolabeling some blood cells, and that they could not confirm
amyloidosis in osteopetrotic mice. Moreover, a coinciding report was soon published by
another group, which confirmed that although there was a deficiency in microglial
density, there was no amyloid deposition or loss of dopaminergic neurons in osteopetrotic
mice (Kondo, Lemere, & Seabrook, 2007).
Although these results with M-CSF were contrary to our initial thoughts, we
nevertheless wanted to investigate each CSF’s effects within the brain’s parenchyma in
relation to already-formed amyloid deposition. Our subsequent work with the
development of the osmotic bilateral catheters had revealed that infused recombinant
proteins remained localized into the respective brain hemisphere of which they are
administered. Thus, we decided to perform intrahippocampal injections of each
recombinant CSF protein into one hemisphere of the brain, and inject vehicle control
contralaterally.
Bilateral Infusion Catheters
Our findings with the development of the bilateral catheter system has several
important implications, not only in our work, but broadly for other future studies of
intracerebral delivery of materials into murine models. We were the first to bilaterally
infuse recombinant peptides and to show that the infused recombinant proteins remain
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localized to the hemisphere in which they are infused. This concept will effectively
reduce the number of animals that are needed for these types of experiments, since each
animal can now be its own control and allow for comparisons of treatment or injury from
one hemisphere of the brain versus the other. This effect will provide great cost benefit to
researchers who will now have more flexibility in selecting murine cohorts, since they
will no longer need age-matched controls. To further this idea of cost-effectiveness, the
ability to infuse compounds, biologicals, etc. into one hemisphere and not the other, can
provide for conditional transgenic models ipsilaterally versus control contralaterally, as
we showed with replication of the triple transgenic PS/APP/ACT model in one
hemisphere versus doube transgenic PS/APP in the other (Figures 10 - 12). As is widely
known, a large amount of breeding, genotyping, housing, and other costs of animal
husbandry are incurred when going from double to triple transgenicity.
Other significant benefits are also provided by the develoment of the bilateral
catheters. For instance, in the commercially-available Alzet® delivery system, the
catheter head is not only too large in diameter to place two of these upon a mouse’s skull,
it is also too thick, in that closure of the scalp after placement is difficult, if not
impossible sometimes. Furthermore, the catheter tubing sometimes protrudes outside of
the skin. In all of these cases, there is obvious discomfort to the animal, and the animals
are known to scratch at the tubing and catheter head, as well as rubbing them against the
housing cage. As a result, it can be logically-assumed that stress hormone levels are
chronically-affected during the course of these trials, and that there is chronic
inflammation in the open wound, as the mice will oftentimes scratch their entire scalp off.
Both of these issues may compromise an experiment, contribute to mortality, cause
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discomfort to the animal, increase research costs for the investigator, and possibly skew
results due to the intrinsic immunological effects from this catheter pathology. Our
bilateral catheter system is adhered directly in contour and upon the skull, so that the skin
can readily close with sutures, staples, or skin adhesive and can then heal with new fur
and absence of inflammation (Figure 9). The mice tolerate these catheter extremely well,
and have significant reductions in mortality rate (almost non-existent). Furthermore, these
animals, once healed in a couple of weeks, can be used in water-based behavioral tasks,
such as the Morris or RAWM. We hope that these improvements to the current methods
of intracerebral infusions will become standard protocol for these types of experiments in
all research vivariums around the country.
Thus, using our gained knowledge from the catheter development, we injected
each CSF unilaterally into one hippocampus and vehicle contralaterally. Upon
subsequent examination of the brains one week post-injection, we found different
functional effects for each intrahippocampal-injected CSF. In the M-CSF injected mice,
there was no effect on amyloidosis, but pathological changes were noticed, such as
swelling and hyperplasia (Chapter 4). Parenchymal overexpression of M-CSF in any
organ is probably not advisable as overexpression of M-CSF and/or its receptor within
mammary glands has similarly resulted in tumor formation and hyperplasia (Kirma et al.,
2004). We also examined several microglial markers in each CSF-treated group of mice,
such as Iba-1, CD68, CD11b, CDllc, F4/80, and CD45 (results not shown). However, we
did not find any differences with any of the microglial stainings between each brain
hemisphere, except for differences in microglial density which directly correlated with
the amyloid plaque burden, as the microglia were found to abundantly decorate the
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plaques. Interestly, the mice in our study do not get NFTs, but in a recent study of
post-mortem human brains of various age and neuropathology (Streit, Braak, Xue, &
Bechmann, 2009), microglia are shown to be dystrophic and extremely fragmented
around degenerating neurons with tauopathy, such as neuropil threads, NFTs, and neuritic
plaques. However, the microglia in non-diseased brains, and the microglia in DS and AD
brains,which are colocalized with amyloid deposition, are shown to be fully ramified and
non-activated, while the microglia in patients with systemic infectious disease were found
to hypertrophic and activated, even in absence of identifiable CNS disease. Furthermore,
the dystrophic microglial phenotypes preceded tau pathology, according to Braak staging
of AD neuropathology, indicating that microglia normally play an important role in
neuroprotection, and that a decline in their populations within the brain may contribute to
onset of AD.
M-CSF and AD
Although we did not find any difference in amyloidosis from intrahippocampal
injections of M-CSF, a recent study, reported that chronic intraperitoneal (i.p.) injection
of M-CSF into Tg AD mice expressing GFP+ bone marrow prevents and reverses
amyloid deposition and cognitive impairment, while inducing a large accumulation of
GFP+ bone marrow-derived microglia into the brain (Boissonneault et al., 2009). The
authors also confirmed previous research (Simard, Soulet, Gowing, Julien, & Rivest,
2006) that bone marrow-derived microglia efficiently phagocytose and internalize Aβ.
However, differences between these data and ours point directly to different study
lengths, route of administration, and dosage effects, with Boissonneault et al. delivering
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peripheral chronic 1.3µg M-CSF per i.p. injection, as compared to our 5µg
intrahippocampal bolus.
Another recent study has also revealed that M-CSF has significantly diminished
levels in AD patients, and that M-CSF may have diagnostic potential within an AD
biomarker panel (Britschgi & Wyss-Coray, 2008; Ray et al., 2007). This same group also
investigated whether M-CSF administration would improve AD pathology in vivo. They
found that i.p. injection of M-CSF into 7-8 month old APP transgenic mice
(Thy1-hAPP), tested 10 months later, had improved performance in the Morris water
maze (Luo J., 2008). Interestingly, there were no changes in microglial activation, or
levels of soluble and insoluble Aβ levels in the brains. Moreover, i.p injection of M-CSF,
one day prior to kainite administration, prevented neurodegeneration and microgliosis,
but did not change microglial density.
Although these different authors did not relate their findings to RA’s inverse
relationship with AD, their data does provide evidence that up-regulated M-CSF in RA
pathogenesis and systemic administration of M-CSF in AD patients may both impart
protection against AD onset or progression. Although the authors have proposed M-CSF
as a curative therapy against AD (Boissonneault & Rivest, 2009), M-CSF’s activation of
mature osteoclasts, macrophages, and other innate leukocytes, its induced
thrombocytopenia (Hubel, Dale, & Liles, 2002; Nemunaitis et al., 1991; Nemunaitis et
al., 1993; Zeigler, Rosenfeld, Nemunaitis, Besa, & Shadduck, 1993), and its autocrine
signaling in some tumors (Patsialou et al., 2009) may limit it’s usefulness in the clinical
setting.
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G-CSF and AD
While our study of intrahippocampal administration of G-CSF showed only a
modest reduction in amyloid burden after one week post-injection (Figure 18), other
studies have shown greater effects against AD pathology from chronic peripheral
administration (Sanchez-Ramos et al., 2009; Tsai, Tsai, & Shen, 2007). In the recent
study by Sanchez-Ramos et al. (2009), the authors used PS/APP mice which had been
lethally-irradiated and transplanted with GFP+ bone marrow at 2 months of age. At 6 to 8
months of age, the GFP+ mice showed a significant increase in bone marrow-derived
microglia which corresponded with about 40% amyloid reductions. A second cohort of
aged predetermined cognitively-impaired mice, which were treated chronically for only
2.5 weeks with G-CSF, demonstrated restoration of cognitive function to about half of
the difference in errors between the Tg and age-matched control group. This partial
reversal of cognitive deficit correlated with decreased amyloid burden, increased
microglial density, increased neuronal synaptic area, and increased neurogenic markers.
The prior study by Tsai et al. (2007) had also subcutaneously administered G-CSF into
Tg AD mouse models and observed some rescue of cognitive function, which correlated
with increased neurogenic staining and with increased expression of the neurotransmitter,
acetylcholine. As with M-CSF, these results were not associated with RA’s protective
role against AD, but the increased ameliorative effects of both M-CSF and G-CSF from
peripheral adminstration versus intracerebral administration is consistent with the
observation that RA, a peripheral disease, can prevent onset of AD, a CNS disease.
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GM-CSF and AD
Although the G-CSF intrahippocampal findings were encouraging, our GM-CSF
intrahippocampal injections into an AD mouse model demonstrated a much more
pronounced reduction of amyloidosis (Figures 19 – 21). These data led us to further
examine GM-CSF on the behavior of aged cognitively-impaired AD mice. Daily
subcutaneous administration of GM-CSF for 20 days resulted in nearly complete reversal
of cognitive impairment, resulting in function similar to that of wild-type mice, with a
corresponding average of about 50% reduction of amyloidosis in Entorrhinal cortex and
Hippocampus. In contrast, M-CSF and G-CSF were shown to only partially reverse
cognitive impairment in aged AD mice, although the preventative chronic study of MCSF administration into young AD mice showed equal cognitive function over time
compared to wild-type controls. One explanation for this increased benefit with GM-CSF
could be due to GM-CSF’s overlapping functions of both M-CSF and G-CSF, resulting in
a combinatory effect of increased macrophage and granulocyte populations derived from
bone marrow-derived monocytic precursors in the periphery, as well as induction or
activation of other innate leukocyte subsets in both the periphery and brain. Indeed, GMCSF has been shown to cross the blood brain barrier (McLay, Kimura, Banks, & Kastin,
1997), and a recent study showed that GM-CSF injected into the brains of normal mice
activates microglia (Reddy et al., 2009). As mentioned in Chapter 2 (Malm et al., 2005),
only after LPS injection into the hippocampi of the 25-month-old aged mice with
established amyloid burden, did reductions in amyloidosis and recruitment of BMDCs
occur, as opposed to the 21-month-old non-treated and normally aged Tg mice. A
following study also showed that LPS activation of microglia was able to reduce
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amyloidosis, possibly through a mechanism of LPS-induced up-regulation of CR3
(CD11b) (Herber et al., 2007). Thus GM-CSF may function to have a role in both the
activation of resident microglia, and also in the recruitment of BMDCs to the brain.
There may also be further explanations for the very robust cognitive benefits of
GM-CSF, including significant reductions in amyloidosis (Figure 24), increased neuronal
plasticity (Figure 26), augmentation of peripheral erythropoietic amyloid-clearance
mechanisms by increasing CR1 availability (Fisher, 2003; Helmy et al., 2006; Rogers et
al., 2006), increased cerebral angiogenesis (U. C. Schneider et al., 2007), neuroprotection
from apoptosis (Schabitz et al., 2008) and increased neurogenesis (Kruger, Laage, Pitzer,
Schabitz, & Schneider, 2007). These effects may also help explain some of the benefits
against AD that were desribed in the M-CSF and G-CSF studies. All three CSFs in the
periphery function in the mobilization, proliferation, and differentiation of innate
leukocyte populations, but G-CSF and GM-CSF are known to have additional roles in the
CNS. Following is a more detailed description of these putative effects for all three CSFs.
Angiogenic Functions of CSFs in the AD Brain
Introduction. All three CSF’s, when given peripherally, result in the reduction of
amyloid plaques within the brain. This may be due to the increased leukocyte populations
that contain receptors, such as CR3 or CR4, which may aid in the phagocytosis of
complement-bound amyloid, or by the secretion of proteases from the bone
marrow-derived microglia, which may then proteolytically degrade the plaques. The
exact mechanisms are not completely known, just that the plaques are decreased and that
there is an influx of bone marrow-derived microglial cells which decorate the plaques.
Since Aβ itself has been shown to be anti-angiogenic (Paris et al., 2010; Patel et al.,
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2010), the removal of amyloid plaque would thus remove this inhibition of angiogenesis
and allow for neovascularization, which would in turn allow for increased cerebral blood
flow and aid in the availability of more erythrocytes and leukocytes to the brain for
further plaque clearance and delivery of oxygen and glucose. Much research within the
field of tumor biology has shown the ability of innate leukocytes to play a central role in
angiogenesis. Thus it would be logical to presume that neovascularization occurs
simultaneously with amyloid removal, given that the same myeloid-derived leukocytes
participate in both roles.
Angiogenic Mediators. There are several studies that show that various
mediators of angiogenesis are found in the AD brain, implying a need and attempt of the
brain for neovascularization, although this effort is intrinically stymied in AD, and
aberrant vascular protrusions emanate from the ends of truncated and occluded vessels
around plaques (Figure 1). For instance, angiopoietin-2 and VEGF are expressed in AD
microvessels, but are not in control microvessels (Thirumangalakudi, Samany, Owoso,
Wiskar, & Grammas, 2006). However, the tissue inhibitors of matrix metalloproteinases
(TIMP)-1,2 are also up-regulated in the AD microvessels and in amyloid plaques
(Lorenzl et al., 2003; Peress, Perillo, & Zucker, 1995), while matrix metalloproteinase
(MMP)-9 activity, which the TIMPs regulate, is undetectable (Thirumangalakudi et al.,
2006). MMPs play a crucial role in promoting angiogenesis by degrading the
extracellular matrix (Bergers et al., 2000; Coussens, Tinkle, Hanahan, & Werb, 2000).
Studies in PS/APP mice show that MMP-9 and other Aβ-degrading enzymes, such as
insulysin and neprilysin, as well as Aβ-binding receptors, such as scavenger receptor A
(SRA), CD36, and receptor for advanced-glycation endproducts (RAGE), are all
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decreased with age (Hickman, Allison, & El Khoury, 2008). Thus the increase of innate
leukocytes, which contain these receptors and proteases, could help remove the plaque
and normalize angiogenic mechanisms, that otherwise have both pro-angiogenic and
anti-angiogenic factors being simultaneously produced in AD microvasculature.
Macrophages. Macrophages are very versatile, multifunctional cells that can
adapt their functions to the environment in which they reside. As mentioned earlier, they
are usually classified at either M1 or M2 phenotypes. The LPS-induced clearance of
amyloid (Herber et al., 2007; Malm et al., 2005) could well have been from M1 types of
microglia, which would also induce angiogenic Cox-2 expression within them
(Hoozemans et al., 2001). In tumors associated macrophages (TAMs), these macrophages
obtain an M2-like phenotype that also promotes angiogenesis through the release of
pro-angiogenic factors, such as VEGF, basic fibroblast growth factor (bFGF), TNFα,
IL-1β, IL-8, COX-2, plasminogen activator, urokinase (uPA), platelet derived growth
factor β (PDGFβ), and MMPs-7,-9, and -12 (Reviewed in (Dirkx, Oude Egbrink,
Wagstaff, & Griffioen, 2006)). TAMs are chemotaxically-attracted to areas of hypoxia,
where they up-regulate HIF-related genes, such as VEGF and NFκB, which in turn skews
them into their M2 phenotype (Hagemann et al., 2008). Furthermore, recent studies have
shown that under sustained stimulation of angiogenic growth factors, that monocytes are
able to transdifferentiate into endothelial cells (Fernandez Pujol et al., 2000; Kuwana et
al., 2006).
Another specific subpopulation of circulating monocytes, which have much more
potent pro-angiogenic activity, are identified through their expression of the angiopoietin
receptor, TIE2 (Venneri et al., 2007). These TIE2-expressing monocytes (TEMs) have
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been found to reside in both perivascular and hypoxic, avascular areas of tumors (De
Palma et al., 2005; Venneri et al., 2007), and although TEMs have not been identified in
AD, its ligand, angiopoietin-2 is specifically expressed in the AD (Thirumangalakudi et
al., 2006) truncated, and occluded microvasculature, thus implying that there may indeed
be potential involvement of TEMs in the dysregulated vasculogenic activity surrounding
amyloid plaques.
Myeloid-Derived Suppressor Cells. Another group of pro-angiogenic leukocytes
are the myeloid-derived suppressor cells (MDSCs), a heterogeneous group of immature
precursor cells for neutrophils, monocytes, and dendritic cells (DCs). MDSC populations
are upregulated by COX-2, prostaglandins, stem-cell factor (SCF) (Pan et al., 2008;
Serafini et al., 2004; Sinha, Clements, Fulton, & Ostrand-Rosenberg, 2007), VEGF
(Gabrilovich et al., 1998), IL-6, M-CSF (Bunt et al., 2007), and GM-CSF (Serafini et al.,
2004). While MDSCs are precursors cells either resembling an immature neutrophil
phenotype (characterized as CD11b+Gr1hi) or an immature monocyte phenotype
(characterized as CD11b+Gr1low) (Movahedi et al., 2008; Sawanobori et al., 2008), they
are potently immunosuppressive as opposed to mature neutrophils and macrophages.
Thus MDSCs are of great interest in cancer research, since they suppress immune
activation against tumors, and because they contribute to angiogenesis via high
expression of MMPs (Yang et al., 2004; Yang et al., 2008). Therefore in M-CSF and
GM-CSF treated AD mice, it could be hypothesized that the induced MDSCs could
release MMPs into the vasculature around the plaques and which may counteract the
overexpressed TIMPs, thus allowing unobstructed VEGF and angiopoietin2 vasculogenic
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effects. However, there are no studies yet that have examined MDSC activity in Tg AD
mice, following peripheral administration of GM-CSF or M-CSF.
Neutrophils. Like their precursor MDSCs, neutrophils are also pro-angiogenic by
their high expression of MMP-9 (Coussens et al., 2000), and studies show that their
number correlates with the microvessel density within tumors (Benelli et al., 2002;
Mentzel et al., 2001; Van Coillie et al., 2001). Furthermore, neutrophils do not express
TIMPs, allowing them to rapidly promote angiogenesis by uninhibited release of MMP-9
(Ardi, Kupriyanova, Deryugina, & Quigley, 2007). Factors, such as TNFα and GM-CSF
cause the neutrophils to de-granulate and release intracellular stores of pro-angiogenic
chemokines, CXCL1 and CXCL8, and MMP-9 (Cassatella, 1999). Neutrophils, although
the most abundant phagocytic leukocyte, are also the shortest lived, with a half-life of
within 24 hours from leaving the bone marrow before undergoing apoptosis (Cohen,
1991). In DS patients, neutrophil survival is shortened by up to 30% compared to non-DS
individuals, implying the DS patients may have even more anti-angiogenic mechanisms
than those described in Chapter 1. Interestingly, GM-CSF and IL-5 could prevent
apoptosis in the neutrophils of control individuals, but not in neutrophils from DS
patients (Yasui, Shinozaki, Nakazawa, Agematsu, & Komiyama, 1999). The
administration of G-CSF and GM-CSF into AD mice would have pro-angiogenic effects
through induced expression of neutrophil populations by both G-CSF and GM-CSF, but
GM-CSF administration may also sustain the neutrophil populations against apoptosis
longer, providing for increased angiogenic and phagocytic acitivity.
Dendritic Cells. Dendritic cells, the major antigen-presenting cells of the body
which are critical in the regulation of the adaptive immune response, also play a major
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role in angiogenesis, as immature DCs (iDCs) release TNFα and CXCL8, which triggers
other cells, like neutrophils, to secrete their various angiogenic growth factors (Caux et
al., 1994). iDCs release other factors, such as osteopontin, which has increased
concentrations in the cerebrospinal fluid of AD and triggers the release of IL-1β (Comi et
al., 2010; Wung et al., 2007), a highly angiogenic cytokine (Naldini et al., 2006).
Cytokines, such as VEGF (Dikov et al., 2001; Laxmanan et al., 2005), hepatocyte growth
factor (HGH) (Okunishi et al., 2005), TGFβ (Alard, Clark, & Kosiewicz, 2004),
prostaglandin E (Pockaj et al., 2004), and osteopontin (Konno et al., 2006) suppress DC
maturation and contribute to the maintenance of this pro-angiogenic iDC phenotype .
Conclusion. Given the angiogenic potential of all of the innate leukocytes
described above, and the increased cerebral blood flow that would result from
neovascularization, it would be expected for these hematopoietic growth factors, M-CSF,
G-CSF, and GM-CSF, to have therepeutic effects in ischemic diseases. While M-CSF has
not been shown to be a potential therapeutic for treatment of stroke, both G-CSF and
GM-CSF have undergone investigation in various models of ischemia. In an experimental
model of cerebral focal ischemia, G-CSF injections up to 3 days post-infarct, was
demonstrated to enhance angiogenesis, with increased vascular surface area, vascular
branching, de novo endothelial cell proliferation, and eNOS/angiopoietin-2 expression, as
compared to PBS control injected rats (Lee et al., 2005). Although, there have not been
any further experimental cerebral ischemic studies performed with G-CSF which have
reported on neovascularization, G-CSF has been shown in a small clinical trial of 5
patients who received G-CSF after acute myocardial infarction (AMI), as compared to 5
control patients, that six days of daily G-CSF treatment increased the vascular growth
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factors, VEGF, bFGF, and MCP-1, while improving ejection fraction and myocardial
perfusion and function (Kuethe et al., 2006).
GM-CSF, on the other hand, has been shown to induce neovascularization in
several models of experimental stroke. In a rat model of vertebral plus left carotid artery
occlusion, s.c. administration of GM-CSF over a course of 3 weeks significantly
increased arteriogenesis and functional hemodynamic measurements, via up-regulated
macrophage populations in the posterior cerebral artery, as compared to saline-treated
animals (Buschmann, Busch, Mies, & Hossmann, 2003). Two similar follow-up studies
by this same group showed similar induction of arteriogenesis by GM-CSF injections
following variations of experimental hypoperfusion in rat brain (Hossmann &
Buschmann, 2005; Schneeloch, Mies, Busch, Buschmann, & Hossmann, 2004). Other
groups have also subsequently shown that GM-CSF treatment completely restores
cerebral blood flow following bilateral carotid artery occlusion (BCO) (U. C. Schneider
et al., 2007) and restores leptomeningeal collaterals following common carotid artery
(CCA) occlusion (Todo et al., 2008).
Although G-CSF and GM-CSF have shown some utility in stroke models for the
restoration of cerebral blood flow and neovascularization, they have yet to be described
with the same effects in Tg AD mice. A very fine analyses of the microvessels would be
needed to examine whether chronic administration of these CSFs over time would
prevent the buildup of amyloid deposits on the parenchymal side of the vessels before
they progress to the large deposits and severly damaged cerebrovasculature, as seen in
Figure 1, as well as whether the microvasculature can be repaired by the CSFs after the
removal of amyloid deposition in aged mice. Further studies, using VCC models and with
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chronic versus acute delivery of the CSFs, will be needed to closely examine these effects
of innate leukocytes.
Neuroprotective Functions of CSFs in the AD Brain
GM-CSF. Many of the experiments with stroke models have also found the CSFs
to be neuroprotective after induced ischemia. A rat model of middle cerebral artery
occlusion (MCAO) of 1 hour duration, in which an intracarotid injection of GM-CSF or
saline upon reperfusion was administered and in which the study animals were assessed 2
days later, showed improved neurological function in the GM-CSF-injected rats, and
their subsequent immunohistochemistry revealed a reduction in infarct volume, an
increase of activated microglia or macrophages, and a decrease of apoptotic cells in the
penumbra surrounding the infarct, as compared to saline injected rats (Nakagawa, Suga,
Kawase, & Toda, 2006). A following study examined the neuroprotective pathways that
GM-CSF induces within two stroke models of MCAO and MCA. In this study, the
authors identified the alpha-chain of the GM-CSF receptor (GM-CSFR), and showed
GM-CSFR to be up-regulated after ischemia, with it broadly expressed throughout the
brain, and with it localized on primary cortical neurons, and oligodendrocytes, as well as
on human neuroblastoma cells. The authors also found that GM-CSF counteracts
apoptotosis via the induction of the phosphatidylinositol 3 kinase (PI3K)-Akt pathway,
and by induction of the anti-apoptotic proteins Bcl-2 and Bcl-xL, as well as increasing
intraparenchymal and leptomeningeal arterioles (Schabitz et al., 2008). Another MCAO
study, combining a glutamate-induced excitotoxicity neuronal injury cell culture model,
showed similar alterations of apoptotic related genes and found GM-CSF to be
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neuroprotective, with decreased infarct volume and improved locomotor function in
GM-CSF-treated rats versus controls (Kong et al., 2009).
G-CSF. Although G-CSF has only one study examining neovascularization in
experimental ischemic models (Lee et al., 2005), it has been extensively studied since
2003 for its neuroprotective roles after cerebral ischemia. G-CSF has also been shown to
protect against glutamate-induced neurotoxicity (Han, Blank, Schwab, & Kollmar, 2008;
Schabitz et al., 2003), to have induced expression following ischemia (Hasselblatt,
Jeibmann, Riesmeier, Maintz, & Schabitz, 2007; Kleinschnitz, Schroeter, Jander, & Stoll,
2004), to reduce infarct volume and improve function after transient focal ischemia
(Gibson, Bath, & Murphy, 2005, 2010; A. Schneider et al., 2006) and intracebral
hemorrhage (Park et al., 2005), and to induce the expression of anti-apoptotic proteins
and pathways (Komine-Kobayashi et al., 2006; Solaroglu, Cahill, Tsubokawa,
Beskonakli, & Zhang, 2009; Solaroglu, Tsubokawa, Cahill, & Zhang, 2006; Yata et al.,
2007).
M-CSF. While M-CSF has not been reported to be used therapeutically in stroke
models for neovascularization or neuroprotection, its receptor, M-CSFR (also known as
c-fms) has been reported to be neuroprotective when overexpressed in a microglialhippocampal oganotypic coculture system, in which microglia overexpressing M-CSFR
rescued neurons from excitoxicity (Mitrasinovic et al., 2005). A similar follow-up study
using the same coculture system, found that M-CSF treatment prevented NMDA-induced
apoptosis (Vincent, Robinson, Simsek, & Murphy, 2002). Cultured microglia
overexpressing M-CSF exhibited enhanced phagocytosis of Aβ (Mitrasinovic & Murphy,
2002) and postmortem analyses of AD patients have increased expression of M-CSFR on
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microglia (Akiyama et al., 1994), although M-CSF levels itself are decreased in AD
patients (Ray et al., 2007). However, as mentioned above, its side effects limit its
usefulness in the clinical setting.
Neurogenic Functions of CSFs in the AD Brain
Both GM-CSF and G-CSF have been reported to have neurogenic capabilities.
The human analogues to both have been FDA-approved since early 1990’s for the
mobilization and collection of peripheral blood stem cells (PBSCs) for transplantation
(Reviewed in (Hubel et al., 2002)). As was discussed in Chapter 2, bone marrow-derived
cells have the ability to enter the brain and become neuronal or other types of brain cells.
However, GM-CSF and G-CSF can both cross the BBB, as well as be secreted by
neurons and oligodendrocytes. Not only do these neuronal cell types contain receptors for
each CSF (Schabitz et al., 2003; Schabitz et al., 2008), neural stem cells (NSCs) have
also been shown to contain receptors for both (Kruger et al., 2007; A. Schneider et al.,
2005), and binding of either CSF to their respective receptor on NSCs induces time and
dosage dependent proliferation and subsequent differentiation. A recent report examining
both bone marrow-derived neuronal progenitors versus brain-derived NSCs found that
the brain-derived NSCs have a higher capacity for proliferation (Song, Song, Zhang,
Cuevas, & Sanchez-Ramos, 2007), although both neuronal progenitors types would be
expected to be involved from peripheral adminstration of the CSFs. In fact the recent
study by fellow investigators show parenchymal incorporation of bone marrow-derived
neurons after G-CSF peripheral administration (Sanchez-Ramos et al., 2009). Although
our studies were not conducted in a manner to examine this effect, it is also expected that
bone marrow-derived neuronal cells were present within our study, given that GM-CSF
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induction encompasses both bone marrow-derived macrophage and granulocyte subsets
of leukocytes, which have independently been shown to become neuronal and glial cells
following their respective peripheral CSF induction .
Research Theory Summary
To restate our theory of what is needed to inhibit and reverse AD pathology, there
must first be simultaneous strategies to remove the cerebral amyloidosis and to provide
neuroprotection to the micro-penumbras that surround the plaques and occluded vessels.
We have shown a remarkable reduction in plaque burden from GM-CSF after just one
week following intrahippocampal administration, and then similarly by 20 days of
subcutaneous delivery. Although, G-CSF had modest effects intrahippocampally, and MCSF did not, other researchers have shown significant reversal of amyloidosis from
peripheral administration. Additionally, many studies that have also shown each CSF to
have neuroprotective properties, which actions would simultaneously be needed in the
penumbras around the amyloid plaques as the plaques are being cleared.
Next after removal of amyloid, we theorized that there must be strategies to
immediately induce neovascularization in the infarcted areas where the plaques were
located and to also induce neuritogenesis and/or neurogenesis to rebuild the neural and
vascular networks in order to restore cognitive function. While we did not have
appropriate models to examine neovascularization, many other models and studies have
shown both GM-CSF and G-CSF to be highly pro-angiogenic. Other studies have also
shown both of these CSFs to also be neurogenic to NSCs, as well as to be peripheral
blood progenitor cell mobilizers. Furthermore, it has been found that neurogenesis and
neovascularization occur simultaneously with the same cues guiding each together. Thus
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with both G-CSF and GM-CSF showing increased synaptic area, with G-CSF showing
evidence of induced neurogenesis, and with all three CSF’s demonstrating reversal of
cognitive deficits, all aspects of our theory are explained by intrinsic mechanisms of
RA’s leukocytic pathogenesis. Furthermore, with GM-CSF’s pronounced effects over
such a short period of time, we are encouraged that the recombinant human GM-CSF will
show similar effects in AD patients.
Clinical Implications
Our results mirror those reported for G-CSF (Sanchez-Ramos et al., 2009), and
supports the current practice of interchangeable prescription of either recombinant human
GM-CSF (Leukine) or G-CSF (Granocyte, Neupogen, and Neulasta) into patients with
depressed bone marrow function. G-CSF primarily treats neutropenia while GM-CSF
treats all leukopenia, and both have long records of safety data from two decades of
FDA-approved usage. Rare adverse events are usually mild febrile incidents that quickly
subside upon cessation of administration. G-CSF is currently in clinical trial for stroke
and was recently approved for an AD Phase II clinical trial. However, GM-CSF/Leukine
is more effective in the AD mouse model and while neutrophils are short-lived
leukocytes, the fact that GM-CSF induces the up-regulation of all innate cells means that
it could potentially impart prolonged protective effects against AD. Furthermore, Leukine
is the only FDA-approved drug to prevent fatal infections in acute myelogenous leukemia
(AML) patients, and thus would also be expected to provide antibiotic-free prophylaxic
immunity against onset of infection in the recipient AD patients, who at their age and
immunodeficient state are highly susceptible to microbial opportunism.
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Conclusion
The failure of NSAID clinical trials in AD and the multiple studies which show
that a defective innate immune system propagates AD pathology, encouraged us to
develop and test our hypothesis that intrinsic pathogenic properties of RA are protective
against AD. The recent 2009 ICAD news by Dr. Breitner of the ADAPT consortium,
which reported a 0.33 hazard ratio for dementia, within cognitively-normal individuals
taking naproxen for over two years, is still more than that of RA patients, in which less
than 5% ever develop concomitant AD, further strengthening our hypothesis that other
intrinsic factors within RA pathogenesis must underlie the protective effect of RA against
AD onset. Indeed the beneficial effects of all three RA-upregulated CSFs, especially
GM-CSF, in mouse models of AD point to a potential new approach to AD therapy and
indicate that age-related depressed hematopoiesis may be etiological for AD
pathogenesis.
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APPENDIX A: A NOVEL TECHNIQUE FOR SIMULTANEOUS BILATERAL
INFUSIONS IN A MOUSE MODEL OF NEURODEGENERATIVE DISEASE

The manuscript entitled, “A novel technique for simultaneous bilateral infusions
in a mouse model of neurodegenerative disease”, by Steven P. Bennett et al., was
accepted for publication on August 27, 2009 in the Journal of Neuroscience Methods.
The device developed and described within this manuscript provided the scientific and
technological framework upon which the findings of GM-CSF against AD were made.
Following is a copy of this manuscript as it can be found in the Journal of Neuroscience
Methods and as it can be accessed through a search of the online PubMed database.
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APPENDIX B: GM-CSF UP-REGULATED IN RHEUMATOID ARTHRITIS
REVERSES COGNITIVE IMPAIRMENT AND AMYLOIDOSIS IN
ALZHEIMER’S MICE

Following is the acceptance email from the Journal of Alzheimer’s Disease of the
latest revision of the manuscript entitled, “GM-CSF Up-regulated in Rheumatoid
Arthritis Reverses Cognitive Impairment and Amyloidosis in Alzheimer’s Mice”.
Curently, we are expecting back proofs of the manuscript as it will be presented in the
journal, and thus the final version is not available for this dissertation.
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ABSTRACT
Rheumatoid arthritis (RA) is a negative risk factor for the development of Alzheimer’s
disease (AD). While it has been commonly assumed that RA patients’ usage of nonsteroidal anti-inflammatory drugs (NSAIDs) helped prevent onset and progression of AD,
NSAID clinical trials have proven unsuccessful in AD patients. To determine whether
intrinsic factors within RA pathogenesis itself may underlie RA’s protective effect, we
investigated the activity of colony-stimulating factors, up-regulated in RA, on the
pathology and behavior of transgenic AD mice. 5μg bolus injections of macrophage,
granulocyte, and granulocyte-macrophage colony-stimulating factors (M-CSF, G-CSF, or
GM-CSF) were administered unilaterally into the hippocampus of aged cognitivelyimpaired AD mice and the resulting amyloid load reductions determined one week later,
using the artificial cerebrospinal fluid-injected contralateral sides as controls. G-CSF and
more significantly, GM-CSF reduced amyloidosis throughout the treated brain
hemisphere one week following bolus administration to AD mice. 20 daily subcutaneous
injections of 5µg of GM-CSF (the most amyloid-reducing CSF in the bolus experiment)
were administered to balanced cohorts of AD mice after assessment in a battery of
cognitive tests. Reductions in amyloid load and improvements in cognitive function were
assessed. Subcutaneous GM-CSF administration significantly reduced brain amyloidosis
and completely reversed the cognitive impairment, while increasing hippocampal
synaptic area and microglial density. These findings, along with two decades of accrued
safety data using Leukine, recombinant human GM-CSF, in elderly leukopenic patients,
suggest that Leukine should be tested as a treatment to reverse cerebral amyloid
pathology and cognitive impairment in AD.
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Introduction
Although numerous studies have reported Rheumatoid arthritis (RA) to reduce the risk of
Alzheimer’s disease (AD), the mechanisms for RA’s protective effect are still unknown
[1]. It was proposed and commonly assumed that RA patients’ usage of non-steroidal
anti-inflammatory drugs (NSAIDs) may help prevent the onset and progression of AD [1].
However, the largest NSAID clinical trials have not demonstrated efficacy in reducing the
incidence of dementia, and recently Naproxen was reported to be detrimental, with
increased risk of cardiovascular and cerebrovascular events [2]. These results
suggested to us that intrinsic, probably immunological factors within RA pathogenesis
itself may underlie RA’s protective effect against AD. We surmised that up-regulated
local cellular populations in RA would have the highest potential to enter into the brain
and inhibit the development of AD pathology and/or neuronal dysfunction.
Alzheimer’s disease is an age-related, progressive neurodegenerative disorder
that presents as increasing decline in cognitive and executive function. Alzheimer
dementia is associated with cerebrovascular dysfunction [3], extracellular accumulation
of amyloid β (Aβ) peptides in the brain parenchyma and vasculature walls [4, 5]
(predominantly Aβ1-42 and Aβ1-40), and intraneuronal accumulation of neurofibrillary
tangles consisting of hyperphosphorylated Tau proteins[6]. Associated
neuroinflammation may contribute to AD pathogenesis [7], as the inflammatory proteins
apolipoprotein E (apoE) and α1-Antichymotrypsin (ACT) catalyze the polymerization of
Aβ peptides into amyloid filaments in vivo and in vitro [8-11], and ACT has been shown
to induce the phosphorylation of Tau [12]. Conversely, it has also been shown that
amyloid plaques form rapidly and then become decorated by microglia [13, 14], both
resident and bone marrow-derived, suggesting an ability and intention to remove
amyloid [15-17]. Thus it is unclear whether neuroinflammation is deleterious or beneficial
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in the AD brain, and indeed the role of microglia in AD is complex and may involve
different states of activation with different activities.
Rheumatoid arthritis is an autoimmune disease in which inflamed synovial tissue
and highly vascularized pannus form, irreparably damaging the cartilage and bone. In
this inflammatory pannus, leukocyte populations are greatly expanded, perhaps as an
endogenous, but ineffective attempt to remove the inflammatory insult. As a result,
many proinflammatory factors are produced that work together in feed-forward
mechanisms, further increasing leukocytosis, cytokine/chemokine release,
osteoclastogenesis, angiogenesis, and autoantibody production (rheumatoid factors and
anti-citrullinated protein antibodies) [18, 19]. Additionally, the adaptive immune system
presents a Th17 phenotype within CD4+ lymphocytes, with ultimate production of
interleukin 17 (IL-17) which is then responsible for inducing much of the
pro-inflammatory effects [20, 21]. Further enhancements of leukocyte populations come
from increased expression of structurally-unrelated colony-stimulating factors: M-CSF
(macrophage), G-CSF (granulocyte), and GM-CSF (granulocyte-macrophage) [22-25].
Although up-regulated leukocytes in response to RA could potentially enter into
the brain and inhibit development of AD pathology and/or neuronal dysfunction,
lymphocytic infiltrates into AD patient brains have not been reported. The lack of
infiltration suggests that RA-induced proliferation and activation of the innate immune
system by the CSFs described above might be responsible for preventing AD pathology
in RA patients. Evidence supporting the innate immune system’s role in AD
pathogenesis show that complement proteins are up-regulated in AD brain, and that
inhibition of C3 convertase significantly increases amyloid pathology in AD mice [26].
Bone marrow-derived microglia also play a critical role in restricting amyloid deposition,
and indeed, microglia activation and many associated receptors and enzymes, such as
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CD36, scavenger receptor A, and receptor for advanced glycation end products,
neprilysin, insulysin, and matrix metalloproteinases, decline with age as risk of AD
pathology increases [17, 27, 28].
To investigate the interplay of the innate immune system and AD, we studied the
effects on AD pathology of the three colony-stimulating factors (M-CSF, G-CSF, and
GM-CSF), which are up-regulated during RA pathogenesis [22-25]. These CSFs
enhance the survival and function of their respective leukocytes and drive their
proliferation and differentiation from myeloid lineage precursors. GM-CSF induces
dendritic cells, macrophages, and granulocytes (neutrophils, basophils, and eosinophils),
while M-CSF and G-CSF respectively induce the macrophage and granulocyte subsets
of the innate immune system. These innate cells have the ability to diapedese from the
circulatory system and to differentiate further into various specialized immune cells
within organs (microglia, Langerhan’s cells, etc.). GM-CSF and G-CSF are also known
to be involved in erythropoiesis, and GM-CSF and erythropoietin act synergistically in
the maturation and proliferation of the burst-forming and colony-forming erythroid units to
the normoblast stage of erythropoiesis [29, 30]. Circulating Aβ binds to complement
opsonin C3b in an antibody-independent fashion, and C3-opsonized particles bind to the
complement receptor, CR1, on erythrocytes and to CR1g on liver-resident kupffer
macrophages [31, 32]. Thus GM-CSF could function in both the peripheral clearance of
Aβ and in bone marrow-derived microglial activity, since it is involved in the proliferation,
differentiation, and maintenance of most innate leukocytes.
Here, we report on experiments that investigated the effect of CSF administration
on amyloid plaque deposition, microglial activation, synaptic function, and associated
cognitive decline in a mouse model of AD. Our results, particularly with GM-CSF,
provide a compelling explanation for RA’s inverse relationship with AD. Moreover, the

192

reduction of amyloidosis and enhancement of cognition by GM-CSF warrant clinical
investigation of Leukine for the treatment of Mild Cognitive Impairment (MCI) and AD
patients, especially with Leukine’s long-standing safety history in leukopenic patients.
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Materials and Methods
All procedures involving experimentation on animals were performed in accordance with
the guidelines set forth by the University of South Florida Animal Care and Use
Committee. Transgene detections were performed using QPCR (Bio-Rad iCycler,
Hercules, CA).
Transgenic Mouse Studies Involving Intracerebral Administration of CSFs
PS/APP mice in this study, which begin accumulating robust amyloid plaques at 6-8
months, were generated by crossing heterozygous PDGF-hAPP (V717F) mice with
PDGF-hPS1 (M146L) on both Swiss Webster and C57BL/6 backgrounds.
Bilateral Intracerebroventricular infusion of M-CSF
M-CSF was bilaterally infused directly into the lateral ventricles (5 µg/day) for 14 days
using a novel intracranial catheter infusion system (patent pending - PCT/US08/73974)
[33]. This completely subcutaneously-contained system allows bilateral intracerebral
infusion of test substances ipsilaterally and vehicle contralaterally, and overcomes the
problem of amyloidosis variance between animals (Supplementary Fig. 1), effectively
making each animal its own control. Briefly, animals (PS/APP, all 8.8 -9.6 months,
numbered sequentially according to date of birth, 25-35 g, both genders) were
anesthetized with 1-2% isoflurane, shaved and scrubbed with 10% Betadine solution at
the site of incision, and placed into a stereotaxic frame (Kopf Instruments, Tujunga, Ca.).
A small (3 cm) incision was made, exposing the skull, and curved Strabysmus surgical
scissors were used to form a subcutaneous pocket along the animal’s back into which 2
osmotic minipumps (Alzet model 1004, average flow rate of 0.12 µL/hour, Durect Corp.,
Cupertino, CA) were inserted. Two holes were drilled into the skull (from Bregma -0.1
mm anterior-posterior, +/- 0.9 mm medial-lateral), and 30 gauge catheters were inserted
at a depth of 3.0 mm, corresponding to the lateral ventricles. Leading from the Alzet
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pump was a proprietary catheter system with the delivery tips fashioned to the contours
of the skull rather than the commercially-available pedestal cannula. The cannulae are
affixed to the skull using Locktite 454 adhesive (Plastics One, Roanoke, VA) and
secured with 1 cm diameter nitrile, followed by silk sutures to close the scalp.

After 2 weeks of M-CSF infusions, mice were perfused, brain tissues were fixed
in 10% neutral buffered formalin, and cryosectioned at 14 µm.
Intrahippocampal injections of CSFs
All three CSFs were stereotaxically-injected (5 µg/injection) into the (ipsilateral)
hippocampus, with artificial cerebrospinal fluid vehicle injected contralaterally into four
PS/APP mice each (all 10-12 months old, 25-35 g, both genders). Two holes were drilled
into the skull (from bregma -2.5 mm anterior-posterior, +/- 2.5 mm medial-lateral, and the
30 gauge needle inserted to a depth of 2.5 mm). Mice were perfused with 0.9% cold
saline 7 days later and their brains placed in 10% neutral buffered formalin.
Recombinant mouse GM-CSF (rmGM-CSF), recombinant murine G-CSF (rmG-CSF),
and recombinant mouse M-CSF (rmM-CSF) (R&D Systems, Minneapolis, MN) will be
referred to as GM-CSF, G-CSF, and M-CSF throughout this publication.
Immunohistochemistry and Image Analysis of Intrahippocampal-injected Mice
Formalin-fixed brains were either coronally cryosectioned at 14-µm, or paraffinembedded and sectioned at 5-µm, with standard deparaffination and antigen retrieval
steps (boiled in 10mM Sodium Citrate buffer for 20 minutes) performed before
immunohistochemical staining. To significantly reduce cost of reagents and antibodies
with paraffin-embedded slides, a novel magnetic immunohistochemical staining device
was developed (patent pending, Tech ID# 09A015). Standard fluorescent
immunohistochemical techniques used primary anti-Aβ antibodies 6E10 (Covance,
Emeryville, CA, 1:1000), and MabTech’s 3740-5 (MabTech, Cincinnati, OH, 1:5000) to
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immunolabel amyloid deposition coupled with Alexa fluorophore-labelled secondary
antibodies (Molecular Probes, Eugene, OR, 1:1000, 1:4000), and Hoechst (Sigma)
nuclear staining. Immunofluorescence was detected and all pictures per section were
taken at the same exposure on a Zeiss Imager.Z1 microscope (Oberkochen, Germany)
using Axiovision 4.7 software. Digital images were quantified using ImageJ (method
described in Supplementary Fig. 6 online). Briefly, each analyzed picture per coronal
section was thresholded equally to the same standard deviation from the histogram
mean, and analyzed for area, perimeter, feret diameter, and integrated density
parameters of each plaque. Area and Perimeter data were calculated from the total and
average number of plaque values in each hemisphere per section, and Feret Diameter
and Integrated Density were calculated from the average values of the plaques
measured in each hemisphere per section. For GM-CSF-injected mice, each section
quantified contained analysis of 15-25 individual 10X pictures of each hemisphere, with
fewer pictures quantified in the anterior brain and more in posterior brain. For G-CSFand M-CSF-injected mice, each section quantified contained analysis of 7-9 individual
5X pictures of each hemisphere Statistical significance was obtained from comparing
parameter values of ipsilateral CSF-injected hemispheres versus contralateral artificial
cerebrospinal fluid-injected hemispheres. Significance was determined by paired
Students t-test with p values <0.5 considered significant.
Behavioral Transgenic Mouse Study Involving GM-CSF Treatment
Mice in this study were derived from the Florida Alzheimer’s Disease Research Center
mouse colony, wherein heterozygous mice carrying the mutant APPK670N, M671L gene
(APPsw) are routinely crossed with heterozygous PS1 (Tg line 6.2) mice to obtain
APPsw/PS1, APPsw, PS1, and non-transgenic (NT) genotype offspring with a mixed
C57/B6/SW/SJL background. Eleven APPsw and 17 NT mice, all 12-months old, were
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selected and evaluated for 8 days in the RAWM task of working memory (as previously
described [34] (Supplementary Fig. 7). Briefly, an aluminum insert was placed into a
100 cm circular pool to create 6 radially distributed swim arms emanating from a central
circular swim area. The number of errors prior to locating which one of the 6 swim arms
contained a submerged escape platform (9 cm diameter) was determined for 5 trials per
day. The platform location was changed daily to a different arm, with different start arms
for each of the 5 trials semi-randomly selected from the remaining 5 swim arms. The
numbers of errors during trials 4 and 5 are both considered indices of working memory
and are temporally similar to the standard registration/recall testing of specific items
used clinically in evaluating AD patients. Following 8 days of pre-treatment RAWM
testing, the 11 Tg mice were divided into two groups, balanced in RAWM performance.
The 17 NT mice were also divided into two groups, balanced in RAWM performance.
Two weeks following pre-treatment testing, one group of Tg mice (n = 5) and one
group of NT mice (n = 9) were started on a 10-day treatment protocol with GM-CSF (5
µg/day given subcutaneously), while animals in the control Tg group (n=6) and control
NT group (n = 8) concurrently received daily vehicle (saline) treatment subcutaneously.
On the 11th day of injections, all mice began four days of RAWM evaluation, were given
2 days of rest, then evaluated in 4 days of Cognitive Interference task testing as
previously described [35, 36]. We designed this task measure-for-measure from a
Cognitive Interference task used to discriminate normal aged, MCI, and AD patients from
one another [34]. Our analogous interference task for mice involves two radial arm
water maze (RAWM) set-ups in two different rooms, each with different sets of visual
cues. The task requires animals to remember a set of visual cues, so that following
interference with a different set of cues, the initial set of cues can be recalled to
successfully solve the RAWM task. A set of four behavioral measures were examined.
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Behavioral measures were: A1–A3 (Composite three-trial recall score from first 3 trials
performed in RAWM “A”), “B” (proactive interference measure attained from a single trial
in RAWM “B”), A4 (retroactive interference measure attained during a single trial in
RAWM “A”), and “A5”(delayed-recall measure attained from a single trial in RAWM “A”
following a 20 minute delay between A4 and A5). As a distracter between trials, animals
are placed in a Y-maze and allowed to explore for 60 seconds between successive trials
of the three-trial recall task, as well as during the proactive interference task. As with the
standard RAWM task, this interference task involves the platform location being changed
daily to a different arm for both of the RAWM set-ups utilized,
and different start arms for each day of testing for both RAWM set-ups. For A1 and B
trials, the animal was initially allowed one minute to find the platform on their own before
they were guided to the platform. Then the actual trial was performed in each case. As
with the standard RAWM task, animals were given 60 seconds to find the escape
platform for each trial, with the number of errors recorded for each trial. Animals were
tested for cognitive interference performance on four successive days, with statistical
analysis performed for the two resultant 2-day blocks. For both RAWM (combined T4
and T5 overall) and cognitive interference testing (each of the four measures overall),
swim speed was analyzed by dividing error numbers by latency and statistical
significance was determined by one-way ANOVA followed by post hoc Fisher’s LSD
(least significant difference) test to determine significant group differences at p < 0.05.
Daily GM-CSF and saline injections were continued throughout the behavioral
testing period. After completion of behavioral testing at 20 days into treatment, all mice
were euthanatized, brains fixed as described above, and paraffin-embedded. Careful
visual examination of all tissues upon necropsy revealed no morphological
abnormalities, and the mice tolerated daily subcutaneous injections well. Each analysis
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was done by a single examiner blinded to sample identities, and statistical analyses
were performed by a single examiner blinded to treatment group identities. The code
was not broken until analyses were completed.
Immunohistochemistry and Image Analysis of Subcutaneous GM-CSF-treated
Mice
Five 5-μm sections (150-μm apart) were made of formalin-fixed, paraffin-embedded
sections throughout the hippocampus of each mouse and immunoreactivity was
developed using the Vectastain ABC Elite kit (Vector Laboratories, Burlingame, CA)
coupled with the diaminobenzidine reaction, according to the manufacturer’s protocol.
Immunostaining used biotinylated anti-Aβ clone 4G8 (Covance, Emeryville, CA, 1:200),
synaptophysin (DAKO, Carpinteria, CA, undiluted), and Iba1 (Wako, Richmond, VA,
1:1000) as primary antibodies. Since the 4G8 antibody was obtained with biotin label,
the secondary step of the ABC protocol was omitted. However, treatment with 70%
formic acid prior to the pre-blocking step was necessary. For 4G8
immunohistochemistry, phosphate-buffered saline (0.1 mM, pH 7.4) was used instead of
primary antibody or ABC reagent as a negative control. For Iba 1 and synaptophysin
immunohistochemistry, normal rabbit serum was used instead of primary antibody or
ABC reagent as a negative control. Images were acquired using an Olympus BX60
microscope and digital images were quantified using SimplePCI software (Compix Inc.,
Imaging Systems, Cranberry Township, PA), according to previous methods [37].
Briefly, a threshold optical density was obtained that discriminated staining from
background, and each region of interest was manually edited to eliminate artifacts. Data
are reported as percentage of immunolabeled area captured (positive pixels) relative to
the full area captured (total pixels). To evaluate synaptophysin immunoreactivity, after
the mode of all images was converted to gray scale, the average intensity of positive
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signals from each image was quantified in the CA1 and CA3 regions of hippocampus as
a relative number from zero (white) to 255 (black).
Statistical significance between GM-CSF-treated versus saline-treated groups was
determined by two-tailed homoscedastic Student’s t-test with a p value of < 0.05
considered significant. Each analysis was done by a single investigator blinded to
sample identities and genotype.
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RESULTS
Intracerebral administration of CSFs
Following bilateral intracerebroventricular infusion of M-CSF for two weeks into PS/APP
mice, immunohistochemical analysis of both experimental and control mice showed
considerable variances of amyloid deposition between mice of similar age
(Supplementary Fig 1), significantly compromising our ability to determine M-CSF’s
effect in a limited mouse cohort. While improving our drug delivery system by developing
novel bilateral brain infusion catheters [33], we found that parenchymally-infused
recombinant peptides remained localized to the infused hemisphere. These findings led
us to administer the CSFs as a unilateral intrahippocampal bolus with a contralateral
injection of vehicle as control, thus obviating the need for large numbers of transgenic
mice and age-matched littermate controls to obtain statistical significance. Each CSF
was stereotaxically injected into the hippocampus of 4 mice, with artificial cerebrospinal
fluid vehicle injected contralaterally. The mice were sacrificed 7 days post-injection.
M-CSF intrahippocampal injections into mice resulted in swelling of the entire
hemisphere as compared to the control side, and in one mouse, an apparent hyperplasia
had formed at the injection site (Supplementary Fig 2). Quantification of amyloid plaque
loads from anterior to posterior of each mouse showed similar deposition in the M-CSFinjected hemispheres as compared to the control sides (data not shown). In contrast to
M-CSF, G-CSF intrahippocampal injections did not induce swelling and showed some
modest reductions of amyloid deposition (Supplementary Fig 3). Since the analyses
were conducted on low magnification (5X) photomicrographs, only the area and
integrated density values achieved significance (p<0.05). Reductions in amyloidosis was
subsequently corroborated by independent observations from fellow investigators
following peripheral G-CSF administration [37].
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GM-CSF-injections, however, demonstrated pronounced decreases in amyloid
deposition, as compared to control hemispheres, in visual observations of coronal tissue
sections (Fig 1a; Supplementary Fig 4). High magnification (10X) quantification of
amyloid plaques anterior to posterior revealed significant reductions within individual
mice and significant overall reductions for all plaque parameters measured (Fig 1b and
Supplementary Fig 5).

Daily subcutaneous injection of GM-CSF
Based upon the positive results from intrahippocampal injections, we investigated the
effect of subcutaneous GM-CSF injection on AD pathology and cognitive function. Prior
to GM-CSF treatment, APPsw (Tg) mice were first confirmed by RAWM testing to be
cognitively-impaired for working memory (Fig 2a). Both the non-transgenic control mice
(NT) and the Tg mice were then sub-divided into two cognitively-balanced groups, for
either GM-CSF or saline treatment. RAWM testing post-injection re-confirmed that Tg
control mice were substantially impaired compared to NT control mice. This impairment
was not only evident in individual blocks of testing, but also over all 4 days of testing (Fig
2b). In sharp contrast, GM-CSF-treated Tg mice performed equally well or better than
NT control mice during individual blocks and overall. GM-CSF-treated NT mice
performed as well as or slightly better than NT controls (Fig 2b).
Before evaluation in the Cognitive Interference Task, the mice rested two days.
This task mimics human interference testing, which discriminates between normal aged,
MCI, and AD patients [36]. In three of four cognitive interference measures assessed
over 4 days of testing (Fig 2c), Tg control mice were clearly impaired compared to NT
mice, and Tg mice treated with GM-CSF exhibited significantly better three-trial recall
and delayed recall compared to Tg controls. Indeed, for all four cognitive measures, GM-
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CSF-treated transgenic AD mice performed similarly to NT mice. A particularly strong
effect of GM-CSF treatment in Tg mice was evident for the proactive interference
measure during the first half of testing (Fig 2d), wherein GM-CSF-treated Tg mice
performed substantially better than Tg controls and identically to both groups of NT
mice. Including this strong effect on proactive interference testing, GM-CSF treatment
resulted in significantly better performance of Tg mice for all four measures of cognitive
interference testing. Proactive interference susceptibility has been reported to be a
more sensitive marker for differentiating MCI and AD patients from aged normals than
traditional measures of delayed recall and rate of forgetting [36]. Parenthetically, even
the GM-CSF-treated NT mice showed a trend towards improved cognition in behavioral
studies, albeit not statistically significant. Analysis of swim speed for both the RAWM
and cognitive interference tasks revealed that Tg control mice were significantly faster
than the other three groups in the RAWM task and for two of four measures in the
Cognitive Interference task (3-trial recall and delayed recall). However, since error
numbers were utilized for statistical analysis of both tasks, this difference in swim speed
was negated since it is important only if latency measures had been used.
Following completion of all behavioral evaluations, subsequent analysis of brains
from Tg mice of this study revealed that GM-CSF treatment induced large reductions in
amyloid burdens within entorhinal cortex (↓55%) and hippocampal (↓57%) compared to
control Tg mice (Fig 3). The improved cognitive function and reduced cortical
amyloidosis of GM-CSF-treated Tg mice were paralleled by increased microglial density
as compared to saline-treated Tg mice (Fig 4), implying an augmented ability to bind and
remove amyloid deposition [27, 28]. The GM-CSF-treated Tg mice similarly
demonstrated increased synaptophysin immunoreactivity in both CA1 and CA3 regions
(Fig 5), indicating increased synaptic area in these hippocampal regions. Prior work has
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shown that adult neural stem cells in hippocampal dentate gyrus (DG) express GM-CSF
receptors, and GM-CSF increases neuronal differentiation of these cells in a dosedependent fashion [38]. Thus, one mechanism for the observed GM-CSF-induced
cognitive improvement is enhanced removal of deposited Aβ in hippocampus, with
ensuing neuronal growth/synaptic differentiation of DG mossy fiber innervation to CA3,
resulting in increased innervation/synaptogenesis of Schaffer collaterals into CA1.
Removal of deposited Aβ from entorhinal cortex may also increase perforant pathway
viability to hippocampal projection fields in DG and CA1.
Thus GM-CSF-induced reduction of amyloidosis and enhancement of
hippocampal/entorhinal cortex circuitry, critical for working (short-term) memory, may
underlie GM-CSF’s reversal of working memory impairment in Alzheimer’s Tg mice.
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DISCUSSION
Since peripheral leukocyte populations are increased in RA and possess the ability to
infiltrate into the brain, we initially investigated M-CSF, G-CSF, and GM-CSF to
determine which CSF might affect amyloidosis after direct injection into the brain. In the
vasculature, all three CSFs work to drive the proliferation, differentiation, and survival of
their respective innate leukocytes from monocytic precursors and would be expected to
have similar effects on microglial precursors.
In our study, we found different functional effects for each intrahippocampalinjected CSF. In the M-CSF injected mice, there was no effect on amyloidosis, but
pathological changes were noticed, such as swelling and hyperplasia (Supplementary
Fig 2). Parenchymal overexpression of M-CSF in any organ is probably not advisable as
overexpression of M-CSF and/or its receptor within mammary glands has similarly
resulted in tumor formation and hyperplasia [39]. In a study by Boissonneault et al.
(2009), the authors published that chronic intraperitoneal injection of M-CSF prevents
and reverses amyloid deposition and cognitive impairment and induces a large
accumulation of bone marrow-derived microglia in the brain [40]. The authors also
confirmed previous research [17] that bone marrow-derived microglia efficiently
phagocytose and internalize Aβ. Although the authors did not relate their findings to RA’s
inverse relationship with AD, their data provide evidence that up-regulated M-CSF in RA
pathogenesis and systemic administration of M-CSF in AD patients may impart
protection against AD onset or progression. However, M-CSF’s activation of mature
osteoclasts, macrophages, and other innate leukocytes, induced thrombocytopenia, and
autocrine signaling in some tumors may limit it’s usage in the clinical setting.
Peripheral administration of G-CSF has also been found to ameliorate amyloid
pathology and reduce cognitive defects in AD models [37, 41], which corroborates our
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observations of modest amyloid reduction by intrahippocampal injection. In the study by
Sanchez-Ramos et al. [37], the authors also show a large increase in bone marrowderived microglia with corresponding amyloid reductions, increased synaptic area, and
partial reversal of cognitive impairment.
Although the M-CSF and G-CSF intrahippocampal findings are encouraging, our
GM-CSF intrahippocampal injections into an AD mouse model demonstrated a much
more pronounced reduction of amyloidosis. These data led us to further examine
GM-CSF on the behavior of aged cognitively-impaired AD mice. Subcutaneous
administration of GM-CSF resulted in almost complete reversal of cognitive impairment,
resulting in function similar to that of wild-type mice, with a corresponding average of
about 50% reduction of amyloidosis in Entorrhinal cortex and Hippocampus. In contrast,
M-CSF and G-CSF have been shown to only partially reverse cognitive impairment in
aged AD mice, although the preventative chronic study of M-CSF administration into
young AD mice showed equal cognitive function over time compared to wild-type
controls. This cognitive advantage of peripherally-administered GM-CSF into aged AD
mice could result from a combinatory effect of increased macrophage and granulocyte
populations from bone marrow-derived monocytic precursors in the periphery, as well as
induction of other innate leukocyte subsets in both periphery and brain. Indeed, GM-CSF
has been shown to pass the blood brain barrier[42], and a recent study showed that GMCSF injected into the brains of normal mice activates microglia[43]. Further explanations
for the very robust cognitive benefits of GM-CSF in our experiments are multiple,
including the aforementioned augmentation of peripheral erythropoietic amyloidclearance mechanisms [31, 32, 44], as well as increased neurogenesis,[38] increased
cerebral angiogenesis [45], neuroprotection from apoptosis[46], reduction in amyloidosis
(Figs 1,3, and Supplementary Fig 5), and increased neuronal plasticity (Fig 5).
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Our results mirror those reported for G-CSF [37], and supports the current
practice of interchangeable prescription of either recombinant human GM-CSF (Leukine)
or G-CSF (Granocyte, Neupogen, and Neulasta) into patients with depressed bone
marrow function. G-CSF primarily treats neutropenia while GM-CSF treats all
leukopenia, and both have long records of safety data from two decades of FDAapproved usage. Rare adverse events are usually mild febrile incidents that quickly
subside upon cessation of administration. G-CSF is currently in clinical trial for stroke
and was recently approved for an AD Phase II clinical trial. However, GM-CSF/Leukine
is more effective in the AD mouse model and while neutrophils are short-lived
leukocytes, the fact that GM-CSF induces the up-regulation of all innate cells means that
it could potentially impart prolonged protective effects against AD.
The failure of NSAID clinical trials in AD and the multiple studies that show that a
defective innate immune system propagates AD pathology encouraged us to develop
and test our hypothesis that intrinsic pathogenic properties of RA are protective against
AD. Indeed the beneficial effects of all three RA-upregulated CSFs, especially GM-CSF,
in mouse models of AD point to a potential new approach to AD therapy and indicate
that age-linked depressed hematopoiesis may be etiological for AD pathogenesis.
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Fig 1. Intrahippocampal injection of GM-CSF (left) and artificial cerebrospinal fluid
(aCSF) (right). (a) Representative coronal tissue cryo-sectioned at 14 µm and stained
with MabTech α-Aβ/Alexa 546. Image is a montage of about 145 pictures taken at 10X.
White spots indicate amyloid plaque immunolabelling (see Supplementary Fig. 4 online
for representative montaged sections of all 4 mice). (b) Significant overall plaque
reductions seen in all 4 plaque parameters measured from 5 quantified sections per
mouse (n = 4 mice). Error bars are ± Standard Error of the Mean. (Area: p < 1.11E-07;
Perimeter: p < 1.41E-06; Feret Diameter: p < 2.36E-09; Integrated Density: p < 1.11E07).
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Fig 2. Behavioral analysis following daily subcutaneous GM-CSF injections.
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(a)Standard Radial Arm Water Maze errors prior to treatment. The final block and
overall performance of the Tg and NT mice during 8 days of consecutive daily
pre-treatment testing in the RAWM maze. The data was analyzed in four 2-day blocks
and overall (Blocks 1-4). (*p < 0.02 or higher significance).
(b) Standard Radial Arm Water Maze errors after treatment. Tg control mice (n = 6)
show substantial impairment on working memory trials T4 and T5 compared to NT
control mice (n = 8) in individual blocks of testing (upper), and over all 4 days of testing
(lower). GM-CSF-treated Tg mice (n = 5) performed as well as or better than NT control
mice on working memory trials T4 and T5 during individual blocks and over all. GM-CSFtreated NT mice (n = 9) performed similarly to or slightly better than NT controls (Note
significantly better performance of NT+GMCSF group versus NT group for T4 of Block
1), although this effect was not significant overall. (**p < 0.02 or higher significance
versus all other groups; † p < 0.02 or higher significance versus Tg+GM-CSF and
NT+GM-CSF).
(c) Cognitive Interference Task. Overall (4 Days) Tg control mice are impaired
compared to NT mice on all four cognitive measures assessed. GM-CSF-treated Tg
mice exhibited significantly better 3-trial recall (A1-A3) and delayed recall (A5) compared
to Tg controls and performed similarly to NT mice in all four cognitive measures. GMCSF treatment of NT mice did not result in significantly better performance compared to
NT controls, although trends for a beneficial GM-CSF effect in NT mice were evident
overall. (*Tg significantly different from NT+GM-CSF, **Tg significantly different from all
other groups).
(d) Cognitive Interference Task. Proactive Interference testing (First 2 days).
GM-CSF-treated Tg mice performed significantly better than Tg controls and equally to
NT and GM-CSF-treated NT mice.
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Fig 3. Amyloid deposition in subcutaneous GM-CSF-injected mice. (a-d)
Photomicrographs of coronal 5-µm paraffin-embedded sections immunolabelled with
anti-Aβ antibody (clone 4G8) in Entorrhinal cortex (E) and hippocampus (H)). Pictures
are representative of amyloid load closest to the mean of the GM-CSF- or saline-treated
Tg groups. Scale bar = 50 µm. (e) Percent of amyloid burden from the average of five
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5-μm sections (150-μm apart) through both anatomic regions of interest (hippocampus
and entorhinal cortex) per mouse of GM-CSF-treated (n = 5) versus saline- treated (n =
6). Entorhinal cortex (*p < 0.026), and Hippocampus (p = 0.12).
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Fig 4. Microglial immunostaining in subcutaneous GM-CSF-injected mice.
(a-d) Photomicrographs of coronal 5µm paraffin-embedded sections immunolabelled
with Iba-1 antibody in Entorrhinal cortex (E) and hippocampus (H). Pictures are
representative of Iba-1 immunolabelling closest to the mean of the GM-CSF- or saline
control- treated groups. Scale bar = 50µm. (e) Percent of Iba1 burden from the average
of five 5-µm sections (150 µm apart) through both anatomic regions of interest (H and
EC) per mouse of GM-CSF-treated (n = 5) versus saline-treated (n = 6).
H(p < 0.02), EC(p < 0.05).
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Fig 5. Synaptophysin immunostaining in subcutaneous GM-CSF-injected mice.
(a-d) Photomicrographs of coronal 5-µm paraffin-embedded sections immunolabelled
with anti-synaptophysin antibody. Pictures are representative of synaptophysin
immunolabelling closest to the mean of the GM-CSF- or saline control- treated groups.
Scale bar = 50 µm. (e) Percent of synaptophysin immunoreactivity from the average of 5
sections per mouse of GM-CSF-treated (n = 5) versus saline control-treated (n = 6).
CA1(p < 0.0013), CA3(p < 0.0023).
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Supplementary Figure 1. Significant variation of amyloid plaque load between
mice.
Standard fluorescent immunohistochemistry used 6E10/Alexa 488 and Hoechst nuclear
stain (blue). Bright green spots indicate amyloid plaques. Pictures taken at 5X. Mouse
numbers 148,160,171, and 211 received bilateral intracerebroventricular infusions of MCSF and mice 164, 170, 176, and 177 received bilateral intracerebroventricular infusions
of artificial cerebrospinal fluid.
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Supplementary Figure 2. Intrahippocampal injection of M-CSF-injected left
hemisphere and artificial cerebrospinal fluid (aCSF)‐injected right hemisphere.
(A) The image is a montage of ~35 5X pictures and is representative of the effects seen
from anterior hippocampus to posterior in all 4 M-CSF-injected mice. (B) This photo
shows enlargement of the M-CSF-injected left hemisphere, as seen following saline
perfusion. Note the small bump at the site of injection (arrow). (C) Image shows cyst or
tumor-like growth formed in the needle track at the site of M-CSF injection.
Cryosectioned at 14 µm and stained with 6E10/Alexa 488 and Hoechst. Picture taken at
20X.

226

227

Supplementary Figure 3. Intrahippocampal injection of G-CSF-injected left
hemispheres and artificial cerebrospinal fluid (aCSF)‐injected right hemispheres.
(A) Images are montages of ~35 5X pictures each. Amyloid plaques indicated as white
spots. Cryosectioned at 14 µm and stained with 6E10/Alexa546 and Hoechst nuclear
stain. Sections numbered 1 through 6 and correspond with anterior to posterior. (B)
Amyloid plaques show a modest reduction of plaque in the left G-CSF-injected
hemisphere. Error bars are ± Standard Error of the Mean.
(Area, Integrated Density: p < 0.05).
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Supplementary Figure 4. Intrahippocampal injection of GM‐CSF‐injected left
hemispheres and artificial cerebrospinal fluid (aCSF)‐injected right hemispheres.
Representative sections of each mouse proximal to injection site. Tissue sections
stained with MabTech α-Aβ/Alexa 488. White spots indicate amyloid plaque
immunolabelling. Images are montages of about 145 pictures taken at 10X. Figures 4AC are from 14 µm frozen sections, and 4D is from a 5 µm paraffin-embedded section.
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Supplementary Figure 5.Quantification of reduced amyloid deposition in
GM‐CSF‐injected left hemispheres versus artificial cerebrospinal fluid
(aCSF)‐injected right hemispheres.
There were 5 montaged sections per mouse quantified. Each montaged section
contained over 140 10X pictures and of these, 15 ‐ 25 pictures per hemisphere were
selected to quantify as described in Supplementary Figure 6 online. Each figure shows
total or average values from the 5 sections/mouse with significance per individual mouse
and significance over all 4 mice. Error bars are ±SEM : (a - b) plaque areas (c - d)
perimeter values (e) average feret diameters (f) average integrated densities
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Supplementary Figure 6. Microscopy and method of Image J analysis of
amyloid deposition
Lateral rows of photomicrographs were taken of coronal sections in a manner that
ensured minimal overlap between each photomicrograph and corresponding anatomical
areas in each hemisphere. Hoechst nuclear staining was used as a tool to scroll through
sections, allowing for minimal overlap between each photomicrograph, and then the
image was taken with the appropriate fluorescence. After all photomicrographs of the
section were taken, they were montaged into a full coronal picture of the section, with
the outline of each photomicrograph displayed (Axiovision 4.7 Panorama Module
software). Photomicrograhs were then selected for analysis from each hemisphere
(Figure 6A). The histogram of each photomicrograph was analyzed and the resulting
means and standard deviations were entered into a spreadsheet. One photomicrograph
of the section was then thresholded to select the amyloid plaques. This thresholded
value was used in the spreadsheet to normalize the threshold values of the other
photomicrographs to the same standard deviation from their respective histogram mean
(Figure 6B). Each photomicrograph was then analyzed for Area, Perimeter, Feret
Diameter, and Integrated Density values from their predetermined threshold values. Any
threshold-selected data, which came in contact with the edges of any photomicrograph,
were deleted via the Image J “Analyze Particles” dialogue box, so that overlap of
photomicrographs did not allow quantification of any amyloid deposition more than once.
Within the Image J “Analyze Particles” dialogue box, the Oulines mask was also
selected to visually confirm that the plaques were quantified accurately (Figure 6C). This
Outline mask also numbered each plaque, which was used for selecting and eliminating
artifact from the results. The results from each individual photomicrograph were copied
into a 2nd separate spreadsheet, such that the data was separated into their respective
hemispheres (CSF-treated versus artificial cerebrospinal fluid-treated). After all
photomicrographs from a coronal section had been analyzed and data entered into the
spreadsheet, the Area and Perimeter values were totaled and averaged. The Feret
Diameter and Integrated Density values were also averaged. The overall data from
each section (sums and averages) were then entered into a 3rd spreadsheet . A total of 5
sections per mouse, anterior to posterior, were analyzed and entered into this 3rd
spreadsheet. A total of 4 mice per intrahippocampal-injected CSF were analyzed.
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Significance per mouse and over all 4 mice per CSF was determined by paired Students
t-test with p values <0.5 considered significant

Supplementary Figure 6A. Coronal section taken at 10X, showing demarcation
of individual photomicrographs to be analyzed for amyloid deposition.
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Supplementary Figure 6B. Thresholding of one photomicrograph and using its
threshold value to find the threshold value for all other photomicrographs within
the coronal section at the same standard deviation from the mean.

Supplementary Figure 6C. Example of the Oulines mask and underlying
ImageJ spreadsheet data.
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Supplementary Fig 7. Behavioral Tasks

Radial Arm Water Maze. For the RAWM task of spatial working memory, an
aluminum insert was placed into a 100cm circular pool to create 6 radiallydistributed swim arms emanating from a central circular swim area. An
assortment of 2-D and 3-D visual cues surrounded the pool. The number of
errors prior to locating which one of the 6 swim arms contained a submerged
escape platform (9cm diameter) was determined for 5 trials/day. There was a 30min time delay between the 4th trial (T4; final acquisition trial) and 5th trial (T5;
memory retention trial). The platform location was changed daily to a different
arm, with different start arms for each of the 5 trials semi-randomly selected from
the remaining 5 swim arms. During each trial (60 s maximum), the mouse was
returned to that trial’s start arm upon swimming into an incorrect arm and the
latency time required to locate the submerged platform was recorded. If the
mouse did not find the platform within a 60-s trial, it was guided to the platform
for a 30-s stay. The numbers of errors and escape latency during trials 4 and 5
are both considered indices of working memory and are temporally similar to
standard registration/recall testing of specific items used clinically in evaluating
AD patients.
Cognitive Interference Task. This task was designed to mimic, measure-formeasure, a cognitive interference task recently utilized clinically to discriminate
between normal aged, MCI, and AD patients. The task involves two RAWM setups in two different rooms, with two sets of visual cues different from those
utilized in standard RAWM testing. The task requires animals to remember a set
of visual cues (in RAWM-A), so that following interference with a different set of
cues (in RAWM-B), the initial set of cues can be recalled to successfully solve
the RAWM task. Five behavioral measures were examined: A1-A3 (Composite
three-trial recall score from first 3 trials performed in RAWM-A), B (proactive
interference measure attained from a single trial in RAWM-B), A4 (retroactive
interference measure attained during a single trial in RAWM-A), and A5 (delayedrecall measure attained from a single trial in RAWM-A following a 20-min delay
between A4 and A5). As with the standard RAWM task, this interference task
involves the platform location being changed daily to a different arm for both
RAWM set-ups. For A1 and B trials, the animal is initially allowed one minute to
find the platform on their own before being guided to the platform. Then the
actual trial is performed in each case. As with the standard RAWM task, animals
were given 60s to find the escape platform per trial, with the number of errors
and escape latency recorded per trial.
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APPENDIX C: COPYRIGHT INFORMATION

In the United States, whenever an author or creator puts their work onto a tangible
media, they automatically obtain copyright protection, for any “original work of
authorship”. Thus the manuscripts that authors submit to various journals are regulated
by copyright laws, and some journal policies require explicit permissions for any further
usage of the works that they publish within their journals, sometimes even by the original
authors themselves. Not only does this dissertation have copyright protections, but also
do the original figures and text which are enclosed within, and which have also been
published in the Journal of Neuroscience Methods and the Journal of Alzheimer’s
Disease. Both journals’ publishers have provided explicit terms regarding authorship and
copyright permissions on their websites. The following pages, obtained directly from
each publisher’s website, explicitly state each publisher’s copyright policies. These
policies give permission for the original materials from both journal articles to be used
within this dissertation.
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The Journal of Neuroscience Methods, is published by Elsevier, a part of the Reed
Elsevier group based out of Amsterdam, which has the following policy stated on its
website, and which can be found at the web link:
http://www.elsevier.com/wps/find/authorshome.authors/copyright
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The Journal of Alzheimer’s Disease, is published by IOS Press, a pulishing house
also based out of Amsterdam and which has the following policy stated on its website,
and which can be found at the web link: http://www.iospress.nl/authco/copyright.html
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APPENDIX D: IMAGEJ ANALYSIS PROTOCOL

This protocol was developed to quantify parameters of amyloid deposition in each
brain hemisphere and enable comparisons to be made between each side. It was critical
that the tissue sections were properly-aligned under the microscope so that the
photomicrographs could be taken in horizontal lateral rows continuously across both
hemispheres of the coronal sections. We examined the Axiovision version 4.7 software
which was used in the acquisition of the photomicrographs to see if it had the capability
to accurately quantify amyloid plaques. However, it did not provide the capability to
select artifactual or non-specific immunopositivity, so that these selections could be
eliminated from the analyses. Thus, we examined several software packages for these
capabilities, and found that the freely-available ImageJ software, which is provided
through the National Institute of Health, could perform these tasks. Following is the
protocol that we developed using the ImageJ software to analyze specific plaque
parameters in the mouse brains, following acquisition of the photomicrographs from
Axiovision version 4.7 software. The compilation of the photomicrographs was
performed using the Axiovision version 4.7 Panorama Module.
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APPENDIX E: MAGNETIC IMMUNOHISTOCHEMICAL
STAINING DEVICE AND METHODS OF USE

This device was constructed in order to spare the usage of valuable antibody
solutions and other reagents during the immunohistochemical (IHC) staining of tissues,
which had been paraffin-embedded and mounted onto glass slides. During traditional
staining protocols of these types of tissue preparations, there was no adequate procedure
for mounting a hydrophobic barrier around the edges of the slide or tissue, which would
allow for concentration of reagent solutions, instead of full submersion of slides in said
solutions. Upon demonstration of this device’s utility in said IHC application, it was
submitted for provisional patent application at the United States Patent and Trademark
Office (USPTO) on June 24, 2008, and subsequently a non-provisional patent application
was filed with the USPTO on June 24, 2009. Following is a copy of the patent application
file on Jun 24, 2009, followed by the higher resolution figures.
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APPENDIX F: METHODS OF TREATING COGNITIVE IMPAIRMENT

Given the quick and remarkable effects of GM-CSF in transgenic (Tg) mouse
models of AD, especially the reversal of already-established cognitive impairment in
these aged Tg mice, implies that the recombinant human GM-CSF
(sargramostim/Leukine) protein may impart the same beneficial effects wtihin AD and
other cognitively-declining patients. Since we were the first to identify GM-CSF to have
these effects, we filed to protect USF’s and our intellectual property rights for the usage
of GM-CSF in the amelioration of pathologies found in specific neurodegenerative
diseases. A provisional patent entitled “Methods of Treating Cognitive Impairment” was
filed with the United States Patent and Trademark Office (USPTO) on August 5, 2008.
On August 5, 2009, a regular patent application, containing some revisions to the
provisional patent application, was filed with the USPTO, as well as in international
filings. Following is a copy of the provisional patent application that was received by the
USPTO on August 18, 2008.
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